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Abstract
Gangliosides are a family of membrane lipids enriched in the central nervous system (CNS)
that play an important role in cell signaling processes on the membrane. Alterations in the
homeostatic distribution of the a-series family of gangliosides has been observed in both preclinical models and human patients with neurodegenerative diseases and injuries, such as
Alzheimer’s disease (AD) and strokes. Ganglioside dysregulation has been implicated as an
important mechanisms driving pathology in the aging brain, yet there is little information on
where and when these lipid changes occur as well as the role of dysregulation during
neurodegeneration. Matrix-Assisted Laser Desorption/Ionization (MALDI) imaging mass
spectrometry (IMS) is a novel imaging technique that can map the distribution of ionizable
molecules on a sample in a 2-dimensional format, making it the ideal tool for analyzing
gangliosides on post-mortem brain tissue sections. A comorbid rat model of stroke and Aβ
toxicity, using an endothelin-1 (ET-1) induced unilateral striatal stroke together with
intracerebralventricular (icv) injections of Aβ(25-35), was used to examine ganglioside
dysregulation in response to neurodegenerative injuries of varying severity. Results indicated
that ganglioside dysregulation was correlated with the severity of the neurodegenerative
injury and showed a characteristic pattern of depleted protective complex gangliosides with
accumulated toxic simple gangliosides at the site of injury. Transgenic (Tg) rats with a
mutation in the Alzheimer’s precursor protein (APP) demonstrated a similar characteristic
shift in ganglioside distribution during aging compared to wild-type (Wt) rats in brain
regions which are susceptible to damage in AD, such as the white matter and hippocampus.
Finally, chloroquine (CQ), a pharmacological inhibitor of ganglioside catabolism, was used
i

as a treatment for ganglioside dysregulation after injury in the rat comorbid stroke model. CQ
was found to prevent ganglioside dysregulation acutely after stroke and was correlated with
reduced pathology and functional impairments. These results support the hypothesis of
ganglioside dysregulation as an important mechanism of neurodegeneration in the aging and
injured brain and highlights the benefits associated with the restoration of ganglioside
homeostasis after stroke injury.
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Chapter 1
1

Introduction

The following chapter contains a review of the literature pertaining to the topics discussed
in this work. Ganglioside dysregulation was examined in the context of neurodegeneration
and aging in rats using a novel imaging technique. Relevant background information on the
pathogenesis of ischemic stroke, Alzheimer’s disease (AD), and the co-morbidity of stroke
and AD are presented, followed by a detailed description of gangliosides and their role
during aging, injury, and neurodegenerative disease. Next, the MALDI imaging mass
spectrometry technique used to examine the distribution of gangliosides in the brain is
described. Finally, background information on a pharmacological compound used to
prevent ganglioside dysregulation is provided.

1.1

Ischemic stroke

A stroke is the abrupt development of neurological deficits due to an interruption of blood
supply, and thus oxygen, to the brain. These injuries can be either hemorrhagic or ischemic
in nature. Ischemic strokes are most common, accounting for roughly 80% of all strokes,
and occur as a result of blood vessel occlusion (Fluri, Schuhmnn, & Kleinschnitz, 2015).
The brain region surrounding the occlusion is starved of oxygen and energy, setting off a
cascade of pathological events that can lead to irreversible tissue damage. Excitotoxicity in
the early stages of the ischemic cascade is caused by a massive release of the excitatory
neurotransmitter glutamate (Lai, Zhang, & Wang, 2014). Neural cells have a large number
of glutamate receptors which makes the brain particularly susceptible to excitotoxic
damage, and thus ischemic injuries (Lai et al., 2014). Glutamate stimulates N-methyl-Daspartate (NMDA) receptors on the cell surface mediate the influx of calcium (Ca²⁺) into
the cell. The increased Ca²⁺ then triggers a secondary intracellular Ca²⁺ overload which
promotes apoptotic cell death (Randall & Thayer, 1992; Szydlowska & Tymianski, 2010).
When excessive intracellular Ca²⁺ is taken up by mitochondria, reactive oxygen species
(ROS) and free radicals are produced leading to oxidative stress, further perpetuating
neurodegeneration (Castilho, Ward, & Nicholls, 1999; Zoppo et al., 2000). The
pathological events in the ischemic cascade are not linear, but rather circular in nature, with
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one factor affecting downstream events and also feeding back to exacerbate the initial
triggering event.
The region immediately surrounding the ischemic occlusion is termed the necrotic
core, where irreversible cellular damage often occurs. The ischemic penumbra is a perilesion area surrounding the necrotic core which is vulnerable to damage but can also be
prevented depending on a number of variables, such as autophagy and inflammation (C
Iadecola & Anrather, 2011). Autophagy is a mechanism in which intracellular components
are broken down and recycled and can be considered a pro-survival mechanism for the cell
when it selectively degrades damaged or malfunctioning cellular components. However,
prolonged exposure to stress, such as an ischemic stroke, can over-activate this process,
leading to apoptotic cell death (Debnath, Baehrecke, & Kroemer, 2005; Mizushima,
Levine, Cuervo, & Klionsky, 2009). Microglia and astrocytes, the brain’s inflammatory
cells, arrive at the site of injury, leading to an upregulation of pro-inflammatory cytokines,
such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, macrophage inflammatory
protein (MIP)-1α, and monocyte chemoattractant protein -1 (MCP-1) (Hawkins et al.,
2017; C Iadecola & Anrather, 2011; Zoppo et al., 2000). When neuroinflammation spreads
outside of the necrotic core, the upregulation of pro-inflammatory cytokines can become
pathological, leading to phagocytic engulfment and pro-apoptotic/autophagic signaling of
potentially viable cells (Hawkins et al., 2017).
Currently, the only effective treatment for stroke is recombinant tissue plasminogen
activator (rtPA), an anti-clotting agent, which must be administered within a very narrow
therapeutic window (within 3 hrs of stroke) and excludes individuals over the age of 80,
those who take anti-coagulant medications, those with mild or recurring strokes, and those
with comorbidities (Fluri et al., 2015; X. Liu et al., 2013; The National Institute of
Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995). A review of rtPA
administration in 2165 stroke patients at a Canadian teaching hospital revealed that 73% of
patients were excluded from treatment as they arrived at the hospital more than 3 hrs after
stroke onset. Of the total patients with ischemic stroke who were present at the hospital
within 3 hrs, only 26% received rtPA treatment once the exclusion criteria listed above was
factored in (Barber, Zhang, Demchuk, & Hill, 2001). Patients who do receive this treatment
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have a significantly decreased risk of severe neurological impairments but it is
accompanied by a 10 fold increase in the risk of intracerebral hemorrhage (Liu et al., 2013;
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group,
1995). Due to the multifactorial nature of the ischemic cascade, it is unlikely that a single
target approach will be sufficient to temper the complex interaction of pathogenesis after
stroke (Fisher, 1997; Liu et al., 2013). Thus, a better understanding of the key mediators of
ischemic damage would allow for a more effective approach to treatment.
Ischemic stroke can be modelled in animals to study the mechanisms governing the
pathogenesis and test possible therapeutic interventions. The most common animal model
of stroke is middle cerebral artery occlusion (MCAO) (Fluri et al., 2015; Longa, Weinstein,
Carlson, & Cummins, 1989; Tamura, Graham, McCulloch, & Teasdale, 1981). This
technique involves sending a suture through the common carotid artery until the MCA is
reached and occluded for a predetermined period (generally 60-120 min in rats), after
which time the occlusion is released and reperfusion begins. Different strains of rats were
found to have distinct responses to MCAO injuries, making the choice of rat strain an
important variable to consider in experimental stroke research. For example, SpragueDawley rats were found to have considerable variability in stroke size in response to
MCAO injuries while Wistar rats exhibited the most consistent results (Howells et al.,
2010; Ström, Ingberg, Theodorsson, & Theodorsson, 2013). Injection of the potent
vasoconstrictive peptide Endothelin-1 (ET-1) is another common model of ischemic stroke.
It is less invasive and results in lower mortality rates than MCAO, and can be administered
directly into discrete brain regions (Fluri et al., 2015). ET-1 is generally administered
topically or to the desired brain region via a stereotaxic injection, where cerebral blood
flow is reduced up to 90% in the surrounding focal region, followed by reperfusion over
several hours (Bogaert, Scheller, Moonen, Sarre, & Smolders, 2000; Fuxe et al., 1997).
Thus, the ET-1 stroke model can be used to simulate smaller, “lacunar” infarcts that are
common in the human aging brain.

1.2 Alzheimer’s disease
Age-related dementia has emerged as one of the biggest health problems of our time,
affecting roughly 35.6 million people world-wide, with that number expected to triple by
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2050 (Costantino Iadecola, 2013; The World Health Organization, 2012). It presents a
devastating societal burden for caregivers and taxpayers alike, as it has become more costly
to manage than both cancer and heart disease in the US (Hurd, Martorell, Delavande,
Mullen, & Langa, 2013). Alzheimer’s disease (AD) is a neurodegenerative disease
characterized by progressive cognitive decline and represents the most common form of
dementia. Alois Alzheimer described four major neuropathological features of the disease
including senile plaques, neurofibrillary tangles, hardening of arteries, and lipid granule
accumulation (Chan et al., 2009; Foley, 2010; Iadecola, 2013). Patients with AD exhibit
altered sensory perceptions most commonly manifesting as memory loss which
progressively worsen leading to a wide array of behavioural deficits as the disease
progresses. The cause of AD remains unclear; however, several genetic and non-genetic
factors have been implicated.
The amyloid cascade hypothesis was one of the most prominent theories of AD
pathogenesis. Generally, it states that the accumulation and deposition of amyloid beta
(Aβ) plaques in the brain lead to neuronal dysfunction and cell death (Goate et al., 1991).
This theory posited that Aβ accumulation was the driving factor in the development of ADrelated symptoms and associated pathologies such as neurofibrillary tangles, inflammation,
neuronal loss, and cognitive decline (Hardy & Higgins, 1992). However, increasing
evidence has countered this hypothesis as the total amyloid burden was not found to be
correlated with cognitive decline or even the manifestation of AD symptoms (Haass &
Selkoe, 2007; McLean et al., 1999; Snowdon et al., 1997). Although Aβ is still considered
an important factor in the pathogenesis of AD, attention has shifted from solid Aβ plaques
to soluble oligomers of Aβ, in conjunction with other predisposing factors, as a major
driver of the disease (Ferreira, Vieira, & Felice, 2007; Li et al., 2009; Tomiyama et al.,
2010).
AD can present in either an early onset form (familial) or late onset form (sporadic).
Genetic factors are thought to be the main cause of familial AD cases. Mutations in several
genes regulating the cleavage and processing of amyloid precursor protein (APP) have
been shown to upregulate the production of Aβ. APP is cleaved by proteases, β- and γsecretase, to form Aβ. Presenilin (PSEN) regulates the activity of γ- secretase to increase
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the ratio of long chain Aβ42 to Aβ40, a toxic fragment of the Aβ protein. The presence of
the apolipoprotein E4 (APOE4) gene has been found to increase the risk for familial AD
and remains the most common genetic screening marker for individuals with a family
history of early-onset AD (Bandaru et al., 2009; Carrieri, Bonafè, Luca, Rose, & Varcasia,
2001; Sanan et al., 1994). The main risk factor for the sporadic form of AD is age, which
is hypothesized to interact with certain environmental and lifestyle factors along with
existing conditions, such as stroke and diabetes, to initiate AD (Purnell, Gao, Callahan, &
Hendrie, 2009; Reitz, 2012).
The vascular system of the brain is thought to play a major role in the development
and progression of AD. Roughly 90% of AD patients present with cerebral amyloid
angiopathy (CAA), which occurs when Aβ (mostly Aβ40) deposits and accumulates in
blood vessels, leading to narrowing of blood vessels and cognitive decline (Attems,
Jellinger, Thal, & Van Nostrand, 2011). The narrowing of cerebral blood vessels increases
the risk for ischemic stroke injuries and impedes the clearance of solutes from the brain
(Jellinger, 2002; Soontornniyomkij et al., 2010). The occipital lobe is the most frequently
and severely affected part of the brain for CAA, followed by the frontal lobe (Attems,
Jellinger, & Lintner, 2005). As the disease progresses, accumulated Aβ leads to
degeneration of vessel smooth muscle, leading to a thinning of vessel walls, making them
more vulnerable to “mini aneurysms” and dysphoric, or structurally abnormal, vessel
formation (Attems et al., 2011). Carriers of the APOE4 gene who develop late-onset
dementia are at a higher risk of developing CAA (Trembath et al., 2007). Thus, the
interaction of Aβ with the brain’s vasculature is a critical component of the pathogenesis of
AD.
Vascular dementia is the second most common form of dementia. It is characterized
by the presence of vascular lesions and is commonly associated with the appearance of
white matter lesions which can accumulate over time in a condition referred to as
leukoaraiosis (Hachinski & Potter, 1987; Iadecola, 2013). This form of dementia is highly
associated with cardiovascular risk factors such as stroke, hypertension, diabetes,
hyperlipidemia and smoking. Many of the symptoms of vascular dementia overlap with
those of AD, often being differentiated solely on the severity or location of
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neurodegenerative or vascular lesions. White matter lesions can grow over time and are
correlated with the evolution of cognitive impairments (Maillard, Carmichael, Fletcher, &
Reed, 2012). Indeed, vascular risk factors are known to play a major role in the initiation
and progression of dementia (Hachinski, Bowler, & Loeb, 1993; Steingart, Hachinski, &
Lau, 1987; Thiel, Cechetto, Heiss, Hachinski, & Whitehead, 2014).

1.3 Comorbidity of AD and Stroke
A number of variables have been shown to correlate and/or increase the risk of developing
AD such as atherosclerotic disease, atrial fibrillation, hypertension and adult-onset diabetes
mellitus (Cechetto, Hachinski, & Whitehead, 2008; Cifuentes et al., 2015). In fact, the
incidence of “pure” dementia is relatively rare, while a mixed vascular-degenerative
presentation is quite common (Dodge, Chang, Kamboh, & Ganguli, 2012; Iadecola, 2013).
Epidemiological evidence is particularly strong pertaining to the relationship between the
incidence of stroke and the development of dementia. Approximately 25% of stroke
survivors develop dementia (Jin, Østbye, Feightner, Di Legge, & Hachinski, 2008).
Patients with both minor cerebral infarcts and AD lesions are more likely to develop the
clinical manifestations of dementia with synergistic effects on dementia related pathology
(Hachinski & Munoz, 2000; Snowdon et al., 1997). Elderly individuals are at a particularly
high risk of “silent strokes”, or lacunar infarcts, which are ischemic lesions in small vessels
that often do not produce observable deficits but can lead to accumulated damage over time
(Masuda, Nabika, & Notsu, 2001). Patients with lacunar infarcts in the basal ganglia,
thalamus, or white matter regions have demonstrated a high prevalence of dementia (Gold
et al., 2005; Prins et al., 2004; Schmidt et al., 2005; Snowdon et al., 1997), therefore, the
location of stroke injury is also a determining factor in the development of subsequent
dementia.
The interaction between stroke and AD has also been shown to be bidirectional,
with increases in Aβ being associated with compromised vascular function (Grammas,
Yamada, & Zlokovic, 2002). For example, Aβ plaques have been observed to accumulate
around cerebral blood vessels leading to vascular degeneration (Kalaria, 2002). On the
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other hand, APP protein has been observed to accumulate around the site of infarcts in rats
(Kalaria et al., 1993). Additionally, hypoxia caused by hypoxia inducible factor 1α (HIF1α) was associated with increased Aβ production and cleavage by β-secretase (BACE1),
which the authors suggest may contribute to triggering the amyloid cascade (Zhang et al.,
2007). Thus, a complex interaction exists between stroke and AD that can synergistically
overlap to produce exacerbated pathology.
Clinical findings of interaction and synergism between stroke and AD have been
recapitulated in a number of animal models which have been useful in teasing apart the
mechanisms involved. Synergistic interactions of pathology have been observed in rats
who have received both icv injections of the toxic Aβ peptide 25-35 in addition to a focal
ET-1 induced striatal stroke (Amtul et al., 2014; Whitehead, Cheng, Hachinski, &
Cechetto, 2007; Whitehead, Hachinski, & Cechetto, 2005). These rats displayed increased
neuroinflammation, progressive increases in infarct size, and performed worse on cognitive
memory tasks than rats with just ET-1 stroke or Aβ toxicity alone. Another study using
transgenic (Tg) APP rats with or without ET-1 stroke injuries, demonstrated that Tg rats
with increased Aβ production displayed increased cognitive inflexibility on an operant set
shifting task compared to Tg rat without a stroke or wild type (Wt) rats with stroke,
suggesting a synergistic effect on cognitive impairment in the comorbid rats (Levit et al.,
2017).
A correlation has been observed between individuals who carry the APOE4 gene
and cerebrovascular disease (Kalmijn, Feskens, Launer, & Kromhout, 1996). The Canadian
Study of Health and Aging examined the joint effect of stroke and APOE4 in 954
participants and found that individuals who had both a stroke and were positive for the
APOE4 gene displayed the highest prevalence of dementia (Jin et al., 2008). However, it
was found that the effect of stroke on the incidence of dementia was not affected by the
presence of the APOE4 gene, suggesting that stroke and APOE4 may increase the risk for
dementia via independent mechanisms (Jin et al., 2008). Conversely, the PSEN1 gene has
been shown to render neural cells vulnerable to hypoxia-induced apoptosis in vitro and was
correlated with increased intracellular levels of Ca²⁺ (Mattson, Zhu, Yu, & Kindy, 2000). In
vivo, PSEN1 knock-in mice display increased brain damage in response to a focal ischemic
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reperfusion injury and worsened behavioural outcomes (Mattson et al., 2000). These
studies suggest that the interaction between AD and stroke may be partially governed by
specific genetic markers.
Common neuropathological features are present in both AD and stroke, with vascular
dysfunction being the most prevalent. Vascular cognitive impairment (VCI), an umbrella
term which encompasses all cognitive disorders associated with cerebrovascular disease
and injury, is thought to occur primarily due to reduced cerebral blood flow and damage to
myelin, leading to cerebral atrophy and dysfunctions in connectivity within the brain
(Appelman et al., 2009; Dichgans & Leys, 2017; Lawrence et al., 2013). VCI is a very
common feature of senile dementia, making up roughly 75% of cases (Gearing et al., 1995;
Hachinski, 2008). Another common neuropathological feature is neuroinflammation. The
activation and proliferation of microglia and astrocytes, increased ROS, upregulation of
inflammatory cytokines and nuclear factor kappa B (NFκB) are all neuroinflammatory
events that are synergistically activated in the presence of both AD and stroke (Bales, Du,
Holtzman, Cordell, & Paul, 2000; Cheng et al., 2006; Stoll, Jander, & Schroeter, 1998; S.
N. Whitehead et al., 2005). The neuroinflammatory response after stroke is exacerbated by
the presence of Aβ toxicity and is implicated as mechanism which can mediate the severity
of cognitive impairments (Amtul et al., 2014; Li et al., 2011; Whitehead, Cheng,
Hachinski, & Cechetto, 2007; Whitehead, Hachinski, & Cechetto, 2005). Indeed, antiinflammatory treatment has shown beneficial effects in reducing the exacerbated
neuroinflammatory response and cognitive impairments associated with stroke and Aβ
comorbidity (Whitehead, Cheng, Hachinski, & Cechetto, 2005). However, antiinflammatory agents alone are not sufficient to prevent the pathogenesis of either stroke or
AD further investigate factors which may be mediating the synergistic interaction between
stroke and AD.

1.4 Gangliosides
Over 60% of the mass of our brains are made up of lipids (Chang, Ke & Chen, 2009) yet
their precise role in the development and pathogenesis of neurodegenerative diseases and
injuries remains unclear. Changes in brain lipids are correlated with the progression of
diseases, such as AD (Ariga, McDonald, & Yu, 2008). Indeed, lipid biomarkers may hold
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the key to identifying individuals at risk of developing neurodegenerative diseases.
Mapstone et al, used a lipidomics approach to identify several plasma phospholipids in
peripheral blood samples that could predict, with 90% accuracy, the conversion from a
cognitively normal phenotype to mild cognitive impairment or AD within a 2-3 year
timeframe (Mapstone et al., 2014). These findings are particularly important given the
disappointing results from biomarkers that target other AD-associated proteins in cerebral
spinal fluid such as Aβ42 and Tau (Irizarry, 2004). Thus, a better understanding of the role
of lipids in the aging brain may reveal important mechanistic clues as to the development
of neurodegenerative diseases and the brain’s response to injury. One group of membrane
lipids, called gangliosides, are of particular interest in the context of neurodegeneration as
they have been shown to be altered in response to a number of neurodegenerative diseases
and injuries. The following section provides background on ganglioside structure, function,
as well as a review of the literature of their role in neurodegenerative diseases and injuries.

1.4.1

Ganglioside Structure

Gangliosides are part of a glycosphingolipid family that contain sialic acid residues. They
have a wide variety of biological functions due to their location on the outer leaflet of
plasma membranes (Lopez & Schnaar, 2009). They make up a crucial component of lipid
rafts, or ganglioside-enriched microdomains (GEMs), where they effect the physical
properties of the membrane as well as their function (Daniotti & Iglesias-Bartolomé, 2011;
Sandro Sonnino & Prinetti, 2010). Lipid rafts are complexes made up of cholesterol,
glycosphingolipids, and proteins which play an important role in signal transduction. The
specific functions of lipid rafts varies depending on their composition which can lead to the
segregation of rafts within the lipid bilayer based on, for example, the type of gangliosides
present (Sonnino, Mauri, Ciampa, & Prinetti, 2013). Lipid rafts cluster molecules with
similar properties together in order to facilitate the molecular interactions required for
specialized cellular functions (Hooper, 1998). Gangliosides play an important role in
stabilizing lipid rafts due to their physical structure, both within the phospholipid bilayer
and on the outer leaflet of the membrane (Sonnino & Prinetti, 2010).
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The hydrophobic portion of the ganglioside molecule is made up of the ceramide
domain which contains a sphingosine moiety with a carbon chain of variable length
attached to a fatty acid (Fig. 1.1). The ceramide domain acts to provide structural integrity
on the membrane but is also suggested to play a more critical role in determining
ganglioside function. Gangliosides with 18 carbons (d18:1) in their sphingosine moiety are
most common in the CNS, however, gangliosides can also have shorter or longer carbon
chains. The length of the carbon chain in the sphingosine moiety can alter the fluidic
properties of the membrane which has functional consequences for glycoprotein
interactions at the cell surface (Masserini, Palestini, & Freire, 1989; Sonnino & Chigorno,
2000). Indeed, gangliosides with varying carbon lengths are thought to have unique
functional roles in the brain (Sonnino & Chigorno, 2000), however, technical challenges in
detecting and visualizing gangliosides with varying carbons lengths has made it difficult to
examine this hypothesis. Alterations in the length of the carbon chain in the ceramide
domain are thought to occur during ganglioside degradation and recycling processes,
however the precise mechanisms remain unclear (Palestini, Masserini, Sonnino, &
Tettamanti, 1990).
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Figure 1.1: Ganglioside Structure. Gangliosides are composed of both a hydrophilic
domain which extends into the extracellular space, and hydrophobic ceramide anchor
(highlighted) embedded within the lipid bilayer. The hydrophilic portion contains an
oligosaccharide chain of variable length with is composed of 3 types of sugar units
(glucose, galactose, N-acetyl galactosamine) as well as sialic acid residues (NeuAc). The
number and type of sugar units along with the number of sialic acid residues attached to
galactose units determines the type of ganglioside (i.e. GM1, GM2, GM3). The
hydrophobic portion of the molecule is made up of a fatty acid, usually stearic acid, and a
sphingosine LCB tail with varying numbers of carbons. The most common form of
ganglioside contains 18 carbons (d18:1) within the sphingosine moiety with the second
most common form having a slightly longer carbon tail with 20 carbons (d20:1). Figure
modified from Weishaupt et al., 2015.
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Ceramide forms the hydrophobic backbone of the ganglioside molecule and is
synthesized in the endoplasmic reticulum (Bisel, Pavone, & Calamai, 2014). The
hydrophilic domain contains an oligosaccharide chain made up of a variable amount of
glucose (Glc), galactose (Gal), and N-acetylgalactosamine (GalNAc), as well as one or
more sialic acid residues. Glycosylation occurs in the golgi apparatus where only a limited
number of oligosaccharides (Glc, Gal, GalNAc) are assembled to form gangliosides. The
number and sequence of sugar units in the oligosaccharide domain act as a coding unit
which are selective to specific glycoprotein interactions, giving each ganglioside species a
unique regulatory function on the membrane (Ledeen & Wu, 2015). The combination of
lactose and ceramide, or LacCer, forms the main lipid core of all gangliosides (Prokazova,
Samovilova, Gracheva, & Golovanova, 2009). GM3 is produced when a sialic acid residue
is added to LacCer by the enzyme GM3 synthase (also known as ST I, ST3Gal V, or CMPNeuAC) (Fig. 1.2). This ganglioside forms the basis upon which all other gangliosides are
synthesized. Oligosaccharide units and/or sialic acid residues are added to GM3 by various
glycosyltransferases and sialyltransferase enzymes to produce the over 200 identified
species of gangliosides (Bisel et al., 2014). Berselli et al., proposed that the activity of
GM3 synthase may be related to the location within the golgi apparatus and can dictate
assembly of either simple gangliosides, such as GM3 or GD3, or more complex
gangliosides, such as GM1 and GD1a (Berselli et al., 2006).
Hydrolysis of sialic acids by Neu3 in lysosomes and on the plasma membrane is the
first step of ganglioside degradation (Ha, Lee, Cho, Kim, & Kim, 2004; Prokazova et al.,
2009). Gangliosides with a sialic acid residue on a terminal chain galactose unit or
polysialic gangliosides are the first to be catabolized and can be degraded directly in the
membrane, while gangliosides with a single sialic acid residue located on a middle chain
galactose unit, such as GM1, are degraded only in the lysosome (Miyagi et al., 1999).
Gangliosides are transported to endosomes and eventually lysosomes where they are
sequentially degraded by hydrolytic enzymes such as sialidase, β-galactosidase (βGal), and
β-hexosaminidase (βHex) (Bisel et al., 2014).
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Figure 1.2: Schematic of A- and B-series ganglioside metabolism. Gangliosides are
synthesized (green) from the conversion of Lactosylceramide (LacCer) to GM3 by the
addition of a sialic acid residue to the galactose unit of LacCer by the SAT I enzyme (or
GM3 synthase). Thus, GM3 is the structural precursor of all other ganglioside species with
more complex species being synthesized from GM3 by various transferase enzymes that
add sugar units (GalNAcT, GalT II) and sialic acids (SAT IV, SAT II). Gangliosides are
catabolized (red) by sialidase as well as sugar cleaving enzymes β-Galactosidase (βGal)
and β-Hexosaminidase (βHex). Catabolism of gangliosides generally occurs within
endosomes and lysosomes, however, there are membrane-bound sialidases which can
directly catabolize gangliosides with sialic acids on terminal galactose units, such as GD1a
and GT1b, directly on the membrane. GM3 is catabolized by a specialized sialidase
enzymes called Neu3, which can only break down GM3.
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1.4.2

GM3

Ganglioside GM3 is the first and simplest member of the ganglioside family and is the
metabolic precursor of more complex gangliosides and thus plays a determining role in the
abundance of all upstream ganglioside species. GM3 is the main ganglioside in extra-neural
tissues, but is present only in small amounts in the CNS (Dawson, Matalon, & Dorfman,
1972; Muthings & Cacic, 1997; Negroni, Chigorno, Tettamanti, & Sonnino, 1996; Nilsson
& Svennerholm, 1982; Ohashi, 1978; Prokazova et al., 2009; Rauvala & Finne, 1980;
Seyfried, Ando, & Yu, 1978). GM3 synthase, which synthesizes GM3 from LacCer, is a
unique sialyltransferase enzyme that is specific only to the GM3 lipid substrate, whereas
other sialyltransferases can sialylate various lipid substrates (Harduin-lepers, Mollicone,
Delannoy, & Oriol, 2005). Therefore, GM3 plays an important regulatory role for the
synthesis of all other downstream gangliosides.
GM3 was identified as a molecule that regulates cell growth leading to interest in its
potential role in the field of oncology. Numerous mechanistic studies examining the effects
of GM3 in various cancer-based in vitro cell lines and in vivo rodent tumor models have
identified important regulatory functions of GM3 including the inhibition of cell growth,
proliferation, migration, adhesion, cell motility, angiogenesis, as well as the upregulation of
apoptotic pathways (Chung et al., 2014; Fujimoto et al., 2005). Additionally, GM3
accumulation can increase the expression of TNF-α, a pro-inflammatory cytokine which
modulates immunity and apoptosis (Kabayama et al., 2005). Exogenous administration of
GM3 to B16 cells and cultured mouse melanoma cells resulted in a drastic increase in
TNF-α

mRNA,

while

cells

treated

with

D-1-threo-1-phenyl-2-decanoylamino-3-

morpholino-1-propanol (D-PDMP), an inhibitor of GM3 synthesis, resulted in decreased
TNF-α mRNA expression (Péguet-navarro et al., 2017; Prokazova et al., 2009; Wang et al.,
2007). The ability of GM3 to modulate a major pro-inflammatory cytokine suggests that it
may play a role in the development of pathological inflammation. Angiogenesis, a critical
factor for tumor growth, is suppressed when GM3 levels are increased through autocrine
and paracrine effects on vascular-endothelial growth factor (VEGF) and by blocking
VEGF receptor 2 (Choi et al., 2006; Mukherjee et al., 2008; Seyfried & Mukherjee, 2010).
However, when complex gangliosides GM1 and GD1a were increased as well,
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angiogenesis was restored suggesting that the balance between GM3 and complex
gangliosides was an important factor in determining GM3’s anti-angiogenic properties
(Abate, Mukherjee, & Seyfried, 2006). In the mouse brain, astrocytomas expressing high
levels of GM3 were found to be less vascularized and grow slower than those expressing
low levels of GM3 (Seyfried & Murkhejee, 2010). GM3’s interaction with TNF-α and
VEGF have also led to interest for researchers in the field of metabolic disease as GM3
accumulation is correlated with insulin resistance in type 2 diabetes (Inokuchi, 2007;
Sasaki et al., 2003; Veillon et al., 2015; Vukovic, Bozic, Markotic, Ljubicic, & Kurir,
2015; Wang et al., 2013; Zador et al., 1993). TNF-α appears to have a bidirectional
relationship with GM3, with increases in the pro-inflammatory cytokine also being linked
to an increase in GM3 synthase in animal models of metabolic disease (Tagami et al.,
2002). Indeed, increases in GM3 have been shown to play a pathological role in animal
models of metabolic disease through suppression of insulin-sensitive glucose transport and
impaired wound healing (Randeria et al., 2015; Tagami et al., 2002). Reducing GM3 levels
was shown to improve wound healing by increasing angiogenesis when applied to the
lesion site and was also associated with increased insulin sensitivity and glucose tolerance
in the liver of mice (Randeria et al., 2015; Yoshizumi et al., 2007). Overall, GM3
accumulation appears to be tied to the inflammatory response and impairs healing by
blocking angiogenesis.
In order to examine the function of GM3 within the CNS, several in vitro and in
vivo knock-out models have been developed. Studies in GM2/GD2 and GM3 synthase
single and double KO mice, which lack complex gangliosides and accumulate simple
ganglioside GM3, have demonstrated severe behavioural deficits that are exacerbated with
aging leading to increased neurodegeneration, severe white matter pathology, and disrupted
axon-glial interactions (Niimi et al., 2011; Sugiura et al., 2005; Tajima et al., 2009;
Yamashita et al., 2005). Single KO GM2/GD2 synthase mice, which lack complex
gangliosides and accumulate both simple gangliosides GM3 and GD3 developed
progressive behavioural neuropathies including deficits in reflexes, strength, coordination
and balance (Chiavegatto, Sun, Nelson, & Schnaar, 2000). Sheik et al., used the same
single KO mouse model and found that the KO mice had reduced expression of myelinassociated glycoprotein (MAG) along with severe deficits in white matter including
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decreased central myelination, axonal degeneration in both the central and peripheral
nervous system, and demyelination of peripheral nerves (Sheikh et al., 1999). These studies
not only suggest that complex gangliosides are essential to maintain the integrity of the
nervous system throughout life but also point to potential toxicity associated with GM3
accumulation in the brain.
A number of in vitro neural models have confirmed many of the findings from
oncology-based studies with regards to the accumulation GM3. Sohn et al., examined the
effect of glutamate toxicity on GM3 levels and GM3 toxicity in HT22 hippocampal cells
and found that glutamate toxicity led to an increase in GM3 in a time dependent manner, as
assessed by high performance thin layer chromatography (HPTLC). GM3, GD3, and GT1
were then exogenously administered to HT22 cells but only GM3 was found to
significantly decrease cell viability (Sohn et al., 2006). HT22 cells transfected with GD3
synthase siRNA to increase GM3 levels showed similar results on cell viability, further
supporting the hypothesis that GM3 accumulation leads to cell death. The authors suggest
that GM3 may be directly connected to toxic events such as the production of ROS and
Ca²⁺ influx by stimulating the oxidative pathway (Sohn et al., 2006). Nakatsuji & Miller
administered GM3, GM1, and GD3 to rat primary astrocyte cultures and found that only
GM3 administration resulted in a significant decrease in cell proliferation, as assessed by
BrdU staining, and led to an increase in apoptosis, as measured by TUNEL staining
(Nakatsuji & Miller, 2001). The authors further examined the effects of GM3 accumulation
in-vivo through icv injections of GM3 into the right ventricle of Sprague-Dawley rats and
examined cell proliferation and apoptosis. BrdU staining was decreased 30% in the lateral
and dorsolateral ventricular regions in GM3 injected rats while there was an increase in
TUNEL positive staining in the same regions in addition to the subventricular zone and
striatum. The authors demonstrate that the inhibition of cell proliferation by exogenous
GM3 is correlated with the increased expression of cell cycle inhibitor p27KIP1 and
suggest that proliferating neural precursors may be more susceptible to GM3 toxicity than
mature, non-proliferating cells (Nakatsuji & Miller, 2001). Thus, GM3 accumulation may
play an important mechanistic role in the development and progression of
neurodegeneration in the brain.
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1.4.3

GM2

Ganglioside GM2 is a minor component of brain gangliosides. It is formed through the
addition of a glucose sugar unit to the oligosaccharide chain of GM3 by GM2 synthase.
There is little direct evidence detailing the functions of GM2. It is thought to be involved in
the process of insulin resistance through interactions with insulin receptors, however, the
precise function of GM2 remains unclear (Higashi et al., 2011). GM2, like GM3, has also
been shown to play a role in oncogenesis. It has been suggested that GM2 plays a
protective role and that its depletion is correlated with greater cancer malignancy (Bisel et
al., 2014). Accumulations of GM2 have been observed in the brains of several pre-clinical
and clinical manifestations of neurodegenerative diseases such as AD and Hunter’s disease
(Bisel et al., 2014; Dufresne et al., 2017; Pernber, Blennow, Bogdanovic, Månsson, &
Blomqvist, 2012).
Studies of GM2 gangliosidosis, wherein an inherited genetic defect in the catabolic
enzyme βHex leads to an accumulation of GM2, have revealed important clues as to its role
in the brain. Patients with GM2 gangliosidoses are characterized by progressive
deterioration of motor, cerebral, and spinocerebellar function caused by a deficiency in
lysosomal enzyme βHex (Maegawa et al., 2007). β-Hex has two main gene variants, HexA,
and HexB. Genetic mutations of a specific gene variant lead to the development of unique
neuropathies. For example, mutation in the HexA gene variant leads to the development of
Tay Sachs disease, while mutations in both HexA and HexB lead to Sandhoff’s disease.
The infantile versions of GM2 gangliosidoses are the most severe, and generally result in
death during infancy. Late-onset forms include juvenile, sub-acute, adult, and chronic
subtypes with the severity and progression being correlated with the level of HexA activity
(Conzelmann & Sandhoff, 1983). Therefore, treatments aimed at increasing the activity of
HexA, and subsequently β-Hex activity, should lead to functional benefits. Pyrimethamine
(PYR), an anti-malarial compound, was found clinically to act as a pharmacological
chaperone that increases HexA levels, thereby decreasing GM2 levels and restoring
ganglioside homeostasis. PYR was administered to several human Tay Sachs and
Sandhoff’s disease cell lines which resulted in an increase of HexA levels (Maegawa et al.,
2007). In 2011, a phase I/II clinical trial of PYR in patients with Tay Sachs or Sandhoff’s
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disease showed a 4-fold increase in HexA levels and is currently moving forward to further
examine the clinical effects in patients (Clarke et al., 2011). These studies demonstrate the
efficacy of targeting the ganglioside metabolic pathway as a treatment for ganglioside
accumulation.
GM2 levels are transiently increased in response to neurodegenerative injuries such
as stroke and traumatic brain injuries (Whitehead et al., 2011; Woods et al., 2013). In a
crucial mechanistic study of a mouse model of fetal alcohol spectrum disorder, Saito et al.,
describe GM2’s potential role in neurodegeneration. Mice were subcutaneously injected
with ethanol on post-natal day 7, which led to a severe apoptotic neurodegenerative
response. GM2 levels were increased in the brain following ethanol injection and peaked at
24 hrs, followed by a decrease at 72 hrs, similar to the GM2 response after a
neurodegenerative injury. The authors examined the abundance of GM2, GM1, and GD1a
using HPTLC and found accumulation patterns which suggest GM2 may be a degradation
product of more complex species. GM2 accumulation was found to occur primarily in
lysosomes, mitochondrial membranes, and activated microglia, and also co-localized with
caspase-3 positive (apoptotic) neurons. The authors hypothesized, based on their results,
that GM2 was involved in mitochondrial-mediated apoptosis and increased in microglia
due to phagocytic functions, as GM2 staining in microglia partially overlapped with
staining for a late endosomal/lysosomal marker LAMP1 (Saito et al., 2013). Overall,
evidence from the literature suggests that GM2 accumulation is correlated with
neurodegeneration and apoptosis.

1.4.4

GM1

GM1, along with GD1a/b and GT1a/b make up the main gangliosides found in the brain.
GD1 and GT1 contain the same oligosaccharide units as GM1 but have additional sialic
acid residues. These additional sialic acids are susceptible to degradation from membranebound sialidase enzymes, however, GM1 is resistant to most forms of sialidase (Miyagi et
al., 1999; Sonnino et al., 2011). GM1 can be found throughout the CNS but has been
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reported to be particularly enriched in the white matter (Vajn, Viljetic, Degmecic, Schnaar,
& Heffer, 2013).
GM1 has numerous signaling and regulatory functions compared to other
ganglioside species (Ledeen & Wu, 2015). It is involved in the maintenance of lipid raft
integrity and modulation of calcium (Ca2⁺), sodium (Na⁺), and potassium (K⁺) ions across
the plasma membrane to maintain homeostasis and promote neurite outgrowth (Rodriguez,
Piddini, Hasegawa, Miyagi, & Dotti, 2001; Suzuki et al., 2007; Gusheng Wu, Lu, Andre,
Gabius, & Ledeen, 2016). Contrary to GM3’s anti-angiogenic properties, complex
gangliosides such as GM1 and GD1 are pro-angiogenic (Gullino, 2017; Margheri et al.,
2015; Ziche, Alessandri, & Gullino, 1989). GM1 can also promote neuritogenesis by
modulating the binding activity of several cell adhesion molecules including neural cell
adhesion molecule, N-cadherin, and laminin which promotes Ca²⁺ influx and tropomyosinrelated kinase A (TrkA) mediated activation of nerve growth receptors (Laitinen,
Leppiinen, Merenmies, & Rauvala, 1987; Ledeen & Wu, 2015; Mutoh, Tokuda, &
Miyadai, 1995; Walsh, Skaper, & Doherty, 1994). GM1 can further modulate neurotrophic
factors through association with trkB receptors to promote the release of brain-derived
neurotrophic factor (BDNF) and the Ret/GFRα complex to promote glial cell-line derived
neurotrophic factor (GDNF), which functions to preserve the viability of catecholaminergic
neurons (Pascual, Hidalgo-Figueroa, & Piruat, 2008; Pitto et al., 1998). Together, these
functions highlight the crucial neuroprotective role of GM1 in the brain.
GM1 began gaining interest as a therapeutic for neurodegeneration after exogenous
administration of mixed brain gangliosides were found to improve peripheral sympathetic
regeneration and re-innervation in cats (Ceccarelli, Aporti, & Finesso, 1976). Since then,
GM1 has demonstrated neuroprotective and restorative effects in a number of
neurodegenerative disease and injury models, as well as in human clinical trials (discussed
below). An important development in the use of GM1 as a therapeutic was the creation of
semisynthetic analogs of GM1 called lysogangliosides (LIGAs) which have identical
biological functions to GM1 but have demonstrated increased membrane permeability in
some cases (Kharlamov et al., 1994; Ledeen & Wu, 2015). While the oligosaccharide
domain and sphingosine moiety are identical in LIGAs to GM1, the fatty acid chain in the

20

ceramide domain is often modified to shorter versions to facilitate permeability across the
blood brain barrier and cellular membranes.
Although there is ample evidence supporting the protective role of GM1 in the
brain, an accumulation can be problematic as well, highlighting the importance of tight
homeostatic regulation. Similar to GM2 gangliosidosis, a genetic defect in the β-Gal
enzyme, which catabolizes GM1 to GM2, results in the accumulation of GM1 in the brain,
a condition termed GM1 gangliosidosis. GM1 gangliosidosis is characterized by
progressive psychomotor deterioration and seizures and has both a severe infantile version
and several late-onset forms. A GM1-mediated mechanism that is thought to contribute to
the symptoms of GM1 gangliosidosis is excessive neurite outgrowth leading to cellular
abnormalities such as “ectopic” growth of dendritic spines and neuro-axonal dystrophy
(Walkley, 2003). These structural abnormalities lead to impaired signal transduction.
Overall, there is ample evidence supporting the neuroprotective functions of GM1,
however, homeostasis appears to be a key factor in dictating its ability to carry out these
functions.

1.4.5

GD1a

GD1a is formed by the addition of a sialic acid residue to the terminal galactose unit of the
GM1 oligosaccharide chain by sialyltransferase. GD1a is highly abundant throughout the
brain but has been reported to be particularly enriched in the olfactory bulb, neocortex,
amygdala, substantia nigra, thalamic nuclei and in myelinated commissural fibers (Vajn et
al., 2013).
GD1a is an endogenous ligand for myelin associated glycoprotein, or MAG, a
ganglioside-binding protein expressed selectively on myelin membrane on axon surfaces
which functions to maintain the long-term integrity of axons and myelin (Pan et al., 2005;
Sheikh et al., 1999). MAG is known to be an inhibitor of axon outgrowth that can limit
recovery after CNS injury, therefore, increasing GD1a is associated with inhibition of axon
outgrowth and regeneration, a process which can be reversed through administration of
sialidase or GM1 (Rubovitch, Zilbe, Chapman, Schreiber, & Pick, 2017; H. J. Yang et al.,
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2011). Although increasing GD1a levels after CNS injury can inhibit regeneration, a
depletion of GD1a can also have deleterious effects on recovery as it is essential in
maintaining appropriate axon-myelin interactions and ensuring the long-term stability of
axons (Suzuki et al., 2007). It is important to note that not all MAG receptors bind GD1a,
therefore the degree of MAG modulation by GD1a may be brain region dependent
(Schnaar, 2010).
Ganglioside GD1a also been extensively studied in the field of Oncology and has
been shown to enhance VEGF induced cell proliferation and migration of endothelial cells
(Lang, Guerrera, Li, & Ladisch, 2001; Mukherjee et al., 2008). Additionally, it has been
observed to enhance epidermal growth factor (EGF) when upregulated in fibroblasts (Liu,
Li, & Ladisch, 2004). Anti-GD1a antibodies are significantly elevated in motor neuron
diseases and syndromes such as Guillain-Barre syndrome (GBS) and Amyotrophic lateral
sclerosis (ALS) (Ho et al., 1999; Kaji et al., 2000; Pestronk et al., 1989). Interestingly, antiGD1a antibodies were only found to be elevated in the axonal form of GBS and not the
demyelinating form, pointing to the important role of GD1a in axon stability (Ho et al.,
1999; Yuki, Yoshino, Sato, Shinozawa, & Miyatake, 1992).
Because of GD1a’s susceptibility to membrane-bound sialidase, one of its hypothesized
roles in the brain is to act as a reserve pool for GM1 (Riboni, Prinetti, Bassi, & Tettamanti,
1991). This has led many to believe that GD1a and GM1 act as one functional unit, in
conjunction with membrane-bound sialidase, to maintain GM1 levels in the brain (Ledeen
& Wu, 2015; Miyagi & Yamaguchi, 2012; Sonnino et al., 2011). Indeed, due to the many
important neuroprotective functions of GM1 and the inhibitory role of GD1a in recovery
from injury, the breakdown of GD1a on the membrane may be an essential neuroprotective
mechanism.

1.4.6

Gangliosides in neurodevelopment and aging

During pre-natal development, GM3 and GD3 are highly abundant in the brain (Yu, Tsai,
& Ariga, 2012). GD3 has been observed to be the major ganglioside in neural stem cells,
making up about 80% of the total ganglioside content (Nakatani, Yanagisawa, Suzuki, &

22

Yu, 2010). This finding suggests that the activity of GD3 synthase, which convert GM3 to
GD3, may be highly active during prenatal development. The tight regulation of
gangliosides during development support the hypothesis that the abundance of each species
is related to the unique functional roles they play during specific stages of development
(Yu et al., 2012). Elevated GM3 and GD3 levels are observed during neural tube formation
and neural cell differentiation (Yu, Nakatani, & Yanagisawa, 2009). GM3 has also been
observed to increase during cell contact formation (Hakomori, 2002). Studies in
mammalian brains have shown that GM1 and GD1 levels are low during the early phases
of neuron migration and mitosis but are rapidly upregulated during process outgrowth,
synaptogenesis, and myelination (Yu et al., 2009; Yu et al., 2012). Complex ganglioside
content increases in postnatal development leading to a shift from structurally simple
gangliosides to complex (Piccinini et al., 2010). Simple gangliosides GM3 and GM2 are
downregulated, while complex species GM1, GD1 and GT1 are upregulated (Ngamukote,
Yanagisawa, Ariga, Ando, & Yu, 2007; Yu, Macala, Taki, Weinfield, & Yu, 1988). This
shift is correlated with an increase in expression of ganglioside synthase genes (Ishii et al.,
2007). Mice lacking complex gangliosides through knock-out (KO) of GM1 synthase
develop progressive, age-dependent neurodegeneration, particularly with regards to axonmyelin interactions (Allende & Proia, 2002; Yao et al., 2014). A rare human disorder has
been identified which results in the congenital loss of function of GM3 synthase, and thus,
of all gangliosides. The disorder is characterized by severe neuromuscular and cognitive
impairments, blindness, and seizures (Simpson et al., 2004; Vajn et al., 2013). These
findings point to the important role of complex gangliosides in maintaining the functional
integrity of nervous tissues in the developed brain.
During aging, the physical and chemical properties of the membrane are altered
resulting in a shift in the balance and/or changed ratios of many lipid species, including
gangliosides (Ariga, McDonald, & Yu, 2008). Barrier et al., 2007 used HPTLC to examine
ganglioside changes during aging in the cortex of mice and found an increase in GM3
between 12 and 24 months, a decrease in GM2 between 6 and 24 months, and a minor
decrease in GD1a between 3 and 6 months (Barrier et al., 2007). Total ganglioside content
has been reported to decrease with age (Aydin, Cengiz, Ag, & Han, 2000; Ohsawa &
Shumiya, 1991). Interestingly, an increase in simple ganglioside GM3 has been found to be
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correlated with cell senescence in vitro (Patschan et al., 2008), a finding which was
recapitulated in a senescence-accelerated mouse model. Oshawa & Shumiya used
senescence-accelerated mice (SAM-P/8), which show earlier onset of irreversible
advancement of senescence, shorter life span, age-related deterioration in learning abilities,
and spongi-form degeneration, and found that they had decreased levels of complex
gangliosides GD1 and GT1 along with a progressive increase in GM3 levels compared to
control mice, as measured by HPTLC (Ohsawa & Shumiya, 1991). These studies indicate
that ganglioside dysregulation, resulting in the depletion of complex gangliosides and the
accumulation of GM3, may occur during the natural aging process.
Interestingly, the ceramide moiety has also been shown to be altered during aging.
Sugiura et al., found an increase in the proportion of d20:1 species of GD1 compared to
d18:1 species in the molecular layer of the mouse hippocampus during aging (Sugiura,
Shimma, Konishi, Yamada, & Setou, 2008). Indeed, previous evidence has also suggested
that the accumulation of 20 carbon species of complex gangliosides is correlated with aging
(Mansson, Vanier, & Svennerholm, 1977; Palestini, Masserini, Sonnino, & Tettamanti,
1990; Palestini, Masserini, Fiorilli, Calappi & Tettamanti, 1993). These studies also
provide evidence that significant anatomical heterogeneity in the age-dependent
accumulation of d20:1 species may be present, however, a comprehensive examination of
these species across the brain during aging has yet to be completed.

1.4.7

Gangliosides in stroke

Ganglioside dysregulation has been observed in the murine brain following
neurodegenerative injuries such as stroke and traumatic brain injuries (TBI). Following
TBI, mice were found to have significant increases in simple ganglioside GM2 in
periventricular, hippocampal, and thalamic brain regions 2 hrs after injury which peaked at
24 hr then returned to control levels by 72 hrs (Woods et al., 2013). A similar transient
increase of simple gangliosides was observed in response to stroke damage. Whitehead et
al., examined the abundance and distribution of both complex and simple gangliosides in a
mouse model of MCAO ischemic stroke. Following MCAO, a significant increase in GM2
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and GM3 species were observed in the ipsilateral hemisphere 3 d post-stroke, which
peaked at 7 d then returned to control levels by 14 d (Whitehead et al., 2011). The authors
further demonstrated that the degree of simple ganglioside accumulation varied depending
on the anatomical brain region, with the striatum and hippocampus showing a more severe
accumulation than the cerebral cortex. Taken together, these studies provide evidence that
simple ganglioside accumulation may be involved in neurodegeneration after injury and
that certain brain regions may be more susceptible than others to dysregulation.
Increasing GM1 levels has been examined as a potential treatment for stroke due to
its neurotrophic and pro-angiogenic properties and was found to be effective in reducing
stroke-induced pathology both pre-clinically and in human patients. Several functions of
GM1 have been described as being particularly important in protecting neural cells from
the damage caused by the ischemic cascade including: 1) protecting against excitotoxicity
by regulating Ca²⁺ influx into the cell (Wu & Ledeen, 1994; Zhang et al., 2015), 2)
protecting cellular membranes by maintaining ion balance (Na⁺- K⁺) and reducing edema in
neurons (Karpiak, Li, & Mahadik, 1987); 3) inhibiting nitric oxide production, lipid
peroxidation, excessive activation of glutamate receptors, excitatory amino acids, and free
radical production (Avrova et al., 1998; Carolei, Fieschi, & Bruno, 1991); 4) improving
survival of neurons by increasing blood flow and axonal growth (Rabin, Bachis, &
Mocchetti, 2002; Rong, Zhou, Xiao-Wen, Tao, & Tang, 2013); and 5) enhancing
neurotrophic activity to strengthen neural remodeling and promote recovery after injury
(Ferrari & Greene, 1996; Marconi et al., 2005). Another mechanism in which GM1 is
thought to confer neuroprotection through inhibition of autophagy. Li et al., administered
GM1 to rats for 3 consecutive days following MCAO and found that a dose of 50 mg/kg
was associated with a decrease in infarct volume and increased neuro-behavioural scores.
The authors found that GM1 treatment after MCAO led to a decrease in autophagy markers
Beclin-1 and LC3-II, suggesting that GM1 may exert a neuroprotective effect through
inhibition of excessive autophagy that would otherwise lead to cell death. Administration
of tat-Beclin-1 to increase autophagy after MCAO in addition to GM1 treatment abolished
in the protective effects of GM1 on infarct size and neuro-behavioural deficits, further
supporting the existence of a neuroprotective GM1-mediated mechanism of autophagy
inhibition (Li, Tian, Long, Chen, & Lu, 2016).
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GM1 is a major component in cerebral white matter and increasing GM1 levels has
been shown to reduce damage to white matter regions after a hypoxic injury. Rong et al.,
used a neonatal rat model of hypoxia-induced white matter damage to show that GM1
treatment for 5 consecutive days reduced structural damage in the brain (edema, apoptosis,
and necrosis around the ventricles), protected against white matter damage (increased
myelin basic protein staining while also decreasing APP and GFAP staining), and reduced
behavioural impairments (Rong et al., 2013).
Despite very promising evidence of a potential GM1-derived treatment for stroke in
pre-clinical models, results of human clinical trials have demonstrated mixed results.
Several human clinical trials failed to demonstrate a significant therapeutic benefit of GM1
treatment in stroke patients (Braune, 1991; Candelise, 2002; Hoffbrand, Bungley,
Oppenheimer, & Sheldon, 1988), while others have shown that significant neurological and
pathological improvements were associated with the treatment (Argentino et al., 1989;
Bassi, Albizzati, Sbacchi, Frattola, & Massarotti, 1984). More studies are needed which
examine the role of ganglioside dysregulation in stroke to address the controversial
findings of these studies.

1.4.8

Gangliosides in neurodegenerative diseases: Parkinson’s disease,
Huntington’s disease, Prion diseases

The accumulation of GM3 and GM2 has been described as characteristic of diseased
neurons (Walkley, 2003). Indeed, it is considered a central feature of diseases such as
Niemann-Pick type C, Gaucher’s disease, and Hunter’s disease (Kreutz et al., 2013;
Dufresne et al., 2017). Ganglioside dysregulation has also been reported in a number of
neurodegenerative diseases including Parkinson’s disease (PD), Huntington’s disease
(HD), Prion diseases, and AD. In each case, despite the varying mechanisms involved, a
depletion of complex gangliosides in the brain is observed which is often accompanied by a
concomitant increase in simple species. Ganglioside dysregulation has been linked to the
abnormal aggregation of proteins that is a central hallmark of the aforementioned
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neurodegenerative conditions: α-synuclein in PD, Huntington in HD, Prion protein in
Creutzfeldt-Jakob disease, and Aβ in AD.
PD is characterized by the progressive loss of dopaminergic neurons in the
substantia nigra pars compacta leading to impairments in motor function (Sulzer &
Surmeier, 2013). Human patients were found to have a depletion of GM1 in the occipital
cortex, an area that is generally thought to not be largely affected in the disease, as
compared to age-matched controls, which the authors suggest could be indicative of a
systemic deficit of GM1 (Wu, Lu, Kulkarni, & Ledeen, 2012). This was associated with
lower levels of phosphorylation of proteins in glial cell line-derived neurotrophic factor
(GDNF) receptors of nigral neurons, which are critical for the survival of
catecholaminergic neurons. These findings were recapitulated by the same group in a
mouse model lacking complex gangliosides which developed symptoms reminiscent of
human PD patients including motor impairments, depletion of striatal dopamine, and
aggregation of α-synuclein protein (Gusheng Wu et al., 2012). GDNF Signaling could be
restored using the semisynthetic GM1 analog LIGA20 (Hadaczek et al., 2015; Gusheng
Wu et al., 2012). Indeed, increasing GM1 levels in the brain through exogenous
administration has shown great promise in pre-clinical PD mouse and primate models,
which eventually led to human clinical trials (Herrero, Perez-Otan, Oset, Kastner, &
Hirsch, 1993; Pope‐Coleman, Tinker, & Schneider, 2000; Schneider, Kean, & DiStefano,
1995).
Ganglioside dysregulation in HD is characterized not only by a depletion of
complex species but also by an increase in GD3. Simple ganglioside GD3 has, similar to
GM3, been linked to toxicity through stimulation of reactive oxygen species, leading to
apoptosis (Scorrano, Petronilli, Lisa, & Bernardi, 1999), and has been implicated as a
mechanism of neurodegeneration in HD (Desplats et al., 2007). Desplats et al., 2007, used
microarray analysis, qPCR, and Western blot to examine changes in lipid gene expression
in a Tg mouse model of HD as well as human caudate post-mortem samples. The authors
found a 38% reduction in GM1 content in the Tg HD mice as compared to Wt along with a
significant upregulation the St8sial gene, which encodes GD3 synthase, in the caudate of
human HD patients (Desplats et al., 2007). Di Pardo et al., examined two different models
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of HD mice (YAC128 and R6/2) and found that both Tg mouse models had significant
deficiencies in complex gangliosides GM1, GD1a, and GT1b in the corpus callosum.
Importantly, the authors found that these changes in gangliosides could be detected in the
early stages of the disease. Taken together, these results suggest that ganglioside
dysregulation may play a mechanistic role in the development of neurodegenerative
diseases, such as HD, and that the white matter may be particularly susceptible to damage
(Di Pardo, Amico, & Maglione, 2016).
Prion diseases, or spongiform encephalopathies, such as Creukfeldt-Jakob’s disease
(CJD), are characterized by a shift in complex and simple gangliosides. In a guinea pig
model of CJD, a marked decrease in total ganglioside content was observed in brain
regions highly affected by the disease such as the cerebral cortex, basal ganglia and
thalamus, and brain stem. When the abundance of each individual ganglioside species in
the brain was quantified using TLC, an increase in simple gangliosides GM3, GD3, and
GD2 were observed along with a decrease in GM1, GD1a, GD1b, and GT1b (Yu &
Manuelidis, 1978). In human CJD patients, a similar trend is observed but with a more
severe depletion of multisialylated complex species GD1a, GD1b, and GT1b along with a
particularly high accumulation of simple ganglioside GD3 (Ando, Toyoda, Nagai, & Ikuta,
1984; Ohtani, Tamai, Ohnuki, & Miura, 1996; Tamai et al., 1979). Di Martino et al., found
a similar shift in complex and simple gangliosides in a Scrapie-infected hamsters, another
type of prion disease (Martino, Safar, Callegaro, Salem, & Gibbs, 1993). Overall
ganglioside content is reduced in the brains of patients with neurodegenerative diseases,
potentially owing to a shift in ganglioside content leading to neuronal loss in affected
regions (Desplats et al., 2007).

1.4.9

Gangliosides in neurodegenerative diseases: Alzheimer’s disease

The role of gangliosides in AD remains unclear as a number of studies point to seemingly
contradictory results. For example, while there is a large amount of evidence implicating
GM1 as major driver of toxic Aβ accumulation in the brain, there is also evidence
demonstrating that GM1 acts in a protective manner against AD pathology (Fantini, Yahi,
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& Garmy, 2013; Grimm et al., 2012; Kreutz et al., 2013; Yanagisawa, Odaka, Suzuki, &
Ihara, 1995; Yang et al., 2013). Regardless of the precise function, ganglioside
dysregulation has been identified as a hallmark of the disease (Ariga et al., 2008).
Proteolytic processing of APP is influenced by the lipid composition of cellular
membranes, with gangliosides having an important role in interacting with Aβ in
membrane rafts (Wolozin, 2004). In particular, gangliosides GM3 and GM1 have a high
affinity for interaction with Aβ. Cholesterol has been shown to promote the binding of Aβ
to GM1 enriched rafts to form what is termed ganglioside-bound Aβ (GAβ), a structure
hypothesized to act as a seed for toxic Aβ fibrilogenesis (Ariga et al., 2008; Fantini, Yahi,
& Garmy, 2013; Yanagisawa, Odaka, Suzuki, & Ihara, 1995). Several studies have
reported that the formation of GAβ can induce conformational changes in Aβ from a
random coiled structure to an ordered structure rich in β sheets when environmental factors,
such as the pH, are favourable (Choo-Smith, Garzon-Rodriguez, Glabe, & Surewicz, 1997;
Matsuzaki, Kato, & Yanagisawa, 2010; Mclaurin & Chakrabartty, 1996, 1997). This
process is thought to occur mostly in early endosomes and leads to increased aggregation
of Aβ in the brain (Kimura & Yanagisawa, 2007; Yamamoto, Nostrand, & Yanagisawa,
2006; Yanagisawa et al., 1995). Toxic Aβ fibrillation has also been shown to be amplified
through binding with GM3 enriched lipid rafts, leading to further dysregulation of
ganglioside activity. In a study by Grimm et al., Aβ binding to GM3 led to a reduction in
the activity of GD3 synthase, and thus decreased turnover from a to b-series gangliosides
(Grimm et al., 2012)
Human AD patients, similar to patients with other neurodegenerative diseases,
show a significant decrease in total ganglioside content as compared to controls which is
suggested to be related to the loss of the more abundant complex gangliosides (Molandermelin, Blennow, Bogdanovic, Dellheden, & Fredman, 2005; Svennerholm & Gottfries,
1994). The degree and location of ganglioside loss varies depending on the time of onset,
with early onset, or familial AD patients having demonstrated a 58-70% decrease compared
to controls in grey matter regions and 81% in frontal white matter, while late-onset patients
appeared to show severe depletions only in the temporal lobe, hippocampus, and frontal
white matter (Ariga et al., 2008; Svennerholm & Gottfries, 1994). Accumulations of simple
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gangliosides GM2 and GM3 have also been observed in brain regions highly susceptible to
neurodegeneration in AD. In a study by Kracun et al., gangliosides were found to be
perturbed in early-onset AD patients such that there was a decrease in complex
gangliosides GM1 and GD1a in the frontal and temporal cortices of the brain. These same
regions were found to have a significant increase in simple gangliosides GM3 and GM2
compared to control brains (Kracun, Kalanj, Talan-hranilovic, & Cosovic, 1992). Gottfries
et al., found a similar ganglioside distribution pattern in the brains of early-onset AD
patients (Gottfries, Jungbjer, Karlsson, & Svennerholm, 1996). Significant accumulations
of GM3 were observed in the entorhinal cortex of late-onset AD patients, a brain region
particularly susceptible to neurodegeneration in AD (Chan et al., 2012). These results point
to the possibility of ganglioside degradation as a mechanism of pathology in AD brains.
Indeed, Pitto et al., observed an upregulation of the GM1 catabolic enzyme β-Gal in
cultured fibroblasts from AD patients compared to controls, leading to the accumulation of
simple gangliosides GM2 and GM3 (Pitto et al., 2005). Overall, the severe depletion of
complex gangliosides and accumulation of simple gangliosides in brain regions which are
highly susceptible to neurodegeneration are consistent with the neuronal loss and
cortical/hippocampal thinning considered the pathological hallmarks of the disease (Ariga
et al., 2008).
Understanding the role of ganglioside dysregulation in AD may not be as
straightforward as a simple shift in the homeostatic distribution, rather, the unique
functional properties of each species may lead to specific interactions with certain types of
Aβ that are more or less favorable depending on various environmental factors. Pre-clinical
animal models of AD have revealed important mechanistic information on the interaction
of gangliosides with Aβ and specific mutations of various genes involved in the
pathogenesis of human AD. Yamamoto et al., showed that different species of gangliosides
reacted to specific types of hereditary Aβ and led to their accumulation. For example, the
authors report that GM1 interacted with the Arctic variant of Aβ, GD3 with the Flemish Aβ
variant, and GM3 with the Dutch and Italian Aβ variants. Interestingly, GM3, and GM2 to
a lesser extent, were found to be the major gangliosides in human cerebrovascular smooth
muscle cells, which the authors suggest may contribute to the accumulation of the Dutch
Aβ variant in vascular walls. The authors further proposed that this differential interaction
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of gangliosides with various hereditary variants of Aβ may contribute to the region-specific
deposition of Aβ fibrils in the brain (Yamamoto, Hirabayashi, Amari, & Yamaguchi,
2005). A follow up study by the same group used a Tg mouse model of AD with double
Swedish/London mutations of the APP gene in addition to a knock out of the GM2
synthase gene, resulting in the accumulation of GM3 and a reduction in complex
gangliosides. The authors found that the Tg KO mice developed a severe dyshoric-form
amyloid angiopathy in which amyloid deposition extended from blood vessel walls into the
surrounding parenchyma and suggests, according to the authors, an important role of GM3
in the development of vascular Aβ pathology in the brain (Oikawa et al., 2009). Barrier et
al., examined several transgenic mouse models of AD and found that the degree and type of
ganglioside perturbation observed was associated with the specific genetic modifications of
the mice. Transgenic APP mice with Swedish and London mutations (APPSL) showed a
significant decrease in all b-series gangliosides within the cortex at 24 m along with a 2-3
fold increase in simple a-series gangliosides GM2 and GM3 compared to controls. Double
transgenic mice with APPSL and PS1 mutations showed a slightly different pattern at 24
m, with a less severe depletion of complex a and b-series gangliosides and an accumulation
of simple ganglioside GD3. However, like the APPSL only mice, the APPSL/PS1 mice
showed a significant increase in simple gangliosides GM3 and GM2 compared to agematched controls. In the double Tg APPSL/PS1 mice, an accumulation of simple
gangliosides could be observed as early as 3 m, which, the authors suggest, implicates
ganglioside dysregulation as an early driver of pathology in AD (Barrier et al., 2007). Thus,
ganglioside dysregulation resulting in the accumulation of toxic simple gangliosides along
with a depletion of protective complex gangliosides is region-specific and is linked to the
proteolytic processing of Aβ, making the restoration of ganglioside homeostasis a
potentially critical point of intervention.
The ceramide domain of gangliosides may also play an important role in the
development and progression of AD as ceramides with longer carbon chains have not only
be observed to increase during the natural aging process, but also accumulate in brain
regions susceptible to neurodegeneration in AD. Cutler et al., examined the distribution of
several lipids in normal aging human subjects and AD patients. Long chain ceramides
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(d24:1) were not only found to accumulate during normal aging in control subjects, but
showed a significant increase in the middle frontal gyrus of AD patients compared to
controls, an area highly susceptible to neurodegeneration. Examination of long chain
ceramide levels in the cerebellum of AD patients, an area generally spared from
neurodegenerative damage, showed no such increase in long chain ceramides, indicating
that there are regional differences in long chain ceramide accumulation that may be
correlated to neurodegeneration in AD. Additionally, the degree of accumulation of long
chain ceramides was found to be correlated with the severity of AD pathology. The authors
further examined the interaction of long chain ceramides with Aβ in hippocampal neurons
and saw an increase in long chain ceramides in response to the exogenous administration of
Aβ1-42. The increase in long chain ceramides was correlated with an increase in oxidative
stress, as measured by lipid peroxidation product 4-hydroxynenonal (HNE), further
supporting the possibility of mechanistic interaction between long chain ceramides and
neurodegeneration (Cutler et al., 2004). Overall, the accumulation of these ganglioside
species represents a potential mechanism of toxicity in the AD brain and is worthy of
further investigation.
Restoring ganglioside homeostasis in the early and later stages of AD progression is
gaining interest as a therapeutic intervention for AD. Contrary to the hypothesized
pathological role of GM1 in toxic Aβ fibril formation, exogenously administered GM1 has
demonstrated therapeutic benefits both pre-clinically and clinically in AD. GM1
administration in the presence of Aβ1-40 or Aβ1-42 injected into the ventricles of rats led
to reduced memory impairments on the novel object recognition (NOR) task and Morris
water maze and was associated with a decrease in oxidative stress and the maintenance of
K⁺-Na⁺ ATPase activity (Kreutz et al., 2013; Yang et al., 2013). In a human clinical trial,
several AD patients were treated with GM1 through continual ventricular injections for a
period of 12 m. The progression of neural deterioration ceased in treated patients while
increases in cerebral blood flow were observed. GM1-treated patients showed
improvements in motor skills and cognitive performance in reading, writing, and
comprehension (Svennerholm et al., 2002). These studies highlight the potential therapeutic
interactions of GM1 in AD. Treatments targeting the accumulation of simple gangliosides
have also demonstrated promise in pre-clinical models of AD. When Dutch APP mice were
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treated with a small molecule pharmacological chaperone that increases the activity of βHex, resulting in a decrease of GM2 levels, anxiety was reduced and learning behaviours
improved on the novel object recognition task (NOR) which was associated with a
reduction in GAβ in the subiculum and perirhinal cortex (Knight et al., 2014). Thus,
targeting ganglioside dysregulation has shown therapeutic benefits in AD models and is
worthy of further investigation.

1.5 Chloroquine
The ideal intervention for the prevention of ganglioside dysregulation in the brain would
block both the degradation of protective complex gangliosides and the accumulation of
toxic simple gangliosides in the brain. While there is currently no known compound which
can selectively accomplish this task, it is possible to transiently block lysosomal activity,
thus disrupting ganglioside catabolism. N-(7-chloroquinolin-4-yl)-N,N-diethyl-pentane1,4-diamine, or Chloroquine (CQ), is best known as an anti-malarial agent.
Pharmacologically, CQ is a weak base leading to its accumulation in acidic cellular
organelles, such as lysosomes. The accumulation of CQ in lysosomes leads to an increase
in vacuolar pH and the subsequent disruption of acidic lysosomal enzymes (Poole &
Ohkuma, 1981; Wang et al., 2016). CQ is characterized by its ability to inhibit autophagy,
act as an anti-inflammatory agent, and alter lipid composition through disruption of
metabolic enzymes.
The autophagy-blocking properties of CQ have demonstrated utility as a therapeutic
agent in oncology, revealing another important function of the compound. CQ can improve
sensitivity of tumours to chemotherapy and prevent metastasis (Zhang et al., 2015). One
mechanism with which it has been shown to exert these effects is through stabilization and
normalization of tumor vasculature by modulating Notch-1 activity, pointing to its vasculoprotective properties (Maes et al., 2014). Indeed, systemically-administered CQ has
demonstrated a neuroprotective effect against damage to the blood brain barrier in mice
(Mielke, Murphy, Maritz, Bengualid, & Ivy, 1997). These protective effects of CQ on the
vasculature may be particularly useful as a therapeutic for vascular injuries, such as strokes.
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The anti-inflammatory properties of CQ garnered interest in the compound as a
therapeutic for inflammatory disorders including rheumatoid arthritis. A series of human
clinical trials led to the conclusion that CQ acts as an effective anti-rheumatic compound in
roughly 90% of patients, although treatment was most effective when paired with
immunosuppressive medications (Ferraz et al., 1994; Freedman & Steinberg, 1960; Popert,
Meijers, Sharp, & Bier, 1961).

Pathological inflammation is also a hallmark of the

ischemic cascade and CQ has been shown to downregulate pro-inflammatory cytokines and
mediate inflammatory responses through inhibition of toll-like receptor (TLR)-3 after
stroke (Cui et al., 2013). CQ further confers protection after a neurodegenerative injury by
reducing ROS and inhibiting autophagy (Hirata et al., 2011). The inhibition of autophagy,
as previously mentioned, is of particular relevance to stroke therapies due to prolonged
environmental stressors which can promote the over-activation of autophagy pathways,
leading to cell death (Li, Tian, Long, Chen, & Lu, 2016). Thus, CQ has a number of
neuroprotective effects that make it a promising therapeutic intervention for strokes.
CQ also exhibits a strong interaction with lipids (Pfau et al., 1997) and has been
used to inhibit the degradation of gangliosides both in vitro and in vivo, leading to the
accumulation of complex gangliosides (Marchesini, Benaglia, Piccinotti, Bresciani, &
Preti, 1998; Pfau et al., 1997). CQ disrupts the activity of lysosomal enzymes β-Gal and βHex leading to an increase in GM1 levels and a decrease in GM1 degradation products
GM2 and GM3 (Riboni, Caminiti, Bassi, & Tettamanti, 1995; Yuyama, Yamamoto, &
Yanagisawa, 2006). Pfau et al., administered a low dose of CQ both pre-natally and postnatally in rat pups in order to examine intrauterine effects of CQ on dendritic maturation in
the hippocampus and found that CQ increased GM1 and decreased GM3 levels in pre-natal
rats with an increase in GM1 levels also observed post-natally. Low dose CQ resulted in a
significant elongation of apical and basilar dendrites of CA3 neurons and early formation
of dendridic spines in the CA1 region of the hippocampus, however, the functional
consequences of this altered dendridic architecture remains unclear (Pfau et al., 1997).
Overall, CQ’s ability to transiently block the degradation of complex gangliosides makes it
a useful tool to examine the potential therapeutic benefits of preventing ganglioside
dysregulation in stroke and AD.
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1.6 MALDI IMS
Mass spectrometry (MS) is an analytical technique that detects the mass-to-charge ratio
(m/z) of ionized molecules (Zaima, Hayasaka, Goto-Inoue, & Setou, 2010). The imaging
component of MS technologies is a fairly recent development and has opened the door to
previously unattainable spatial distribution information. This is particularly true in the area
of lipidomics, where visualization of lipids in tissue sections previously relied upon
techniques such as Immunohistochemistry (IHC). These techniques are especially
problematic where membrane lipids are concerned due to their hydrophobic core being
embedded within the plasma membrane and thus inaccessible for antibody-epitope binding.
Antibodies for the various ganglioside species, if they exist, can only differentiate between
ganglioside species based on their hydrophilic oligosaccharide domain. While this
information may provide a general idea of ganglioside distribution patterns, it lacks the
required specificity to reach meaningful biological conclusions on its own. Alternatively,
ganglioside expression has been quantified using thin layer chromatography techniques,
however these techniques require homogenization of tissue samples for lipid extraction
which can be problematic when examining ganglioside distribution in discrete brain
regions.
There are three main ionization platforms which can be paired with an imaging
modality for imaging MS experiments, each with its own advantages and disadvantages
(Barceló-coblijn

&

Fernández,

2015;

Chaurand,

2012):

Matrix-Assisted

Laser

Desorption/Ionization (MALDI) uses a laser to ablate laser-absorbing matrix-coated
samples under vacuum to achieve ionization of intact analytes of a wide molecular weight
range from metabolites to proteins, Secondary Ion Mass Spectrometry (SIMS) uses a
primary ion beam to sputter the surface of the sample then collects and analyses secondary
ions, producing primarily fragmented ions in most cases (Guerquin-Kern, Wu, Quintana, &
Croisy, 2005), Desorption Electrospray Ionization (DESI) requires minimal sample
preparation and takes place under atmospheric pressure but has diminished sensitivity for
larger molecular weight analytes (Wiseman & Laughlin, 2005). Adaptations and evolution
in technologies are leading to increasing variations and complementary pairings in
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ionization sources to maximize the specific advantages of each and customize the
technology to suit the desired experimental paradigm (Monroe et al., 2008; Trimpin &
Deinzer, 2007; Zhang, Wang, Liu, Han, & Xiong, 2016). Most importantly, IMS
technology is capable of simultaneously detecting and imaging the ionic distribution of
numerous molecules in a label-free manner from a variety of biological samples such as
animal and human tissues, plants, and bacteria. MALDI IMS can detect a wide range of
molecules, from very small molecules (m/z < 1000) to large molecules (m/z > 100 kDa),
making it very versatile in experimental applications (Svatos, 2010; Yates, 1998; Zaima et
al., 2010). Because the mass range of a-series gangliosides falls within an m/z of 1000 –
2500 and high spatial resolution is required to examine discrete brain structures, MALDI
IMS provides the ideal imaging platform for the detection and visualization of gangliosides
in the brain.
Sample preparation, including tissue freezing, sectioning, matrix selection, and
method of matrix deposition all play a critical role in determining the quality of MALDI
IMS data (Chaurand, 2012). It is preferable that samples for MALDI IMS remain
chemically unmodified for analysis, which is why flash freezing, using either dry ice or
liquid nitrogen, are generally used during sample preparation as opposed to chemical
fixation. Further, chemical fixation using formaldehyde is generally avoided due to crosslinking of proteins which can disrupt and/or distort MALDI data (Zaima et al., 2010).
Ionization efficiency, which refers to the number of ions generated relative to the total
number of molecules consumed, is a critical factor to consider during sample preparation
and is influenced by the thickness of the tissue section (Murray et al., 2013; Sugiura,
Shimma & Setou, 2006). Molecules with a lower molecular weight can be imaged from
sections between 5 – 20 μm thick while it is recommended that thinner sections (2 – 5 μm)
be used for molecules with a higher molecular weight (Zaima et al., 2010).
MALDI IMS requires the coating of a matrix to facilitate ionization of analytes in
the sample. The matrix can have several important roles in MALDI IMS depending on the
solvent system used including: 1) extraction of molecules from the sample based on their
chemical properties, 2) absorbing laser energy and transferring of the energy to analyte
molecules, and 3) influencing spatial imaging resolution. Homogenous deposition of the
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matrix on the sample and minimization of analyte delocalization during matrix deposition
are crucial for achieving high spatial resolution. Gangliosides have a negative charge due
the sialic acid residues on their structure, which means they are primarily imaged in
negative polarity ion mode when analyzed via MALDI IMS. This negative charge also
influences the types of matrices that will be used during sample preparation, as some
matrix-solvent mixtures have a greater affinity for extracting negatively charged lipids than
others (Thomas, Charbonneau, Fournaise, & Chaurand, 2012). The method of matrix
deposition is a factor which is particularly important when imaging lipids, such as
gangliosides. While wet matrix application techniques, wherein a solvent is used to
dissolve a powdered matrix, are most common, they present an increased likelihood of
large crystals forming on the surface of the sample as well as an increased risk of molecular
delocalization, both of which can greatly reduce detection and imaging quality. Dry matrix
application techniques, such as sublimation, can circumvent these limitations. Additional
factors such as solvent rinses and incubation times may also lead to improvement in
ganglioside signals at the expense of possible analyte delocalization (Angel, Spraggins,
Baldwin, & Caprioli, 2012; Appendix 1).
Once in the MALDI MS instrument, MS spectra are acquired through a series of
repetitive laser pulses at predefined x-y coordinates. Broadly, the sample surface is
irradiated using laser energy wherein protonation or deprotonation of molecules leads to
the formation of either positively or negatively charge ions. Time-of-flight (TOF) analyzers
are most common for MALDI IMS applications and allow ions to separate based on their
m/z ratio (Dreisewerd, 2003; Zaima et al, 2010). The ions are finally quantified by a
detector and MALDI MS data is then represented as peaks on a mass spectrum that
indicates the relative abundance of each ion within the sample. This analytical data is
accompanied by a “molecular map” of the ionic distribution of each peak across the intact
tissue section formed by the numerous laser acquisition points. Because of the variability
that is inherent in the sample preparation process and run-to-run variation related to
ionization efficiency and background matrix suppression, MALDI IMS is considered a
semi-quantitative technique. Various normalization and statistical approaches can be
implemented to reduce errors caused by between-scan variability in order to pool data from
multiple imaging experiments.
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MALDI IMS has already been used to address various fundamental questions
regarding the localization and biological role of gangliosides in the brain, including in preclinical models of neurodegenerative disease and injury (Colsch, Jackson, Dutta, & Woods,
2011; Dufresne et al., 2017; Hirano-Sakamaki et al., 2015; Whitehead et al., 2011; Woods
et al., 2013). For example, recent evidence using a combination of MALDI IMS and IHC
examined ganglioside distribution in a Tg mouse model of AD. Tg Arc/Sw mice, which
develop Aβ plaques, contained significantly increased levels of simple gangliosides GM2
d18:1 and GM3 d18:1 and d20:1, but not GM1 in cortical and hippocampal Aβ plaques
(Kaya et al., 2017). The authors suggest that this increase in simple gangliosides are likely
a result of complex ganglioside degradation or inhibition of lysosomal storage and
degradation. Because of the semi-quantitative nature of MALDI IMS, pairing the technique
with another form of ganglioside detection has become common and can aide in
interpreting findings (Jones et al., 2017; Kaya et al., 2017).

1.7 Rationale and objectives
Gangliosides belong to a large family of glycosphingolipids enriched in the CNS that have
important regulatory functions on the cell plasma membrane. Their abundance is tightly
regulated by lysosomal enzymes in order for each species to carry out their unique
functions (Yamamoto et al., 1996; Yu, Nakatani, & Yanagisawa, 2009). Alterations in
ganglioside homeostasis is hypothesized to play an important role in the pathogenesis of
neurodegenerative diseases and injuries (Ariga et al., 2013; Cutler et al., 2004; Whitehead
et al., 2011; Woods et al., 2013), however, the nature of the relationship between
neurodegeneration and ganglioside dysregulation remains unclear.
Novel imaging technologies, such as MALDI IMS, can be used to examine the
distribution and abundance of gangliosides with greater sensitivity and specificity than
traditional lipid imaging techniques, making it the ideal tool for a comprehensive and
detailed analysis of a-series gangliosides in the brain.
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The overarching hypothesis of these studies was that ganglioside dysregulation
occurs in the aging brain and in response to neurodegenerative injuries and that restoring
ganglioside homeostasis will result in functional benefits after injury in rats.
The main objectives of this study were: 1) Examine ganglioside dysregulation in
response to neurodegenerative injuries of varying severity to determine if specific patterns
of alteration are associated with the neurodegenerative response (Chapter 2); 2) Examine
changes in the ganglioside long chain base throughout the brain during aging in a-series
gangliosides (Chapter 3); 3) Determine if a-series gangliosides are altered differently in the
normal aging rat brain versus a rat model of prodromal AD to identify specific patterns of
dysregulation which may be tied to the development of neurodegeneration in the aging
brain (Chapter 4) and; 4) Examine the potential pathological and functional benefits
associated with preventing ganglioside dysregulation after stroke (Chapter 5).
In Chapter 2, the degree of toxic simple ganglioside accumulation was found to be
correlated with the severity of the neurodegenerative insult, with the d20:1 species often
showing a more severe alteration in response to the injury than the d18:1 species. Little is
known on the role of d20:1 versus d18:1 species of gangliosides, however, the d20:1
species are hypothesized to accumulate in an age-dependent manner relative to the d18:1.
In chapter 3, the ratio of d20:1 to d18:1 species of A-series gangliosides was examined
during aging in Fischer rats. Interestingly, only complex gangliosides were observed to
have an age-dependent increased in the d20:1/d18:1 ratio whereas this ratio decreased for
simple gangliosides across the brain, with the exception of white matter regions. In chapter
4, A-series gangliosides were examined individually in Wt and Tg APP rats in order to
better understand the age-dependent alterations of simple and complex gangliosides during
normal aging and in the prodromal stages of AD. Interestingly, an age-dependent depletion
of complex ganglioside GD1 d18:1 was observed in the white matter of the brain.
Additionally, Tg APP21 rats were found to have increased levels of toxic ganglioside
species GM2 and GM3 than their Wt counterparts, pointing to a toxic pattern of
ganglioside dysregulation in Tg APP rats. Finally, in chapter 5, an intervention using a
pharmacological compound (chloroquine) aimed at preventing ganglioside dysregulation
was examined after a severe stroke injury. Restoration of ganglioside homeostasis after
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stroke was associated with reduced motor and cognitive impairment in Wistar rats. This
work highlights the important role of ganglioside dysregulation in the rat brain during
aging and neurodegeneration and the therapeutic benefits associated with maintaining
ganglioside homeostasis after stroke injury.
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Chapter 2 : Increased expression of simple ganglioside species GM2
and GM3 detected by MALDI Imaging mass spectrometry in a
combined rat model of Aβ toxicity and stroke

2.1 Abstract
The aging brain is often characterized by the presence of multiple comorbidities resulting
in synergistic damaging effects in the brain as demonstrated through the interaction of
Alzheimer’s disease (AD) and stroke. Gangliosides, a family of membrane lipids enriched
in the central nervous system, may have a mechanistic role in mediating the brain’s
response to injury as their expression is altered in a number of disease and injury states.
Matrix-Assisted Laser Desorption Ionization (MALDI) Imaging Mass Spectrometry (IMS)
was used to study the expression of a-series ganglioside species GD1a, GM1, GM2, and
GM3 to determine alteration of their expression profiles in the presence of beta-amyloid
(Aβ) toxicity in addition to ischemic injury. To model a stroke, rats received a unilateral
striatal injection of endothelin-1 (ET-1) (stroke alone group). To model Aβ toxicity, rats
received intracerebralventricular (icv) injections of the toxic 25-35 fragment of the Aβ
peptide (Aβ alone group). To model the combination of Aβ toxicity with stroke, rats
received both the unilateral ET-1 injection and the bilateral icv injections of Aβ₂₅₋₃₅
(combined Aβ/ET-1 group). By 3 d, a significant increase in the simple ganglioside species
GM2 was observed in the ischemic brain region of rats who received a stroke (ET-1), with
or without Aβ. By 21 d, GM2 levels only remained elevated in the combined Aβ/ET-1
group. GM3 levels however demonstrated a different pattern of expression. By 3 d GM3
was elevated in the ischemic brain region only in the combined Aβ/ET-1 group. By 21 d,
GM3 was elevated in the ischemic brain region in both stroke alone and Aβ/ET-1 groups.
Overall, results indicate that the accumulation of simple ganglioside species GM2 and
GM3 may be indicative of a mechanism of interaction between AD and stroke.
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2.2 Introduction
As we age, our brains become more vulnerable to diseases and injuries. Elderly patients
often simultaneously experience two or more medical conditions which complicates the
study of age-related neurodegenerative diseases such as Alzheimer’s disease (AD). When
multiple conditions are present simultaneously (comorbidity), synergistic effects on
pathology and cognitive outcomes can be observed as demonstrated in the case of AD and
stroke. A key study which examined the incidence of dementia among a group of elderly
nuns diagnosed with AD found that only 57% of those diagnosed with AD developed
dementia, while 93% of those who had suffered small subcortical infarcts plus a
pathological diagnosis of AD developed dementia (Snowdon et al., 1997). AD and stroke
comorbidity has also been observed in carriers of the APOE4 gene. Data from the Canadian
Study of Health and Aging (CSHA) showed that prevalence of dementia was increased
among those who had a history of stroke and were also APOE4 carriers (Jin et al., 2008).
Furthermore, another study demonstrated that APOE4 carriers with a history of stroke were
five times more likely to develop dementia than APOE4 carriers without such a history
(Jonston et al., 2000). Although the clinical evidence for the interaction between AD and
stroke has been well documented, the mechanism(s) for this interaction remains unclear. A
potential mediator for this interaction may lie within a family of cellular membrane lipids
known as gangliosides.
Gangliosides are glycosphingolipids characterized by the presence of sialic acid
residues. Being embedded within the plasma membrane, gangliosides perform a wide
variety of biological functions by interacting with signaling molecules both within and
outside of the cell. Some of these biological functions include cell signaling, proliferation,
differentiation, embryogenesis, oncogenesis, neurodegeneration, and apoptosis (Prokazova
et al., 2009; Yu, Suzuki & Yanagisawa, 2010). Ganglioside metabolism is controlled by the
activities of several enzymes, which can add or remove sialic acid residues and/or
oligosaccharide units to form the various derivatives that make up the ganglioside
molecules. A-series gangliosides are the first, structurally simplest group of gangliosides
derived from the addition of a sialic acid residue to lactosylceramide and contain the most
abundant ganglioside species in the mammalian central nervous system, GM1, as well as
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GD1a, GM2, and GM3 (Ando, Chang & Yu, 1978) (Fig 2.1). Every form of ganglioside is
hypothesized to have unique functions within the cell and a normal homeostatic
distribution of each species is maintained within healthy organisms (Yamamoto et al.,
1996; Yu, Nakatani & Yanagisawa, 2009; Sekigawa et al., 2011). Complex gangliosides
GM1 and GD1a are more abundant in the brain than the simple species GM2 and GM3 and
have been shown to be beneficial for recovery when exogenously administered in a number
of in vitro, animal, and human disease and injury studies (Schneider et al., 2013; Kreutz et
al. 2011).
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Figure 2.1: Chemical Structure and Metabolic Pathways Involved in Ganglioside
Synthesis and Catabolism. Gangliosides are composed of a hydrophobic domain called
ceramide (Cer) and a hydrophilic domain made up of a series of sugar units (glucose – Glc,
galactose – Gal, and N-acetylgalactosimine –GalNAc) with a sialic acid residue (Sia)
attached to a galactose sugar unit. The number and type of sugar units and sialic acids
present in the hydrophilic domain determines the type of ganglioside species (GM3, GM2,
etc.). A group of transferase enzymes adds either a sugar unit (GalNAcT, GalT) or a sialic
acid residue (sialyltransferase - SAT) to synthesize different ganglioside species. A
different set of catabolic enzymes within the lysosome can also break down these
components, thus a homeostatic abundance of each ganglioside species is maintained in a
healthy organism.
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Little is known of the functions of ganglioside GM2 in the adult mammalian brain.
However, GM2 gangliosidosis, a group of autosomal recessive disorders caused by
dysfunction in enzyme metabolic pathways, such as Tay Sachs and Sandhoff’s disease, can
lead to accumulation of GM2 in neuronal cells resulting in a broad spectrum of
neurological disorders (Bley et al., 2011). More recently, GM2 expression has been found
to be elevated within the mouse brain at the injury site after a focal brain injury such as a
traumatic brain injury or stroke (Whitehead et al., 2011; Woods et al., 2013). GM3, an
essential component of the plasma membrane and lipid rafts (Prokazova et al., 2009), is
structurally the simplest member of the ganglioside family and acts as a metabolic
precursor to the other more complex ganglioside species (Fig 2.1). As such, GM3 plays a
crucial role in regulating the level of expression of all other ganglioside species in cells.
Although GM3 is one of the main gangliosides expressed in extra-neural tissues of
vertebrates, it is generally expressed only in very small quantities in the healthy adult
mammalian brain (Prokazova et al., 2009). Accumulation of GM3 in neural tissue has been
shown to lead to toxic effects and apoptosis (Nakatsuji & Miller, 2001; Prokazova et al.,
2009; Sohn et al., 2006). GM3 has been successfully used as a treatment for tumors due to
its potent anti-angiogenic and apoptotic effects (Abate, Mukherjee & Seyfried, 2006;
Chung et al., 2009; Seyfried & Mukherjee, 2010). An increase in GM3 expression has also
been observed in both human and animal models of AD (Chan et al., 2012), as well as in
mouse models of stroke—reperfusion injury (Whitehead et al., 2011). Finally, additional to
the sugar chains, the functions of gangliosides may also be determined by ceramides. In
particular, certain gangliosides differ only by the length of their sphingosine backbone,
d18:1 and d20:1 (18 carbon and 20 carbon species), and have been suggested to have
unique roles within the cell (Angel, Spraggins, Baldwin & Caprioli, 2012; Kotani et al.,
1994; Whitehead et al., 2011; Woods et al., 2013).
Labelling and visualizing gangliosides within tissue using immunohistochemistry
(IHC) is a commonly used technique for identifying different species of gangliosides.
However, the efficacy of antibody labelling on lipids in general is controversial and the
availability of specific ganglioside antibodies for certain species can be very limited or
non-existent (Richards et al., 2012). Moreover, immunolabelling is also incapable of
distinguishing between the d18:1 and d20:1 species as the ceramides are hidden within the
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cell membrane, inaccessible to antibodies for labelling. An alternative approach is the
detection of gangliosides based on their molecular mass through spectrometry. MatrixAssisted Laser Desorption/Ionization Imaging Mass Spectrometry (MALDI IMS) can
detect ganglioside molecules directly within tissue sections without any kind of
immunological labelling. The masses and intensities of all ganglioside ions are recorded
simultaneously within an anatomical reference point (Fig 2.2).
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Figure 2.2: MALDI IMS Workflow. Following surgery, rats are euthanized via anesthetic
overdose and decapitated. Fresh brains are isolated and sectioned at 10μm on a cryostat
onto MALDI plates. Sections sprayed with CMBT matrix using an airbrush are processed
on a MALDI mass spectrometer (Sciex 4700). Regions of interest (ROIs) are chosen with
reference to the rat brain atlas by Paxinos and Watson. Stroke regions are identified and
mass spectra are averaged from the infarct as well as from the corresponding non-injured
striatum on the contralateral hemisphere. Mass spectra are generated from each ROI, and
the peak height for the species of interest is calculated. Quantified data are represented as
the ratio of the peak height between the ipsilateral (stroke) and contralateral ROIs.
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Perturbations in the normal homeostatic expression of gangliosides have been
observed in several models of neurodegeneration such as AD (Barrier et al., 2007;
Svennerholm & Gottfries, 1994), Huntington’s disease (Desplats et al., 2007), Parkinson’s
disease (Schneider et al., 2013), and prion diseases (Martino et al., 1993); however, this has
not yet been reported within the context of comorbidities. Previous work using the same
animal model as this study, has demonstrated that a synergistic relationship exists between
animal models of stroke and AD both pathologically and behaviourally (Cechetto,
Hachinski & Whitehead, 2008; Whitehead, Cheng, Hachinski & Cechetto, 2007), however
the mechanism of this interaction remains unclear. This study utilizes both the novel
MALDI IMS technique and, where possible, traditional IHC to examine changes in a-series
ganglioside expression in rats who underwent either surgical striatal endothelin-1 (ET-1)
injection (stroke alone group), bilateral icv injections of beta-amyloid (Aβ25–35) (Aβ alone
group), or ET-1 with bilateral icv injections Aβ25–35 (combined Aβ/ET-1 group). The ET1 subcortical stroke model was chosen as it produces subcortical lacunar type infarcts that
resemble those typically seen in patients who, upon post-mortem examination, have been
identified as having pathological correlates of both AD and stroke (Snowdon et al., 1997).
In addition, previous studies have demonstrated that targeted injections of ET-1 produced a
transient focal ischemia-reperfusion injury in rats (Jiwa, Garrad & Hainsworth, 2010;
Whitehead, Hachinski & Cechetto, 2005; Whitehead, Cheng, Hachinski, & Cechetto,
2005).

2.3 Materials and Methods
2.3.1

Animals Models

Rats were weighed before being anaesthetized in a Harvard anesthesia box with 3%
isoflurane in 2 L/min oxygen and placed in a Kopf stereotaxic apparatus. Using an
operating microscope, an incision was made in the scalp and the skull was exposed.
Bregma was used as a reference point for all injection sites: Injections were administered
with a Hamilton glass syringe at a rate of 1 μL over 30 sec. The syringe was left in place
for 3 min after each injection then slowly removed. Rat body temperature was maintained
at 37°C on a heating pad during the surgical and recovery periods before being returned to
a cage. To induce Aβ toxicity, rats received 15 μL bilateral icv injections of the toxic Aβ
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fragment, Aβ25–35 (50 nmol), at coordinates -0.8 mm (anterior/posterior), ±1.4 mm
(medial/lateral) and -4.0 mm (dorsal/ventral). Aβ25–35 (Sigma-Aldrich Co., St. Louis,
USA) was dissolved in saline and stored at -80°C in 30 μL aliquots and kept on dry ice
prior to injection to prevent aggregation and allow better diffusion throughout the
ventricles (Whitehead, Hachinski & Cechetto, 2005; Whitehead, Cheng, Hachinski, &
Cechetto, 2005). To induce stroke, rats received a 3 μL unilateral injection of the potent
vasoconstrictor ET-1 (60 pmol) into the right striatum, at coordinates +0.5 mm
(anterior/posterior), -3.0 mm (medial/lateral) and -5.0 mm (dorsal/ventral). ET-1 (SigmaAldrich Co., St. Louis, USA) was dissolved in sterile water and stored at -80°C in 8 μL
aliquots and kept on dry ice prior to injection. To induce the comorbid Aβ/ET-1 model, rats
received bilateral icv injections of Aβ25–35 followed by a unilateral ET-1 injection into the
striatum at the same concentrations and coordinates as above. Sham surgery group animals
underwent the same surgical procedure as the combined Aβ/ET-1 group rats but did not
receive any chemical injections, only needle insertion to the appropriate brain regions. The
mortality rate was slightly (but not statistically significantly) higher in ET-1 groups but was
less than 10% of the total animals used and was attributed to the effects of the interaction
between ET-1 and anesthesia.
2.3.2

Euthanasia

For histochemical and IHC analysis, rats were euthanized at 3 or 21 d post-surgery via
Euthanyl overdose (0.5 mL, i.p.). Animals were then perfused transcardially with 0.01 M
phosphate buffered saline (PBS) (pH 7.4) followed by 4% paraformaldehyde (PFA) (pH
7.4). Brains were removed and kept in the same PFA solution for 24 hr, then cryoprotected
in 30% sucrose until they were fully submerged. Brains were sectioned coronally on a
Cryo3 Cryostat (TissueTek, Dublin, USA) into 35 μm thick sections and were stored in
cryoprotectant at 4°C until used for immunohistochemistry. For MALDI IMS analysis, rats
were euthanized via Euthanyl overdose (0.5 mL i.p.) at either 3 or 21 d post-surgery. Rats
were decapitated and fresh whole brains were carefully removed and immediately frozen
on dry ice. Frozen brains were stored at -80°C until used for MALDI IMS analysis.
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2.3.3

Immunohistochemistry

Sections from each experimental group were processed simultaneously to reduce variability
between groups. Sections were washed in 0.1 M PBS (3 x 15 min each), then quenched for
15 min in 1.5% hydrogen peroxide. Sections were washed in PBS (3 x 5 min each), then
blocked in 1.5% bovine serum albumin (BSA) (Serological Research Institute, Richmond,
USA) diluted in PBS with Triton-X (PBST) for 30 min. Sections were incubated with
primary antibodies diluted in 1.5% BSA (PBST) for 48 hr at 4°C on a shaker. IHC
procedure was similar for: mouse anti-rat OX-6 (1:1000, BD Biosciences, Mississauga,
Canada), NeuN (1:1000, EMD Millipore, Billerica, USA), GFAP (1:1000, EMD Millipore,
Billerica, USA) GM3 (1:500, Seikagaku Corporation, Tokyo, Japan), GM1 and GD1b
(1:500, Ronald Schnaar, Johns Hopkins University, USA); however Triton-X was not used
for GM3, GM1 or GD1b staining due to its membrane delocalizing effects (Lopez &
Schnaar, 2009). Sections were then washed in PBS (3x 15 min each) then incubated with
HRP-conjugated secondary antibodies diluted in 1.5% BSA (PBST) for 1 hr. HRPconjugated (anti-mouse IgG) (1:200, Vector Laboratories, Burlington, Canada) and antirabbit IgG secondary antibodies (1:200, Vector Laboratories, Burlington, Canada) were
used for the appropriate primary antibodies. Sections were washed in PBS (3 x 15 min
each) then incubated in avidin-biotinylated complex (ABC) reagent (Vector Laboratories,
Burlington, Canada) for 1 hr. Sections were then washed in PBS (3 x 5 min each) and
developed in fresh 0.001% diaminobenzidine (DAB) (Vector Laboratories, Burlington,
Canada) at 10 mg in 20 mL PBS with 300 μL 3% H2O2, Sigma for 5 min. Sections were
washed in PBS (3 x 15 min each) then mounted onto VWR microscope slides coated in
0.3% gelatin, dehydrated, cleared with xylene and then cover-slipped with Depex (Fisher
Scientific).
2.3.4

Immunofluorescence

Free-floating sections were washed in PBS (3 x 10 min) then blocked in 1.5% BSA for 1 hr
at room temperature. Sections were incubated with antibodies to GM3 [1:500] and either
NeuN (1:1000, Millipore, Billerica, USA), GFAP (1:1000, Millipore, Billerica, USA) or
IBA-1 for activated microglia/macrophages (1:1000, Santa Cruz Biotechnology Inc., Santa
Cruz, USA) in 1.5% BSA for 48 hrs at 4°C. Sections were washed in PBS (3 x 10 min
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each) then incubated with FITC conjugated anti-mouse IgG (1:300, Santa Cruz
Biotechnology Inc., Santa Cruz, USA) and TR-conjugated anti-rabbit IgG (1:300, Santa
Cruz Biotechnology Inc., Santa Cruz, USA) for 1 hr at room temperature in the dark.
Sections were washed in PBS (3 x 10 min) and mounted onto microscope glass slides and
cover-slipped with Fluoroshield mounting media (Sigma-Aldrich, Toronto, Canada).
Fluoro Jade B. FJB is commonly used as a marker of neurodegeneration in the brain.
Sections were washed in PBS (6 x 10 min each) then mounted onto microscope slides with
0.3% gelatin and allowed to dry overnight. Slides were placed in 1% sodium hydroxide and
in 80% ethanol for 5 min. Slides were then rehydrated in 95% ethanol for 3 min; 70%
ethanol for 3 min; 50% ethanol for 2 min, and finally distilled water (3 x 1 min each).
Slides were then incubated in 0.06% potassium permanganate (KMnO4) for 15 min on a
shaker, in the dark. Slides were washed in distilled water (3 x 1 min each), then placed in
fresh 0.0004% FJB (Millipore, Billerica, USA) in 0.1% acetic acid for 20 min on a shaker
in the dark. Slides were washed in distilled water (3 x 1 min each) then allowed to dry in
the fume hood before a xylene clearance step (1 min) and cover-slipped with Depex.
Microscopy Imaging. Images were taken on a Leica DC300 (Leica Microsystems,
Concord, Canada) microscope camera. Analysis and quantification was carried out using
Image J (Wayne Rasband, National Institute of Health, Bethesda, USA) by one observer
who was blinded to the experimental groups.
2.3.5

MALDI Imaging Mass Spectrometry

Fresh frozen rat brains were sliced on a CM 1850 cryostat and 10 μm coronal sections were
taken from the striatum (stroke injury site) for MALDI IMS analysis. Sections were thaw
mounted onto a MALDI target plate and dried in a desiccator for 10 min. An artist’s
airbrush (Iwata HPBH, Japan) was used to apply 2 mL of 15 mg/mL 5-Chloro-3mercaptobenzothiazol (CMBT) (Sigma-Aldrich, Toronto, Canada) matrix dissolved in a
4:4:1 mixture of chloroform: ethanol:water solvent, allowing each layer to dry completely
before spraying the next layer thus minimizing delocalization of molecules within the
tissue. Once the matrix was uniformly applied to the plate surface and dried, the plate was
inserted into a Sciex MALDI 4700 TOF/TOF mass spectrometer (Sciex, Foster City, CA,
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USA). Prior to acquiring an image, the instrument was calibrated using five peptide
standards (4700 Calibration Mixture, Sciex) at 50 ppm mass tolerance. Reflectron and
negative ion modes were used for all image acquisitions. During the scanning process, a
laser beam is directed across the selected tissue sections at 100 μm steps and a mass
spectrum is collected for each x,y coordinate. The laser ablates the tissue and causes the
desorbed molecules in the tissue to ionize. These ions travel down a flight tube where they
separate based on their mass-to-charge (m/z) ratio to a detector which records this data and
compiles it into both a mass spectrometry data plot and a molecular image. The instrument
took approximately 2 hr for acquisition of each image. The region of interest (ROI) for this
MALDI IMS study included both the core of the infarct and the periphery in order to assess
general changes in ganglioside metabolism after stroke and Aβ toxicity within the site of
stroke injury. Representative MALDI IMS images were selected for the ET-1 group and
Aβ/ET-1 combined group for each species of ganglioside in order to better visualize the
changes in expression. Representative IMS images from the Aβ alone and control groups
were not included as there were no significant alterations in ganglioside expression in any
of these groups. The location of stroke injury within the striatum is highlighted with a
green arrow in the MALDI IMS images. Three day (d) and 21 d time points were examined
for each a-series ganglioside. The appropriate m/z ratio for each ganglioside species was
confirmed using the Lipidmaps database (www.lipidmaps.org). Data was collected and
analyzed as previously described (Fig 2.2).
2.3.6

Data Analysis

A single MALDI IMS image scan contains molecular information on the expression of
each type of a-series ganglioside, the d18:1 and d20:1 species, as well as some unknown
metabolic species. The molecular image can be used to locate a specific region of interest
(ROI) such as the stroke region in the striatum where a mass spectrometry data plot is
produced for that specific region for quantification. Multiple ROIs can be selected for
comparison purposes. In this case, the injury site in one hemisphere was compared to the
same location on the contralateral side of the brain. The peak height of each a-series
ganglioside was quantified in both ROIs and, after baseline subtraction, a ratio was
calculated for the differences in expression in the injured and non-injured tissue. The ratios
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for multiple brain tissue scans in each group were compiled and a one way ANOVA was
performed followed by a post-hoc Tukey’s multiple comparisons test to determine if there
were any differences in expression between the surgical groups and the controls at both
time points. Error bars represent the standard error of the mean (SEM) for each group. A pvalue of <0.05 was considered to be significant, n = 4 for each surgical group.

2.4 Results
2.4.1

Increased GM3 expression within infarcted region of combined Aβ/ET-1
group persists at 21 d

MALDI IMS results indicated a persistent perturbation in GM3 expression following stroke
within the stroke region. Even though the MALDI MS instrument was capable of
differentiating between the d18:1 and d20:1 species of GM3, signals from the d20:1 species
fell below the threshold of detection and only signals from the d18:1 species were detected
and quantified. At 3 d following surgery, MALDI IMS analysis demonstrated that GM3
expression did not change following ET-1 injection alone or Aβ injections alone, however
did increase in the combined Aβ/ET-1 group (Fig 2.3 A and 2.3 B) within the stroke
region. By 21 d after surgery, GM3 expression remained at control levels in the Aβ alone
group while GM3 significantly increased in the ET-1 alone group and remained elevated in
the combined Aβ/ET-1 group within the stroke region (Fig 2.3 A and 2.3 B). To
complement the MALDI IMS data, GM3 was detected by IHC 3 and 21 d following
surgery. There was no GM3 signal detected in control treated animals (data not shown), as
expected due to the low abundance of this species in the healthy adult brain. By 3 d
following surgery, GM3 signal was detected within the stroke region of both ET-1 alone
and combined Aβ/ET-1 groups (Fig 2.3 C and 2.3 D). By 21 d following surgery, GM3
expression decreased within the infarct region of the ET-1 alone group compared to 3 d
levels, whereas GM3 expression increased in the combined Aβ/ET-1 group over 3 d levels
(Fig 2.3 C and 2.3 D). Similar to control and sham treated rats, there were no differences in
GM3 expression (and all other gangliosides evaluated) within the right and left striatum of
Aβ alone rats.
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Figure 2.3: Increased GM3 expression within infarcted region of combined Aβ/ET-1
group persists at 21 d. (A) Representative MALDI IMS images of ganglioside GM3 d18:1
in stroke (ET-1 alone) and combined Aβ/ET-1 animals 3 and 21 d following surgery.
Arrows indicate region of stroke induced infarct. Light regions in images represent areas of
high expression while dark regions represent low levels of expression as indicated by
intensity bar. (B) MALDI IMS quantification of ROIs from the striatum of control, sham
surgery, Aβ alone, ET-1 alone, and combined Aβ/ET-1 animals at 3 d and Aβ alone, ET-1
alone, and combined Aβ/ET-1 animals at 21 d. Data are expressed as the ratio of ipsilateral
to contralateral ROIs. * indicates statistical significance +/- SEM over control and sham
surgical groups, one-way ANOVA, Tukey’s post-hoc, p<0.05 (n = 4 for each group). There
was an increase in expression observed in both the ET-1 alone and combined Aβ/ET-1
groups from 3 to 21 d, however this was only statistically significant in the ET-1 alone
group as the expression at 3 d was at control levels. (C,D) IHC detection and quantification
of GM3 within the infarct region. Panel (C - right) is a higher magnification image of panel
(C - left). * indicates statistical significance +/- SEM between groups, one-way ANOVA,
Tukey’s post-hoc, p<0.05 (n = 6 for each group).
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2.4.2

GM3 accumulation is associated with increased neurodegeneration and
decreased cell survival at 21 d at the site of injury

To evaluate the consequence of elevated GM3 expression within the stroke region, levels
of cellular degeneration and neuronal loss were assessed. FluoroJade B (FJB) staining, a
non-specific marker of cell death, was used to assess cellular degeneration at both 3 and 21
d after surgery. Extensive FJB positive staining was observed within the borders of the
infarct in both the ET-1 alone and combined Aβ/ET-1 groups (Fig 2.4 A). Quantification of
FJB positive cells revealed no significant difference between the ET-1 alone and combined
Aβ/ET-1 groups at 3 d following surgery (Fig 2.4 B). At 21 d post-surgery, the number of
FJB-positive cells were lower in both ET-1 alone and combined Aβ/ET-1 groups compared
to 3 d, however the combined group had significantly more degenerating cells (35%
reduction from 3 d levels) within the ischemic region compared to the ET-1 alone group
(65% reduction from 3 d levels). NeuN, a marker for mature neurons was used to assess the
number of neurons that survived between 3 and 21 d within the infarcted striatum. At 3 d
following stroke, there were equal numbers of NeuN positive neurons between ET-1 alone
and combined Aβ/ET-1 groups. However, by 21 d, there were fewer NeuN positive
neurons within the infarcted striatum in the combined group compared to the ET-1 alone
group. Taken together with the FJB results, this suggests that the combined Aβ/ET-1 group
experienced greater neuronal degeneration within the damaged striatum following stroke.
To assess if GM3 expression was localized within neurons and if these neurons underwent
degeneration, dual immunofluorescence labeling was performed (Fig 2.4 D). There was a
high level of co-localization between NeuN and GM3 as well as between FJB and GM3,
indicating that GM3 was expressed in degenerating neurons following stroke.
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Figure 2.4: Effects of GM3 accumulation on neurodegeneration following stroke. (A)
Photomicrographs of fluorojade-B immunofluorescence staining within the infarcted
striatum of ET-1 and combined Aβ/ET-1 coronal rat brain sections. (B and C)
Quantification of cell counts of FJB and NeuN cell counts. At 21 d following surgery, there
was more FJB positive cells and less NeuN positive cells in the combined Aβ/ET-1 group
compared to the ET-1 group according to one-way ANOVA and Tukey’s post-hoc, p<0.05
(n = 6 for each group). (D) Photomicrographs of immunofluorescence dual labelling
showing co-localization between NeuN and GM3 (shown individually and overlayed) and
FJB and GM3 (shown individually and overlayed) in the infarct region of a 21 d combined
Aβ/ET-1 animal.
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2.4.3

Elevated GM2 at 3 d remains elevated at 21 d only in combined Aβ/ET-1
group

Since GM3 levels were differently expressed between surgical groups, we next evaluated
the levels of GM2. Interestingly, GM2 expression levels were slightly different than the
observed changes in GM3. The expression patterns of both the d18:1 and d20:1 species
were profiled and quantified by MALDI IMS (Fig 2.5). By 3 d following surgery, both
GM2 d18:1 and GM2 d20:1 expression in the combined Aβ/stroke group was found to be
significantly elevated compared to Aβ alone and control groups (grey bars in Fig 2.5 B and
2.5 D). Although GM2 expression in the ET-1 alone group also showed a very strong trend
of increased expression in the GM2 d18:1 species, it was not found to be statistically
significant (black bars in Fig 2.5 B). It was, however, found to be significantly elevated in
the GM2 d20:1 species compared to Aβ alone and control groups (black bars in Fig 2.5 D).
At 21 d post-surgery, GM2 expression returned to control levels in the ET-1 alone group
for both the d18:1 and d20:1 species, but remained increased in the combined Aβ/ET-1
group compared to Aβ alone and control groups (grey bars in Fig 2.5 D), though this
increased expression was only statistically significant in the d20:1 species.
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Figure 2.5: Elevated GM2 Expression at 3 d Remains Increased only in Combined
Aβ/ET-1 Group. (A and C) Representative MALDI IMS images of GM2 d18:1 (A) and
d20:1 (C) in stroke (ET-1 alone) and combined Aβ/ET-1 animals 3 and 21 d following
surgery. Arrows indicate region of stroke induced infarct. (B and D) MALDI IMS
quantification of ROI’s from the striatum of control, sham surgery, Aβ alone, ET-1 alone,
and combined Aβ/ET-1 animals at 3 d and Aβ alone, ET-1 alone, and combined Aβ/ET-1
animals at 21 d. Data are expressed as the ratio of ipsilateral to contralateral ROIs. Light
regions in images represent areas of high expression while dark regions represent low
levels of expression as indicated by intensity bar. There was no statistical increase in GM2
expression between 3 and 21 d in any group, however, GM2 expression in the ET-1 group
decreased significantly from 3 to 21 d (back to control levels). * indicates statistical
significance +/- SEM over control and sham surgical groups, one-way ANOVA, Tukey’s
post-hoc, p<0.05 (n = 4 for each group).
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2.4.4

Elevated GM1 expression in combined Aβ/ET-1 group.

Analysis of GM1 d18:1 expression was performed and data indicated no statistical
difference between the ET-1 alone, Aβ alone, and control groups 3 d following surgery,
however, GM1 expression in the combined Aβ/ET-1 group was significantly elevated
compared to the other surgical and control groups (Fig 2.6 B). At 21 d, GM1 d18:1
expression showed the same expression profile between experimental groups with no
statistical differences (Fig 2.6 B). Analysis of the d20:1 species of GM1 demonstrated
significantly increased expression in the combined Aβ/ET-1 group compared to all surgical
and control groups at both 3 and 21 d post-surgery (Fig 2.6 D).
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Figure 2.6: Elevated GM1 Expression in Combined Aβ/ET-1 Group. (A and C)
Representative MALDI IMS images of GM1 d18:1 (A) and d20:1 (C) in stroke (ET-1
alone) and combined Aβ/ET-1 animals 3 and 21 d following surgery. Arrows indicate
region of stroke induced infarct. (B and D) MALDI IMS quantification of ROI’s from the
striatum of control, sham surgery, Aβ alone, ET-1 alone, and combined Aβ/ET-1 animals at
3 d and Aβ alone, ET-1 alone, and combined Aβ/ET-1 animals at 21 d. Data are expressed
as the ratio of ipsilateral to contralateral ROIs. Light regions in images represent areas of
high expression while dark regions represent low levels of expression as indicated by
intensity bar. There were no statistically significant changes in GM1 expression between 3
and 21 d in any of the groups. * indicates statistical significance +/- SEM over control and
sham surgical groups in panel (B) and statistical significance over control, sham and ET-1
alone surgical groups in panel (D), one-way ANOVA, Tukey’s post-hoc, p<0.05 (n = 4 for
each group).
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2.4.5

Increased GD1a [Na+] expression at 3 d in combined Aβ/ET-1 group

All MALDI IMS experiments presented in this work were performed using negative ion
mode. The most intense signals observed for GM1, GM2, and GM3 were their singly
charged anions, [M - H+]1- (M minus H+ ions). Given that sialic acid is the most acidic site
of these gangliosides, and each GM1, GM2, and GM3 has one sialic acid, the
deprotonation site is likely the sialic acid. GD1a on the other hand is the only ganglioside
studied in this work having two sialic acid groups. However, the doubly charged GD1a
anion, [M - 2H+]2-, was not observed by MALDI MS. Instead, the sodium and potassium
adducts were observed as two distinct peaks, [M - 2H+ + Na+]1- and [M - 2H+ + K+]1-, likely
due to its considerable presence in tissue. Interestingly, GD1a showed very different
patterns of expression for the sodium and potassium adduct ions. (Figs 2.7 and 2.8). At 3 d
post-surgery, GD1a [Na+] d18:1 showed significantly increased expression in the combined
Aβ/ET-1 group compared to controls (Fig 2.7 B and 2.7 D).
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Figure 2.7: Increased GD1a [Na+] Expression at 3 d in Combined Aβ/ET-1 Group (A
and C) Representative MALDI IMS images of GD1a [Na+] d18:1 (A) and d20:1 (C) in
stroke (ET-1 alone) and combined Aβ/ET-1 animals 3 and 21 d following surgery. Arrows
indicate regions of stroke induced infarct. (B and D) MALDI IMS quantification of ROI’s
from the striatum of control, sham surgery, Aβ alone, ET-1 alone, and combined Aβ/ET-1
animals at 3 d and Aβ alone, ET-1 alone, and combined Aβ/ET-1 animals at 21 d. Data are
expressed as the ratio of ipsilateral to contralateral ROIs. Light regions in images represent
areas of high expression while dark regions represent low levels of expression as indicated
by intensity bar. GD1a [Na+] expression significantly decreased from 3 to 21 d in the d18:1
species. There were no other significant changes in expression between 3 and 21 d in any
of the groups. * indicates statistical significance over control and sham surgical groups
one-way ANOVA, Tukey’s post-hoc, p<0.05 (n = 4 for each group).
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2.4.6

Decreased expression of GD1a [K+] at 3 d in ET-1 alone group

The d18:1 species expression in the combined Aβ/ET-1 group decreased at 21 d and was no
longer different from the other groups. The potassium adduct of GD1a, (GD1a [K+]) (Fig
2.8) showed a completely different pattern of expression from the GD1a [Na+]. At 3 d postsurgery, the ET-1 alone group demonstrated a significantly decreased expression of GD1a
[K+] compared to Aβ alone and control groups, but this returned to control levels by 21 d,
whereas no statistical difference was observed at either time point in the combined Aβ/ET1 group, although there was a trend of decreased expression as well (Fig 2.8 A and 2.8 B).
A similar trend was observed for the GD1a [K+] 20:1 species (Fig 2.8 C and 2.8 D).
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Figure 2.8: Decreased expression of GD1a [K+] at 3 d in ET-1 alone group. (A and C)
Representative MALDI IMS images of GD1a [K+] d18:1 (A) and d20:1 (C) in stroke (ET-1
alone) and combined Aβ/ET-1 animals 3 and 21 d following surgery. Arrows indicate
regions of stroke induced infarct. (B and D) MALDI IMS quantification of ROI’s from the
striatum of control, sham surgery, Aβ alone, ET-1 alone, and combined Aβ/ET-1 animals at
3 d and Aβ alone, ET-1 alone, and combined Aβ/ET-1 animals at 21 d. Data are expressed
as the ratio of ipsilateral to contralateral ROIs. Light regions in images represent areas of
high expression while dark regions represent low levels of expression as indicated by
intensity bar. There were no statistically significant changes in expression between 3 and
21 d in any of the surgical groups. * indicates statistical significance over control groups,
one-way ANOVA, Tukey’s post-hoc, p<0.05 (n = 4 for each group).

85

2.5 Discussion
Based on evidence from the literature (Chung et al., 2009; Nakatsuji & Miller, 2001;
Prokazova et al., 2009; Sekigawa et al., 2011; Sohn et al., 2006; Woods et al., 2013; Yu,
Suzuki & Yanagisawa, 2010; Yamamoto et al., 1996), the observed increase in simple
ganglioside species GM2 and GM3 in the stroke region of the Aβ/ET-1 combined group at
both 3 and 21 d after surgery is indicative of a more severe pathological response compared
to ET-1 or Aβ alone. GM2 has been shown to be elevated immediately after TBI (Woods et
al., 2013) and GM3 accumulation has been shown to increase toxicity and induce apoptosis
in cells (Chung et al., 2009; Nakatsuji & Miller, 2001; Seyfired & Mukherjee, 2010; Sohn
et al., 2006). The observed reduction of GM2 expression back to control levels following
ET-1 alone at 21 d may imply that the brain has begun repair processes or the injury was
less severe. GM2 expression levels within the combined Aβ/ET-1 rat brain remained
elevated at 21 d which may indicate that the injury is persisting and thus more brain
damage is occurring. This hypothesis supports previous pathological and behavioural
findings using this combined animal model of Aβ/ET-1 in our lab (Amtul et al., 2014;
Whitehead, Hachinski & Cechetto, 2005; Whitehead, Cheng, Hachinski, & Cechetto, 2005;
Whitehead et al., 2007; Whitehead et al., 2011). It is possible that the observed
accumulation of simple gangliosides is a result of the breakdown of the more complex aseries gangliosides via enzymatic degradation; however, the expression patterns of both
GM1 and GD1a observed in this study suggest that the degradation pathways may be more
complex. A slight decrease in GM1 ganglioside occurred in the ET-1 alone group while an
increase the simple species GM2 (at 3 d) and GM3 (at 21 d) was observed. This finding
supports our initial A-series degradation hypothesis. Contrarily, in the combined Aβ/ET-1
group, in which previous studies have shown that stroke induced damage was more severe
(Whitehead et al., 2005; whitehead et al., 2007; Amtul et al. 2014), a significant increase in
GM1 expression was observed despite there also being a significant increase in both GM2
and GM3 at both 3 and 21 d. This finding does not rule out the A-series degradation
hypothesis but suggests that the mechanism of simple ganglioside accumulation is more
complex than degradation along the A-series pathway. Ganglioside synthesis from the
common precursor GM3 can occur by adding sugar units to the oligosaccharide chain (i.e.
along most of the A-series pathway) or by the addition of sialic acid residues (i.e. A to B-
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series pathway). It is possible that in the combined Aβ/ET-1 group, where an increase in
both simple and complex a-series gangliosides was observed, the accumulation was due to
the degradation of the sialic acid residues of B- or C-series gangliosides thus resulting in an
increase in the A-series species. Further study into the enzymatic activities that regulate
ganglioside metabolism during and post-brain injury is warranted to address this question.
The accumulation of the simple ganglioside species GM3 is of particular interest
due to evidence supporting its potential apoptotic properties (Chung et al., 2009; Nakatsuji
& Miller, 2001; Seyfired & Mukherjee, 2010; Sohn et al., 2006). The immediate and
significant increase along with the sustained expression of GM3 over time observed within
in the combined Aβ/ET-1 rat brain may be reflective of the increased pathological response
that was previously observed in this animal model (Amtul et al., 2014; Whitehead,
Hachinski & Cechetto, 2005; Whitehead, Cheng, Hachinski, & Cechetto, 2005; Whitehead
et al., 2007; Whitehead et al., 2011). Interestingly, GM3 did not show the same pattern of
expression in the ET-1 alone brain, with a trend of increased expression only at 21 d postsurgery, suggesting that the interaction between Aβ and the stroke injury was responsible
for the observed accumulation of GM3 in the combined group and may have played a
mechanistic role in the synergism of these two pathologies. Unexpectedly, results from the
GM3 IHC and MALDI IMS images from the ET-1 alone group (Fig 2.2) were not fully
congruent. This may be explained by the difference in the techniques themselves as IHC
and MALDI IMS do not necessarily measure the same thing, especially with respect to
detection of lipids. IHC measures the ability of the ganglioside antibody to bind to, and
label GM3 on cellular membranes while MALDI IMS measures the signal intensity of ions
of a particular mass-to-charge ratio corresponding to GM3 molecules. The lack of
specificity for ganglioside antibodies to bind and label tissues in IHC is a significant
challenge in the glycosphingolipid field and thus is the principle reason MALDI IMS was
chosen as the main technique in this study.
Previous work using a mouse model of stoke-reperfusion injury examined
ganglioside expression in a number of key anatomical regions for ischemic risk, including
the striatum, and found that there was an increase in complex ganglioside species GM1 and
GD1a immediately after stroke which peaked at 3 d after injury then returned to basal
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levels at later time points (Whitehead et al., 2011). This trend is similar to the results of the
combined group in the current study. However, following stroke alone there was a decrease
in GM1 and GD1a [K+] expression after injury. The differences in these results may be
explained by the type and severity of injury the animals received. Whitehead et al. (2011)
used a mouse model of middle cerebral artery occlusion (MCAO) that causes a severe,
focal ischemic insult that damages a large region within the cerebral cortex, striatum, and
hippocampus. This contrasts with the site specific striatal ET-1 ischemia model used in this
study which was chosen as it best emulates the smaller, lacunar strokes seen in aging
individuals who are at risk of developing dementia. The combination of Aβ-toxicity and
stroke resulted in a more severe response than stroke alone, which may explain why the
results of that surgical group better resemble the results of the severe MCAO stroke injury
(Whitehead et al., 2011).
Since the d18:1 and d20:1 species are hypothesized to have unique functions within
the cell (Sekigawa et al., 2011), where possible, both species were quantified and analyzed.
Although the main patterns of expression were similar, significant changes in expression
were observed in the d20:1 species that did not reach statistical significance in the d18:1
species. This leads to the possibility that a greater change in expression was occurring in
the d20:1 species than its more prevalent d18:1 species within the site of ischemic injury;
however, further investigations are needed to follow up on this finding. The significance of
this finding lies in the potential for future therapeutics targeting gangliosides as the d20:1
form may prove to be a more efficient therapeutic target than the d18:1 species.
Although MALDI IMS has proven to be an invaluable and reliable tool for the
investigation of ganglioside expression, this study is not without limitations. The most
limiting factor to the use of MALDI IMS in clinically-relevant research is that it is
generally considered to be only a semi-quantitative technique. According to Stoekli et al.
(2007) and Lietz et al. (2013), MALDI IMS images differ from each other due to three
main factors which vary from image to image: tissue heterogeneity, sample preparation,
and ion suppression effects. These variations make it difficult to quantitatively compare
between MALDI IMS images without producing a significant amount of error. However,
this study was uniquely designed to circumvent all major sources of error that arise from
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these factors. Firstly, MALDI IMS images from this study were not compared to each other
but instead were compared to themselves. By comparing the stroke-injured hemisphere
with the contralateral non-injured hemisphere, variability due to sample preparation and
matrix application was negligible. Secondly, because the two quantified regions of interest
were from the same tissue section on mirrored regions of each hemisphere of the brain, it
can be assumed that any tissue heterogeneity would be equivalent in both regions and thus
not a significant source of error. Finally, ionization suppression effects, which are mass
spectrometry signals other than the signal of interest that suppress the overall signal
obtained, can also be assumed to be equivalent based on this method of quantification.
Quantification of MALDI IMS images remains a controversial and heavily researched area
of study, and while our method of quantification does not eliminate all sources of error,
variability, the largest source of error, was significantly minimized.
This study was able to show, for the first time, that ganglioside expression was not
only altered in stroke injury but is also differentially altered in a comorbid rat model of Aβ
toxicity and stroke. Translating these animal findings to a potential clinical environment,
changes in ganglioside expression may be indicative of a new mechanism of synergy and
possible site of intervention for those at risk or currently suffering from AD and stroke
comorbidities.
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Chapter 3 : Age dependent and regional heterogeneity in the longchain base of A-series gangliosides observed in the rat brain using
MALDI Imaging
3
In Chapter 2, both d18:1 and d20:1 species of a-series gangliosides were altered in response
to the various neurodegenerative injuries. Interestingly, the d20:1 species often showed a
more a severe perturbation of their homeostatic distribution in response to the injuries,
suggesting that these species may be particularly susceptible to dysregulation. Little is
known of the functional implications of gangliosides with varying carbon lengths,
particularly for the less abundant simple ganglioside species, however, complex
gangliosides with longer carbon chains have been reported to accumulate in an agedependent manner (Sugiura et al., 2008; Palestini et al., 1990; Sonnino et al., 2000).
Limitations in the sensitivity and spatial resolution of MALDI IMS images of ganglioside
observed in Chapter 2 meant that the d20:1 species of GM3 could not be detected. This led
to establishment of refined sample preparation methodologies that, coupled with an
upgraded instrument, led to dramatic improvements in ganglioside detection and spatial
resolution (Appendix ii). Specifically, a modified sublimation protocol was developed
which was tailored for the optimal detection of a-series gangliosides and published in the
Journal of Visualized Experiments (Appendix iii). Therefore, armed with an improved
MALDI IMS protocol, we sought to better understand the role of simple and complex
ganglioside carbon chain length in the context of aging in Wt and Tg APP21 Fisher rats.

3.1 Abstract
Alterations in the long chain base of the sphingosine moiety of gangliosides have been
shown to play a role in neurodevelopment and neurodegeneration. Indeed, the
accumulation of d20:1 sphingosine has been referred to as a metabolic marker of aging in
the brain, however, this remains to be shown in simple gangliosides GM2 and GM3. In this
study, MALDI IMS was used to examine the neuroanatomical distribution of A-series
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gangliosides with either 18 or 20 carbon sphingosine chains (d18:1 or d20:1) in Fisher 344
rats across the lifespan. The ratio of d20:1/d18:1 species was determined across 11 regions
of interest in the brain. Interestingly, a decrease in the d20:1/d18:1 ratio for GM2 and GM3
was observed during early development with the exception of the peri-ventricular corpus
callosum, where an age-dependent increase was observed for ganglioside GM3. An agedependent increase in d20:1 species was confirmed for complex gangliosides GM1 and
GD1 with the most significant increase during early development and a high degree of
anatomical heterogeneity during aging. The unique neuroanatomically-specific responses
of d20:1 ganglioside abundance may lead to a better understanding of regional
vulnerability to damage in the aging brain.

3.2 Introduction
Gangliosides are a class of glycosphingolipids that are found throughout all cells of the
body, with certain species enriched in the central nervous system (CNS). They are part of a
large family of lipid species that form an important structural and functional component of
lipid rafts, a functional domain of the cell membrane enriched in phospholipids,
cholesterol, and gangliosides in which protein-lipid interactions occur leading to signal
transduction (Sonnino, Mauri, Ciampa, & Prinetti, 2013; Yu, Tsai, & Ariga, 2012). Within
the CNS, each ganglioside appears to have unique effects on signal transduction. For
example, ganglioside GM1 has been shown to enhance neuroprotection through modulation
of neurotrophin release (Rabin, Bachis, & Mocchetti, 2002) and ion transport (Wu &
Ledeen, 1994), while accumulation of ganglioside GM3 has been shown to lead to
apoptotic cell death in astrocytes (Nakatsuji & Miller, 2001) and neurons (Sohn et al.,
2006). Moreover, perturbations in the homeostatic distribution of gangliosides has been
observed in rodent models of brain injury such as middle cerebral arterial occlusion
(MCAO) stroke (Whitehead et al., 2011), co-morbid stroke and amyloid beta toxicity
(Caughlin et al., 2015), and traumatic brain injury (Woods et al., 2013), as well as in
preclinical models and human patients with neurodegenerative diseases (Desplats et al.,
2007; Di Pardo, Amico, & Maglione, 2016; Kaya et al., 2017; Oikawa et al., 2009;
Yamamoto, Nostrand, & Yanagisawa, 2006). Thus, there has been increasing interest in the
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maintenance/enhancement of ganglioside homeostasis as a treatment for neurodegenerative
conditions.
Gangliosides are structurally composed of a hydrophilic domain, containing sialic acid
residues attached to an oligosaccharide chain, along with a hydrophobic domain made up
of a ceramide complex (Fig. 3.1 A). Ceramide is composed of a fatty acid attached to a
sphingosine long-chain base (LCB). Gangliosides can be differentiated from each other
based on the length of their oligosaccharide chain and the number of sialic acid residues in
their hydrophilic domain, which determines the type of ganglioside as described by their
designation (e.g. ganglio-monosialo 3 or GM3). Gangliosides can also be differentiated by
the type of fatty acid and number of carbons present within their ceramide domain. The 18
carbon sphingosine, chemically denoted as d18:1, is the predominant species in brain
gangliosides, with 20 carbon species (d20:1) being present in lower, but variable quantities
(Rosenberg & Stern, 1966).
Alterations in the LCB have been linked to neurodevelopment and also implicated as a
potential mechanism in the development of neurodegeneration (Caughlin et al., 2015;
Tamai et al., 1979). Structurally, the additional carbons present on the ceramide moiety
lead to an increase in volume of the hydrophobic portion of the molecule. This alters the
organization of the membrane and its fluid properties (Masserini, Palestini, & Freire,
1989). Changes in the organization of the membrane has consequences for the ability of
gangliosides in lipid-rich domains to interact with the external environment and carry out
their function as modulators of cell signaling (Sonnino & Chigorno, 2000). Therefore, the
presence of d18:1 or d20:1 species in the membrane may alter the effectiveness of signal
transduction at the cell surface. The d20:1 species have also been referred to as a metabolic
marker of aging (Palestini, Masserini, Sonnino, & Tettamanti, 1990) as these species have
consistently been observed to increase with age in murine (Palestini et al., 1990; Palestini
et al., 1993; Rosenberg & Stern, 1966; Sugiura et al., 2008; Valsecchi, Palestini, Chigorno,
& Sonnino, 1996) and human brains (Mansson, Vanier, & Svennerholm, 1977). However,
the literature on this topic has focused almost exclusively on major complex gangliosides
GM1, GD1, GT1, and GQ1, with minimal neuroanatomically-specific information, and has
not described how the LCB of minor, simple gangliosides shift during aging. This
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information may be crucial as there is increasing evidence pointing to the potential role of
simple ganglioside, such as GM3 and GM2, in the development and pathogenesis of
neurodegenerative diseases and injuries (Caughlin et al., 2015; Whitehead et al., 2011;
Woods et al., 2013), however, the role of the ceramide moiety remains unclear due to
technical challenges in the detection of these low abundance species.
Previous investigations have used MALDI IMS to visualize d18:1 and d20:1 species of
ganglioside GM1 (Caughlin et al., 2015; Sugiura et al., 2008; Weishaupt, Caughlin, Yeung,
& Whitehead, 2015; Whitehead et al., 2011). This technique has the advantage of
simultaneously detecting multiple species of gangliosides (and other molecules) within the
same sample based on their abundance and neuroanatomical location. This tool is also a
powerful technique to differentiate carbon numbers within ganglioside LCB, which cannot
be done using antibody labelling. A study describing the expression of d18:1 and d20:1
species of all A-series gangliosides during the aging process has not yet been done.
Therefore, the following study provides the first detailed examination of age-dependent
changes in the LCB of both simple and complex A-series gangliosides across a large
number brain regions in wildtype (Wt) and APP21 transgenic (Tg) Fisher 344 rats that
contain the human mutations to the amyloid precursor protein (Agca et al., 2008;
Weishaupt et al., 2015). We hypothesized that there would be significant regional
differences in the ratio of d20:1 species relative to d18:1 across the brain throughout aging
and that this would be enhanced in the Tg APP21 rat. To achieve this, we used MALDI
IMS (Fig. 3.1 B+C), for accurate neuroanatomically-localized detection of d18:1 and d20:1
species across intact tissue sections.
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Figure 3.1: Ganglioside structure and detection using MALDI IMS. Chemical structure
and MALDI IMS of d18:1 and d20:1 gangliosides. (A) Gangliosides are composed of both
a hydrophilic domain which extends into the extracellular space, and hydrophobic ceramide
anchor (highlighted) which is embedded in the cell membrane. The hydrophillic portion
contains an oligosaccharide chain and sialic acid residues which determine the type of
ganglioside (i.e. GM1, GM2, GM3). The hydrophobic portion of the molecule is made up
of a fatty acid and a sphingosine LCB tail with varying numbers of carbons. (B)
Representative MALDI IMS molecular image depicting anatomical distribution of d18:1
(blues), and d20:1 (yellow) GM3 species across a sagittal section of a P0 Fisher 344 rat
head. (C) Representative mass spectrum using DAN matrix in negative reflection mode
depicting the mass of a-series gangliosides (and corresponding m/z values) analyzed in the
current study. From left to right: GM3 d18:1 (1179 Da), GM3 d20:1 (1207 Da), GM2
d18:1 (1382 Da), GM2 d20:1 (1409 Da), GM1 d18:1 (1543 Da), GM1 d20:1 (1572 Da),
GD1a[K+] d18:1 (1872 Da) and GD1a[K+] d20:1 (1901 Da).
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3.3 Materials and Methods
3.3.1

Animal model

All procedures involving live animals were in accordance with the guidelines of the
Canadian Council on Animal Care and approved by the University of Western Ontario
Animal Use Committee (Protocol 2014–2016). Wt and Tg APP21 Fisher 344 rats were
kindly provided by Dr. Yukel Agca (University of Missouri) and bred in-house. Tg APP21
rats contained both human Swedish and Indiana mutations for the amyloid precursor
protein gene. Because there were no significant transgene effects at each individual time
point, the data for both Wt and Tg APP21 rats was pooled for all analysis for a final n value
of 10 per group. Rats were aged to 4 different time points to be as representative as
possible of the full lifespan, leading to a total of 40 rats included in the study. Rats were
sacrificed via fresh-frozen extraction (described elsewhere) at either P0 (newborn), 3
months (m, young rats), 12 m (middle aged), or 20 m (old). Brains were stored at −80°C
until processed for MALDI IMS.
3.3.2

MALDI IMS

Brain tissue (or whole heads for P0 rats) were sectioned on a cryostat (Termo-Fisher
Scientifc CryoStar NX50) at a thickness of 10 μm and thaw mounted onto electrically
conductive Indium-Tin-Oxide (ITO) slides (Hudson Surface Technology Inc., Old Tappan,
NY, USA). The slides were then coated in a thin layer of 1,5-Diaminonapthalene (DAN,
Sigma-Aldrich, Oakville, ON, Canada) matrix via sublimation and incubated at −20 °C
overnight. After a 10 min desiccation period, a 5 peptide calibration standard was applied
(Sciex, Farmingham, MA. USA) and allowed to dry. An image of the plate was scanned for
reference in the instrument and the instrument calibrated using the spotted standards to a
mass tolerance of 50 ppm. Images were acquired using a Sciex MALDI 5800 TOF/TOF
instrument in negative ion reflectron mode. MS images were acquired at a 70 μm raster
with 20 shots/spectrum. This protocol has been previously described in detail (Caughlin et
al., 2017). Representative MALDI IMS images of each ganglioside species quantified in
the current study are shown in Fig 3.2.
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Figure 3.2: Representative MALDI IMS images of each a-series ganglioside in all 4
tissue sections. Representative images from the most anterior tissue section contained the
ROIs for the cortical layers, striatum and aCC (A). The second tissue section contained the
ROIs for the LSN and PVCC (B). The third section was at the level of the hippocampus
and was used for all hippocampal ROIs (C). The most posterior section contained the ROI
for the substantia nigra (D). Images are ordered from the earliest time point (P0 – left) to
the latest time point (20 m – right) for each tissue section.
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3.3.3

Data Analysis

The regions of interest (ROIs) were confirmed using the rat brain atlas by Paxinos &
Watson (1998). A total of 11 ROIs were quantified across the brain and were grouped into
discrete anatomical/functional regions for quantitation. These clustered groups include:
sub-cortical structures (striatum, lateral septal nucleus, and substantia nigra), the cortex
(superficial, intermediate, and deep layers of the cortex), the hippocampus (CA1, dentate
gyrus molecular layer, dentate gyrus granular layer), and white matter (anterior corpus
callosum and peri-ventricular corpus callosum). MALDI IMS images were analyzed using
TissueView sofware (Version 2, Sciex). A total of 4 tissue sections per brain were used to
isolate discrete anatomical regions in order to quantify the 11 regions of interest, for a total
of 160 MALDI MS images (40 rats×4 sections) and 440 total datasets (40 rats×11 ROIs).
Peaks corresponding to major a-series gangliosides were isolated and identified, as
confirmed by previous studies (Chan et al., 2009; Dufresne et al., 2017; Sugiura et al.,
2008; Woods et al., 2013) and the Lipidmaps database (www.lipidmaps.org). For
quantification of MALDI-IMS data, the area under the curve (AUC) of the three largest
isotopic peaks was determined and a ratio was obtained between the AUC of each species
and total AUC. This corrected value was used to perform a ratio of the d20:1 species of
each a-series ganglioside to the d18:1 species. This ratio value was used to make between
group comparisons so as to reduce error produced by variability in sample preparation
between images as previously published (Caughlin et al. 2015). For GD1, the more
abundant K+ adduct peaks were used. Statistical analysis was performed using either a
student’s t-test or a two-way ANOVA, followed by a Tukey’s post-hoc test.

3.4 Results
3.4.1

Genotype differences in LCB restricted to GM3 within the peri-ventricular
corpus callosum.

No significant differences in regional abundance across age were observed between Wt and
Tg APP21 rats with the exception of ganglioside GM3 in the peri-ventricular corpus
callosum where the fold increase of d20:1/d18:1 between P0 and 20 m was found to be
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significantly higher in Tg APP21 rats than their Wt counterparts (Fig. 3.3). Given the lack
of genotype specific differences in d20:1/d18:1 ratios at each individual time point, all
future analysis used pooled data from both Wt and Tg APP21 rats.
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Figure 3.3: Increased d20:1/d18:1 GM3 ratio in PVCC between birth and old age in
TgAPP21 rats. Quantification of MALDI IMS data showing the fold change in
d20:1/d18:1 signal between birth (P0) and old age (20 m) in the PVCC (A) and corpus
callosum (B). Tg APP21 rats showed a significant increase in the d20:1/d18:1 LCB ratio
between birth and old age compared to their Wt counterparts in the PVCC. A similar
pattern was observed in the aCC, however, the fold change was not statistically different in
this region. This transgene difference explains the high degree of variability observed at
each individual time point in white matter regions. Data represented as group Means ±
SEM,* indicates statistical significance, p < 0.05, via student’s T test, n=5 for each time
point.
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3.4.2

Significant anatomical heterogeneity throughout the rat life span within
subcortical and basal ganglia structures for gangliosides GM1 and GM3

Sub-cortical structures are susceptible to age related changes associated with Alzheimer’s
disease (basal forebrain) Parkinson’s disease (substantia nigra) and Huntington’s disease
(striatum). We measured the ratio between d20:1 and d18:1 species of gangliosides within
the lateral septal nucleus (LSN) of the basal forebrain, substantia nigra (SN), and striatum
of rats from P0 to 20 m of age (Fig. 3.4 A). There were no regional differences in GM1
d20:1/d18:1 ratios in P0 rats. At 3 m, the d20:1/ d18:1 ratio was significantly lower in the
SN (0.15) than the striatum (0.21), and remained the lowest of the three regions up to 20 m
(Fig. 3.4 B). At 12 m, the ratio of GM1 d20:1/d18:1 species was significantly higher in the
striatum (0.28) than the SN (0.20), with the LSN between the two (0.24), however, by 20
m, the regional differences shifted back to a similar pattern as that of 3 m, with both the
striatum (0.25) and LSN (0.23) demonstrating significantly higher GM1 d20:1/d18:1 ratios
than the SN (0.17). When measuring differences in d18:1/d20:1 ratios for GD1, no regional
differences were observed at any time point in the basal ganglia (Fig. 3.4 C). The GD1
d20:1/d18:1 ratio increased from P0 to 12 m in all subcortical structures then dropped
slightly by 20 m.
With respect to simple ganglioside GM3 during aging, the d20:1/d18:1 ratio
increased slightly from P0 (0.43, 0.34) to 12 m (0.49, 0.39) within the LSN and striatum
respectively. The d20:1/d18:1 GM3 ratio within the SN decreased significantly from 0.6 in
P0 rats to 0.32 at 3 m, which then continued to decrease slightly up to 20 m (0.27) (Fig. 3.4
D). These divergent patterns for the GM3 LCB ratio during aging are indicative of
significant regional differences within subcortical structures. Indeed, at P0, a regional
difference was observed with significantly higher d20:1 content observed in the SN (0.6)
over the striatum (0.35) and LSN (0.43). This pattern shifted at 12 m where the SN
d20:1/d18:1 ratio decreased to 0.32 while the LSN ratio increased to 0.49, leading to a
significant difference between these two brain regions. These regional differences
disappeared at 20 m as the d20:1/ d18:1 ratio dropped in the LSN (0.38) (Fig. 3.4 D). There
were no regional differences observed in the GM2 species (Fig. 3.4 E), however, all brain
regions showed a significant decrease in the d20:1/d18:1 ratio between P0 and 3 m which
then remained stable up to 20 m.
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Figure 3.4: Significant regional heterogeneity in ganglioside LCB ratio among subcortical structures. Visualization of regional and age-dependent shifts in a-series
gangliosides in sub-cortical rat brain structures. (A) Representative MALDI IMS overlay
images showing the anatomical distribution of GM1 d18:1 (red) and d20:1 (green). (B–E)
Quantification of the d20:1/d18:1 ratio at each time point for GM1 (B), GD1 (C), GM3
(D), and GM2 (E). The d20:1/ d18:1 LCB ratio increased in an age-dependent manner for
complex gangliosides GM1 and GD1 up to 12 m then plateaued up to 20 m (GM1) or
decreased slightly (GD1). Significant anatomical heterogeneity in the LCB ratio was
observed from simple ganglioside GM3 among sub-cortical structures, with a decrease
during early development in the SN, and a stable ratio in the striatum and LSN throughout
the lifespan. Data represented as group Means ± SEM, *indicates statistical significance, p
< 0.05, via two-way ANOVA, Tukey multiple comparisons test, n = 10 for each time point.
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3.4.3

Cortical layers show regional heterogeneity in ganglioside of LCB length

Regional differences between the superficial, intermediate, and deep layers of the cerebral
cortex have previously been reported (Weishaupt et al., 2015). The present study used
similar cortical ROIs (Fig. 3.5 A) to evaluate alterations in the LCB length during aging in
the rat. When measuring the LCB length of GM1, a similar d20:1/d18:1 ratio of 0.07–0.09
was observed in all three layers of the cortex of P0 rats (Fig. 3.5 B). All three layers
demonstrated variable but increased d20:1/d18:1 GM1 during aging with a plateau
observed at 12 m. Interestingly, the intermediate layer demonstrated the highest ratio of
d20:1/d18:1 expression for GM1 which became apparent at 3 m (intermediate – 0.30,
superior – 0.25, deep – 0.20) and continued to be significantly higher than the deep layers
up to 20 m. A similar pattern was observed for LCB length of GD1 whereby P0 rats had
similar ratios of d20:1/d18:1 throughout all layers of the cortex followed by an increase in
the ratio of d20:1/d18:1 at 3 m and a plateau at 12 m (Fig. 3.5 C). Like GM1, GD1 in the
intermediate layer of the cortex also demonstrated the greatest increase in the LCB ratio
which was most apparent at 12 m (intermediate – 0.61, superficial – 0.39, deep – 0.45) and
continued to be significantly higher than the other cortical layers up to 20 m. The aging
abundance profile of simple gangliosides GM3 and GM2 LCBs was the opposite of their
complex ganglioside counterparts whereby the d20:1/d18:1 ratio was highest at P0, and
then decreased during early development, plateauing at 3 m (Fig. 3.5 D,E). The deep layers
of the cortex showed a significantly higher d20:1/d18:1 ratio at 3 m (0.43) than the
superficial layers (0.32) (Fig. 3.5 D). GM2 demonstrated regional differences only at 20 m
(Fig. 3.5 E), with the intermediate layers of the cortex showing a significantly higher
d20:1/d18:1 LCB ratio (0.78) than the superficial layers (0.66).
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Figure 3.5: LCB ratio highest in superficial layers of the cortex and shows opposite
pattern during early development among complex and simple gangliosides.
Visualization of regional and age-dependent shifts in a-series gangliosides in the cerebral
cortex of the rat. (A) Representative MALDI IMS overlay images showing the anatomical
distribution of GM1 d18:1 (red) and d20:1 (green) across tissue along with the anatomical
location of the ROIs in the superficial, intermediate, and deep layers of the cerebral cortex.
(B–E) Quantification of the d20:1/d18:1 ratio at each time point for GM1 (B), GD1 (C),
GM3 (D), and GM2 (E). The ratio of d20:1/d18:1 species increased in an age-dependent
manner in complex gangliosides GM1 and GD1 up to 12 m of age, with the highest ratio
observed in the intermediate layers of the cortex. The ratio then plateaued or decreased
slightly at 20 m. The LCB ratio dropped between P0 and 3 m in simple gangliosides GM3
and GM2. Data represented as group Means ± SEM, *indicates statistical significance, p <
0.05, via two-way ANOVA, Tukey multiple comparisons test, n = 10 for each time point.
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3.4.4

Hippocampus: Age-dependent accumulation in d20:1/d18:1 species in the
dentate gyrus molecular layer observed in complex gangliosides only.

Three regions of the hippocampus (Fig. 3.6 A) were selected for analysis based on previous
reports of regional differences in the ratio of d20:1/d18:1 for GM1 (Sugiura et al., 2008;
Weishaupt et al., 2015). The d20:1/d18:1 ratio of GM1 increased in an age-dependent
manner within the CA1 and dentate gyrus (DG) molecular layer (mol) of the hippocampus,
however, the ratio remained stable in the granular layer (gr) of the DG throughout the rat
lifespan (Fig. 3.6 B). There were no regional differences within the hippocampus at P0,
however, pronounced regional differences were observed between all three layers postnatally. The ratio of d20:1/d18:1 GM1 was highest in the DG mol where it increased from
0.14 at P0 to 0.44 at 3 m and continued to increase up to 20 m (0.51). A similar pattern was
observed within the CA1 (P0–0.18, 3 m – 0.27, 20 m 0.33). The DG gr showed the lowest
d20:1/d18:1 ratio of GM1 within the hippocampus remaining relatively unchanged from P0
(0.18) to 20 m (0.17). As noted in the previous brain regions, the d20:1/d18:1 ratio of GD1
was higher at P0 than for GM1. However, unlike GM1, not all layers of the hippocampus
showed age-dependent increases in the ratio of d20:1/d18:1 species. This trend was only
observed in the DG mol where the d20:1/d18:1 ratio increased from 0.26 at P0 to 0.4 at 3
m, and continued to increase to 0.52 at 12 m, where it plateaued up to 20 m (Fig. 3.6 C).
The DG gr demonstrated an unexpected decrease in the ratio of GD1 d20:1/d18:1 between
P0 (0.37) and 3 m (0.25) which then increased at 12 m (0.34) only to drop back down at 20
m (0.24). Equally interestingly, the CA1 region showed no change in the LCB ratio
between P0 and 3 m, but increased between 3 m (0.26) and 12 m (0.37), then dropped
slightly at 20 m (0.3).
As was observed in the cortex, the ratio of d20:1/d18:1 for simple gangliosides
GM2 and GM3 was highest at P0 followed by a large decrease at 3 m where it remained at
this level or decreased slightly at 20 m (Fig. 3.6 D,E). There were no regional differences
in the GM3 LCB ratio within the hippocampus, however, the d20:1/d18:1 ratio did
decreased between P0 and 20 m (CA1 0.61–0.26, DG mol 0.55–0.22, DG gr 0.48–0.22),
with the most significant drop occurring in early development. There were modest but
statistically significant differences in the GM2 d20:1/d18:1 ratio at P0 (Fig. 3.6 D; CA1 –
1.17, DG gr – 1.31) and 12 m (DG mol – 0.86, DG gr – 0.72) within the hippocampus.
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Figure 3.6: Significant regional heterogeneity in d20:1/d18:1 ratio during aging
among hippocampal layers. Visualization of regional and age-dependent shifts in A-series
gangliosides in the hippocampus of the rat. (A) Representative MALDI IMS overlay
images showing the anatomical distribution of GM1 d18:1 (red) and d20:1 (green). (B–E)
Quantification of the d20:1/d18:1 ratio at each time point showing the significant regional
differences across the lifespan for each A-series ganglioside, GM1 (B), GD1 (C), GM3 (D),
and GM2 (E). Significant anatomical heterogeneity in the age-dependent accumulation of
d20:1 species was observed in the various sub-regions of the hippocampus for complex
gangliosides GM1 and GD1 while the LCB ratio dropped during early development in
simple gangliosides GM3 and GM2. Data represented as group Means ± SEM,* indicates
statistical significance, p < 0.05, via two-way ANOVA, Tukey multiple comparisons test, n
= 10 for each time point.
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3.4.5

Age-dependent increase in LCB ratio observed in the white matter for both
complex gangliosides and simple ganglioside GM3.

Changes in white matter have been linked to several aging related neurodegenerative
diseases. We investigated two distinct regions within the corpus callosum that clinically
demonstrate differing vulnerability to structural changes in AD patients (Gao et al., 2014)
(Fig. 3.7 A). The two regions used in our analysis were the anterior corpus callosum (aCC)
adjacent to the striatum, and a more caudal sampling from the white matter adjacent to the
ventricles, peri-ventricular corpus callosum (PVCC). Interestingly, the PVCC expressed
higher ratios of d20:1/d18:1 ganglioside species than the more rostral aCC. Both GM1 and
GD1 gangliosides showed an increase in d20:1 species up to 12 m which then plateaued to
20 m (Fig. 3.7 B,C). For GM1 (Fig. 3.7 B), the d20:1/d18:1 ratio increased significantly
from P0 (aCC–0.07, PVCC – 0.08) to 3 m (aCC – 0.13, PVCC – 0.14), and continued to
increase at 12 m (aCC – 0.18, PVCC – 0.21). A more pronounced age-dependent increase
in d20:1 species was observed for ganglioside GD1 in the PVCC. The d20:1/d18:1 ratio
increased between each time point (Fig. 3.7 C; P0 – 0.22, 3 m – 0.48, 12 m – 0.7, 20 m –
0.75). For the aCC, a similar pattern was observed to that of the PVCC, however, the
d20:1/d18:1 ratio dropped between 12 m (0.5) and 20 m (0.4). Interestingly, regional
differences were observed between the two white matter regions for the GD1 LCB ratio
which became apparent at 3 m (PVCC – 0.48, aCC – 0.3) and continued at 12 m (PVCC –
0.7, aCC – 0.5) and 20 m (PVCC – 0.75, aCC – 0.4).
The aging shifts of LCBs were completely different between simple gangliosides
GM2 and GM3 (Fig. 3.7 D,E). The ratio of d20:1/d18:1 for GM3 increased steadily in the
PVCC throughout aging, similar to what was observed for GM1 and GD1 (Fig. 3.7 D; P0 –
0.58, 3 m – 0.67, 12 m – 0.82, 20 m – 0.96) whereas the aCC remained relatively constant
(P0 – 0.5, 3 m – 0.54, 12 m – 0.59, 20 m – 0.55) resulting in significant differences
between the aCC and PVCC ratios at 12 and 20 m of age. This was the only brain region to
show an increase in the GM3 d20:1/d18:1 ratio during aging. Simple ganglioside GM2
(Fig. 3.7 E) showed a similar pattern to that of the other brain regions, with a significant
decrease in the d20:1/d18:1 ratio from P0 (aCC–1.06, PVCC–1.14) to 3 m (aCC–0.74,
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PVCC – 0.74) where the ratio remained unchanged up to 20 m in the PVCC (0.75) and
dropped slightly in the aCC (0.65).
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Figure 3.7: Unique pattern of d20:1 LCB accumulation in the white matter for simple
ganglioside GM3 as well as significant differences among white matter regions during
aging. Visualization of regional and age-dependent shifts in a-series gangliosides in the
white matter of the rat. (A) Representative MALDI IMS overlay images showing the
anatomical distribution of GM1 d18:1 (red) and d20:1 (green) (B–E) Quantification of the
d20:1/d18:1 ratio at each time point showing the significant regional differences across the
lifespan for each a-series ganglioside, GM1 (B), GD1 (C), GM3 (D), and GM2 (E). An
age-dependent increase in the d20:1/d18:1 ratio was observed in the PVCC for gangliosides
GM1, GD1, and also simple ganglioside GM3. Data represented as group Means ±
SEM,*indicates statistical significance, p < 0.05, via two-way ANOVA, Tukey multiple
comparisons test, n = 10 for each time point.
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3.4.6

Overall age effects

In order to make global anatomical and age-dependent comparisons between all 11 regions
of interest in d20:1/d18:1 content, the fold change was calculated between P0 and 3 m old
rats (Fig. 3.8 A–D). This time period corresponds to the early post-natal stages of
neurodevelopment and also served as the time period of the greatest observed changes in
LCB length in the current study. We also calculated the fold change between 3 m and 20 m,
a time period corresponding adolescence and old age in Fisher rats (Fig. 3.8 E–H).
There was a 1.5–4 fold increase in the ratio of d20:1/d18:1 species between P0 and
3 m for ganglioside GM1 in most brain regions examined, with the exception of the DG gr
layer of the hippocampus, which remained unchanged. The largest fold increases occurred
in the cerebral cortex, striatum, and the DG mol (Fig. 3.8 A). There was a 1.5–3 fold
increase in the d20:1/d18:1 ratio for ganglioside GD1 between birth and 3 m, with the
exception of the CA1 and DG gr of the hippocampus, in which the former remained
unchanged, and the latter decreased 1.5 fold (Fig. 3.8 B). The largest fold increase in GD1
d20:1/d18:1 content during early development occurred in the cerebral cortex and white
matter regions. GM3 d20:1/d18:1 content decreased 1.5 to 3 fold across the brain with the
exception of the two white matter regions, the LSN, and the striatum which remained
unchanged (Fig. 3.8 C). GM2 d20:1/d18:1 content decreased roughly 2 fold across all brain
regions examined, with the largest drop occurring in the superficial layer of the cortex and
DG gr of the hippocampus (Fig. 3.8 D).
During adulthood, the PVCC showed the largest fold increase for gangliosides
GM1, GD1, and GM3 (Fig. 3.8 E–G). The PVCC was the only brain region which the
d20:1/d18:1 ratio was significantly altered between 3 and 20 m of age. For ganglioside
GD1, the PVCC along with the intermediate layers of the cerebral cortex and DG mol layer
of the hippocampus had significantly elevated d20:1/d18:1 ratios, all other regions
remained either unchanged or increased less than 50% during adulthood (Fig. 3.8 F). The
PVCC was the only region where the LCB of GM3 was significantly increased between 3
and 20 m, however, the DG gr layer of the hippocampus showed a significant decrease
within the same period, while all other brain regions remained statistically unchanged (Fig.
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3.8 G). There were no significant alterations in the d20:1/d18:1 ratio of GM2 between 3 m
and 20 m of age (Fig. 3.8 H).
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Figure 3.8: Differential alterations in LCB during early brain development and
adulthood in Fisher rats. Overall age effects of d20:1/d18:1 ratio during post-natal rat
brain development and adulthood. Quantification of the fold-change in the d20:1/d18:1
ratio between P0 - 3 m (A–D) and 3 m–20 m (E–H). Ganglioside GM1 shows a significant
fold increase between P0 and 3 m (A) which only continued to increase in the PVCC
during adulthood (E). Ganglioside GD1 increased in all brain regions except the CA1 and
DG gr layers of the hippocampus in early development (B) with a few regions continuing
to increase into old age (F). Ganglioside GM3 showed either a decreased or stable LCB
ratio in early development (C) which remained unchanged throughout adulthood except for
the PVCC, which increased, and the DG gr, which decreased (G). Ganglioside GM2 LCB
ratio decreased significantly in early development across the brain (D) and remained stable
throughout adulthood (H). In order to calculate the global changes in early development
and adulthood, an average value for the d20:1/d18:1 ratio was calculated (either P0 or 3 m)
and used for comparison to each animal in the later time point (3 m or 20 m). Data
represented as group Means ± SEM, *indicates statistical significance, p < 0.05, via twoway ANOVA, Tukey multiple comparisons test, n = 10 for each time point.
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3.5 Discussion
Work in this study describes the age-dependent changes in the d20:1/d18:1 ratio of
gangliosides across multiple cortical, subcortical, and white matter regions of the brain
using MALDI IMS. It is the first to examine age-related alterations in the LCB of minor
ganglioside components GM2 and GM3 which are currently gaining interest as potential
mediators of neurodegeneration in a number of neurodegenerative diseases and injuries
(Caughlin et al., 2015; Dufresne et al., 2017; Kaya et al., 2017; Whitehead et al., 2011;
Woods et al., 2013). This work builds upon previous studies by Weishaupt et al. 2015,
which described regional differences in the d18:1/d20:1 ratio of ganglioside GM1 in 3 m
old Fisher rats, as well as the work of Sugiura et al. 2008, which was the first to use
MALDI IMS to described age-dependent changes within hippocampus of mice. The
current study confirmed many of the findings from the aforementioned studies pertaining to
complex gangliosides GM1 and GD1. For example, Weishaupt et al. 2015 used similar
regions of interest in the cortex and found, like the current study, that the lowest
d20:1/d18:1 ratio occurred in the deep layers of the cortex, with significantly higher ratios
in the intermediate and superficial layers. Anatomically, the intermediate and superficial
layers of the cortex have a particularly high density of neurons which receive inputs from
cholinergic neurons in the basal forebrain (Garofalo, Ribeiro-da-Silva, & Cuello, 1993)
while the deep layers of the cortex have high connectivity to thalamic nuclei (Zarrinpar &
Callaway, 2006). A heterogeneous expression of A-series gangliosides have also been
reported in various layers of brain cortices of normal and injured mice. Specifically, Kwak
et al. 2005 found that ganglioside GM3 was upregulated in deep layers of the cortex (layers
4-6) after an MCAO stroke injury while GM1 was upregulated in more superficial layers
(2-3) as well as the deep layers. The regional differences in the d20:1/d18:1 ratio observed
in the current study may also reflect important functional differences in connectivity within
the cortex that play a role in normal brain aging as well as the brain’s response to injury,
however, this connection remains unclear and would be an interesting avenue of further
investigation.
We also observed significant regional differences within the various layers of the rat
hippocampus from 3 m of age through to 20 m. The DG mol showed the highest ratio of
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d20:1/d18:1 gangliosides followed by the CA1 and DG gr. Sugiura et al. 2008 reported an
age-dependent accumulation of d20:1 species of ganglioside GD1 compared to d18:1
species in the DG molecular layer of the mouse hippocampus. While this age-dependent
accumulation was also observed in the current study, the CA1 region was only observed to
increase between P0 and 12 m of age, while the DG gr showed a decrease in d20:1/d18:1
between P0 and 20 m. This data suggests that not all layers of the hippocampus show an
increase in GD1 d20:1/d18:1 ratio between birth and old age, which may be related to the
various functions of different anatomical domains within the hippocampus. For example,
the DG mol is known to be a critical area of connectivity in the perforant pathway, which
receives input from the entorhinal cortex and sends connections to the CA3 (Witter &
Amaral, 1991). It has been previously suggested that the high proportion of d20:1 species
observed in the DG mol could be linked to the particular vulnerability of this perforant
pathway to neurodegeneration during the development of Alzheimer’s disease (HiranoSakamaki et al., 2015). Similarly, the sub-cortical structures examined in the current study
are particularly vulnerable to the development of neurodegenerative diseases and
perturbations in ganglioside homeostasis, as previously mentioned. Treatments focused on
restoring depleted complex ganglioside GM1 have been therapeutically promising both in
pre-clinical models of neurodegenerative diseases and clinically (Kreutz et al., 2011;
Maglione et al., 2010; Schneider et al., 2013), pointing to the importance of understanding
these ganglioside perturbations during aging. Interestingly, very different patterns of
d20:1/d18:1 LCB ratios were observed for simple ganglioside GM3 among these subcortical structures throughout the lifespan of the Fisher rats. The LCB ratio dropped during
early development only in the SN (similar to the hippocampus and cortex) while levels
remained unchanged in the striatum and LSN. This regional and age-dependent
heterogeneity in GM3 LCB suggests that the d20:1 species of GM3 is differentially
regulated within these subcortical structures and may be an indicator of regional
vulnerability to damage and/or disease during aging.
While information on general alterations in the LCB length of simple gangliosides is
scarce, our findings do not match with what has been hypothesized to occur based on
previous studies conducted on complex gangliosides. Specifically, the age dependent
accumulation of d20:1 species in the brain has been suggested to be a hallmark of the aging
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process (Palestini et al., 1993), however this assertion was based on the analysis of
complex gangliosides only. The results of the current study demonstrated that, relative to
the d18:1 species, d20:1 content generally decreased between P0 and 3 m of age for
gangliosides GM2 and GM3 and this ratio remains fairly constant throughout adult life.
One potential reason for the observed decrease in the d20:1/d18:1 ratio in the early life of
the rat may be related to the role of these gangliosides during neurodevelopment. It is
possible that the observed decrease in d20:1 content in simple gangliosides may be due to
an increase in d18:1 content during the first 3 months, however, this remains unclear in the
current study and is thus an important caveat. Future studies which examine and compare
alterations in individual ganglioside species may address this pitfall.
Overall, data from this study showed that the greatest changes in LCB composition
occurred between P0 and 3 m of age in the rat. This finding is in accordance with previous
literature, using alternative techniques, focused on the very early stages of development
(Palestini et al., 1990; Valsecchi et al., 1996). We demonstrated that the alterations in LCB
length between P0 and 3 m of age was highly variable depending not only on the
ganglioside species, whether it be simple or complex, but more importantly on the brain
region as well. In addition to examining the changes in LCB length in the early stages of
rat brain development, we included a detailed report of the LCB length changes in the
mature brain in order to determine if there are distinct regions and/or gangliosides that are
particularly connected to the process of aging in the rat brain. Interestingly, the PVCC
showed the largest fold increase in the d20:1/d18:1 ratio during adulthood for complex
gangliosides GM1 and GD1, as well as the pro-apoptotic simple ganglioside GM3. This
accumulation of d20:1 species in the PVCC suggests that this region of the brain may be
particularly susceptible to the effects of aging and neurodegeneration in rats. Indeed,
alterations in gangliosides abundance has been shown to produce abnormalities in white
matter (Sheikh et al., 1999) and more recently, Di Pardo, Amico, and Maglione 2016 found
decreased levels of complex gangliosides in the corpus callosum of a mouse model of
Huntington’s disease. Moreover, the PVCC was the only region that showed an agedependent increase in the proportion of simple ganglioside GM3 d20:1. This finding in
particular supports the notion of susceptibility to neurodegeneration due to the toxic nature
of GM3 accumulation reported in the literature (Chung et al., 2009; Nakatsuji & Miller,
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2001; Prokazova, Samovilova, Gracheva, & Golovanova, 2009; Sohn et al., 2006), the
reported accumulation of GM3 in senescence-accelerated mice (Ohsawa & Shumiya,
1991), as well as increased simple ganglioside content in the brains of both animal models
and clinical patients with AD (Kaya et al., 2017; Oikawa et al., 2009; Yamamoto et al.,
2006). Regional differences between the two sub-regions of white matter observed in the
current study may also have clinical relevance. In a study using magnetic resonance
imaging to evaluate white matter hyperintensities in human patients with cerebrovascular
diseases, the authors found that PVWM hyperintensities, but not deep white matter
hyperintensities, were associated with aging and the incidence of dementia (Gao et al.,
2014). Future studies should focus on evaluating the mechanism for ganglioside LCB
alterations during aging in order to determine whether there are links to white matterspecific pathological changes associated with brain aging and disease.
Although the mechanisms involved in the age-dependent accumulation of d20:1
gangliosides are not fully understood, there are several theories as to what may contribute
to this finding. Firstly, it has been suggested that different types of enzymes, or enzyme
modulators capable of distinguishing between LCB, may be present and are differentially
active throughout neurodevelopment and aging (Palestini et al., 1990; Sonnino &
Chigorno, 2000). Alternatively, Palestini et al. 1990 suggested that d20:1 intermediates
may be preferentially used during biosynthesis and recycling of ganglioside degradation
products with aging. Rosenberg and Stern 1966 were one of the first to report an agedependent increase in d20:1 sphingosine in the murine brain. In that study, using whole
brain extracts, they also found that there was an age-dependent decrease of stearic acid
content in ganglioside fractions. Overall, these studies along with the current study suggest
that understanding the role of LCB length in mediating in neurodevelopment and brain
aging are worthy pursuits for continued investigation.
MALDI IMS is currently the only technique capable of simultaneously providing
accurate detection, ionic abundance, and anatomical distribution data of gangliosides based
on both their oligosaccharide and ceramide moieties, making it a powerful analytical tool
for the study of gangliosides in the brain. The evolution of MALDI instrumentation along
with refined sample preparation protocols allows for very high resolution imaging for the
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visualization and analysis of discrete anatomical structures within intact tissue sections.
This technique, however, is not without drawbacks. It is considered a semi-quantitative
technique due to variability in sample preparation and instrumentation between runs.
Additionally, detection of multisialylated ganglioside species such as GD1 are susceptible
to in-source fragmentation and ionize attached to salt adducts [Na+] and [K+] (Richards et
al., 2012). These factors dampen the signal obtained for this species and complicate the
interpretation of GM1 data as well. However, because the current study quantified the ratio
of one species to another within the same spectrum (d20:1/d18:1), direct comparisons
between images and individual species abundance was avoided, thus reducing the effects of
dampened signal and error produced by between-scan variability. In the end, the numerous
benefits of MALDI IMS outweigh the pitfalls and it continues to be the most valuable tool
for the investigation of membrane lipids in the brain.
Overall, data from our study, for the first time, provide insight into the changing
composition of simple ganglioside LCB throughout the brain during aging and provide a
more in depth examination of LCB alterations in complex gangliosides. This study contains
the most detailed examination of the anatomical distribution of d18:1 and d20:1
ganglioside species to date in order to better understand the role of these membrane lipids
during aging. Detailed analyses of ganglioside anatomical distribution patterns and
abundance during healthy and pathological aging may provide valuable insight for the
creation of effective lipid-derived therapeutics for neurodegenerative diseases and injuries.
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Chapter 4 : Membrane lipid homeostasis in a prodromal rat model of
AD: Characteristic profiles in ganglioside distributions during aging
detected using MALDI imaging mass spectrometry

In the previous chapter, accumulation of d20:1 ganglioside species in the aging brain was
found to be more complex than previously thought. Firstly, simple gangliosides GM3 and
GM2 generally showed a stable or decreased ratio of d20:1/d18:1 species during aging,
countering the hypothesis that the accumulation of d20:1 species is a hallmark of the aging
process (Palestini et al., 1990). Secondly, the pattern of the d20:1/d18:1 ratio during aging
was highly heterogeneous across the brain, particularly for simple ganglioside GM3. To
build upon the findings of the previous chapter, we next examined the abundance of each
ganglioside species separately for a more detailed examination and comparison of simple
and complex ganglioside patterns during aging in wild-type (Wt) and transgenic (Tg)
APP21 Fisher rats. Additionally, a MALDI tandem MS (MS/MS) experiment was
performed in order to identify some of the major ganglioside species examined in this
work. The results has been provided as an appendix (Appendix iv).

4.1 Abstract
Accumulation of simple gangliosides GM2 and GM3 and gangliosides with longer longchain bases (d20:1) have been linked to toxicity in the brain and the pathogenesis of
Alzheimer’s disease (AD). Conversely, complex gangliosides, such as GM1, have been
shown to be neuroprotective. Recent evidence using matrix-assisted laser desorption
ionization (MALDI) imaging mass spectrometry (IMS) has demonstrated that a-series
gangliosides are differentially altered during normal aging, yet it remains unclear how
simple species are shifting relative to complex gangliosides in the prodromal stages of AD.
Ganglioside profiles in Wt and Tg APP21 Fischer rats were detected and quantified using
MALDI-IMS at P0 (birth), 3, 12, and 20 months (m) of age and each species quantified to
allow for individual species comparisons. Tg APP21 rats were found to have a decreased
level of complex gangliosides in a number of brain regions as compared to Wt rats and
showed higher levels of ganglioside GM3. A unique pattern of expression was observed in

124

the white matter as compared to gray matter regions, with an age-dependent decrease in
GD1 d18:1 species that was more pronounced in Tg APP21 rats coupled with significantly
elevated levels of GM3 only in Tg APP21 rats. These results are indicative of a
pathological shift in ganglioside homeostasis during aging that is worsened in Tg APP21
rats.

4.2 Introduction
Mounting evidence points to the complex interaction of risk factors that can lead to the
development of neurodegenerative diseases in the aging brain. As such, there is increased
interest in identifying early indicators of brain vulnerability. These early changes could
hold the key to a better understanding of disease progression and help identify mechanisms
for preventative intervention. The cell membrane is the first line of defense against changes
in the external environment. It can dictate how cells respond to adverse stimuli and
ultimately determine the fate of the cell. Gangliosides are sialic acid-containing
glycosphingolipids (GSLs) enriched within brain which form an important component of
lipids rafts in cell membranes Lipid rafts are a major site of cell signal transduction and
serve as a platform for protein-protein and protein-lipid interactions (Sonnino et al., 2013;
Yu et al., 2012). The healthy brain maintains a homeostatic distribution of gangliosides in
order to regulate signal transduction, however, perturbations in this distribution have been
observed in both pre-clinical models and clinical cases of neurodegenerative diseases such
as Alzheimer’s disease (AD) (Oikawa et al., 2009), Huntington’s disease (Maglione et al.,
2010), Parkinson’s disease (Schneider et al., 2013), as well as prion diseases (Ohtani et al.,
1996; Tamai et al., 1979). Ganglioside distribution has also been found to be perturbed in
response to neurodegenerative injuries such as stroke (Caughlin et al., 2015; Whitehead et
al., 2011) and traumatic brain injury (Woods et al., 2013).
Glycosphingolipids are made up of two main domains, an oligosaccharide moiety
exposed to the extracellular environment, and a ceramide moiety embedded within the lipid
bilayer. The oligosaccharide moiety acts as a coding unit which can dictate the types of
interactions that take place within a specific microdomain (Ledeen & Wu, 2015). The
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ceramide moiety contains a sphingosine tail with varying numbers of carbons which can
alter the fluidic properties of the membrane and has regulatory effects on the
oligosaccharide moiety (Masserini et al., 1989). A-series gangliosides contain structurally
simpler precursor species GM3 and GM2 and complex species GM1 and GD1. Complex
gangliosides are the predominant form of gangliosides expressed within the healthy adult
brain while simple gangliosides are only expressed in small quantities.
The quantity of simple and complex gangliosides shifts during early development
and is dictated by the expression and activity of metabolic enzymes such as sialyltransferases and glycosyltransferases. After birth, synthesis of complex gangliosides is
upregulated while synthesis of simple gangliosides is downregulated (Rosenberg & Stern,
1966). This shift in expression during early development is related to the function of each
ganglioside. For example, simple ganglioside GM3 has been shown to upregulate apoptotic
and inhibit angiogenic vascular endothelial growth factor (VEGF) signalling pathways in
vitro (Chung et al., 2009; Nakatsuji & Miller, 2001; Sohn et al., 2006), an important
function in early brain development to regulate plasticity, but potentially problematic if
upregulated in the adult brain. Moreover, accumulations of simple gangliosides in the brain
have been linked in a number of neurodegenerative diseases (Dufresne et al., 2017) and
injuries (Caughlin et al., 2015; Whitehead et al., 2011; Woods et al., 2013).
Ganglioside GM1 is highly expressed throughout the mammalian brain but is
particularly abundant in cerebral white matter (Ledeen & Wu, 2015; Rubovitch et al.,
2017). In rats, increases in GM1 during development are thought to be linked to myelin
thickening (Aydin et al., 2000). GD1 is highly expressed in the dendrites and synapses of
rat brains and is thought to play an important role in cell differentiation as well as cell
contact and interaction during development (Aydin et al., 2000; Palestini et al., 1990).
Total ganglioside content has been observed to increase 8 fold in adult mouse brains
compared to embryonic mouse brains. In humans, complex gangliosides GM1 and GD1
increase 12 – 15 fold between gestation and infancy (Yu et al., 2009). This increase in
complex gangliosides is thought to be vital to the proper maintenance of brain networks
during adulthood.
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Altered ganglioside homeostasis has been observed in the brains of patients with
AD such that there is a depletion of protective complex gangliosides GD1 and GM1 along
with an increase in simple gangliosides GM2 and GM3. In early onset AD, complex
gangliosides have been observed to decrease 58-70% in gray matter regions and 81% in
frontal white matter (Svennerholm & Gottfries, 1994). An accumulation of simple
ganglioside GM3 has been observed both clinically in patients with AD and in transgenic
mouse models of AD, which show regional accumulations of GM3 in the entorhinal cortex,
forebrain, and surrounding cerebral blood vessels (Chan et al., 2012; Knight et al., 2014;
Yamamoto et al., 2006). Previous evidence has shown that there are significant regional
differences in the vulnerability to altered lipid metabolism in the human AD brain (Cutler
et al., 2004; Hirano-Sakamaki et al., 2015). The balance between complex and simple
gangliosides may play an important role in the development and progression of AD.
Indeed, Oikawa et al. showed that transgenic mice overexpressing mutant amyloid
precursor protein (APP) coupled with a defective GM2 synthase gene demonstrated
increased GM3, decreased GM1 and a concomitant deposition of beta-amyloid within their
brain (Oikawa et al., 2009).

Additionally, alterations in the ceramide moiety of

gangliosides may also play an important role in the development of neurodegenerative
diseases. The accumulation of long chain ceramides during normal aging has been
observed in the mouse brain (Cutler et al., 2004; Sugiura et al., 2008).

Moreover, post-

mortem brains of patients with AD have shown that the accumulation of long chain
ceramides was exacerbated in regions which were susceptible to neurodegeneration and
was correlated with disease severity (Cutler et al., 2004). Oikawa et al. 2009, found an
increased ratio of d20:1 to d18:1 species of GD1b in the cerebral cortex of brains of
patients with AD compared to controls and suggested that this increased ratio may be a
major cause of enhance Aβ assembly in the brain. An altered d20:1/d18:1 species ratio was
also observed in the molecular layer of the hippocampus in human AD brains suggesting a
role for variable sphingosine base length in mediating neurodegeneration along the
perforant pathway (Hirano-Sakamaki et al., 2015). These studies highlight the importance
of examining both the ceramide and oligosaccharide domains of gangliosides within the
context of patients with AD.
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To date, there is very little understanding from a neuroanatomical perspective on how
gangliosides change their composition profile during aging, partly due to a lack of
technology capable of performing such analysis. MALDI IMS can overcome this challenge
by performing mass spectrometry directly on intact brain tissue to provide neuroanatomical
spatial information with respect to the gangliosides. The following study uses MALDI IMS
to detect and quantify gangliosides in multiple brain regions during aging in the rat. We can
further test the hypothesis of ganglioside perturbation as an early indicator of AD using a
Tg rat (APP21). These Tg rats were created on a Fischer 344 background and express the
human amyloid precursor protein (APP) gene with both the Swedish and Indiana mutations
(Agca et al., 2008). As reported previously, these rats do not develop histological hallmarks
of AD spontaneously when aged up to 30 months (Rosen et al., 2012). They do, however,
develop histopathological signs of AD when challenged with brain extract from AD
patients injected intracerebrally (Rosen et al., 2012), or when experimental hydrocephalus
is induced (Silverberg et al., 2015). More importantly, these rats show age related cognitive
impairment related to white matter damage, making them a strong pre-clinical model to
investigate the prodromal phase of AD (Levit et al., 2017).

4.3 Materials and Methods
4.3.1

Animal Model

All procedures involving live animals were in accordance with the guidelines of the
Canadian Council on Animal Care and approved by the University of Western Ontario
Animal Use Committee (Protocol 2014–2016). Wild-type (WT) Fischer and transgenic
(Tg) APP21 rats (Agca et al., 2008) were kindly provided by Dr. Yuksel Agca (University
of Missouri) and bred in-house. Tg APP21 rats are homozygous for both human Swedish
and Indiana mutations for the APP gene. Rats were euthanized at either P0 (newborn), 3
months (m, young rats), 12 m (middle aged), or 20 m (old), with an N of 5 rats (either Wt
or Tg APP21) per group. Intact fresh frozen brains were stored at -80° C until processed for
MALDI IMS.
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4.3.2

MALDI IMS

Brain tissues (or whole heads for P0 rats) were sectioned on a cryostat (Thermo-Fisher
Scientific CryoStar NX50, Toronto, Canada) at a thickness of 10 μm and thaw mounted
onto electrically conductive Indium-Tin-Oxide (ITO) slides (Hudson Surface Technology
Inc., Old Tappan, NY, USA). Slides were then coated with a thin layer of 1,5Diaminonapthalene (DAN, Sigma-Aldrich, Oakville, ON, Canada) matrix via sublimation
and incubated at -20° C overnight. After a 10 min desiccation period, calibration standards
were applied (Sciex, Farmingham, MA. USA) and allowed to dry before an image of the
plate was scanned for reference in the instrument. Images were acquired using a Sciex
MALDI 5800 TOF/TOF instrument in negative ion reflectron mode. The instrument is
equipped with a 349 nm Nd:YLF “OptiBeam On-Axis” laser. The laser pulse rate used was
1000 Hz. Data acquisition and processing of profiling data were respectively done using a
TOF-TOF Series Explorer and Data Explorer (SCIEX). ITO-coated glass slides with tissue
sample sections were mounted onto a MALDI plate adapter and loaded into the mass
spectrometer. Mass calibration was conducted at a 50 ppm mass tolerance and MS images
were acquired at a 70 μm raster with 20 shots/spectrum. This protocol has been previously
described in detail elsewhere (Caughlin et al., 2017).
4.3.3

Data Analysis

The regions of interest (ROIs) were confirmed using the rat brain atlas by Paxinos &
Watson (1998). A total of 11 ROIs (Fig. 4.1) were quantified across the brain and were
grouped into discrete anatomical/functional regions for quantitation. These clustered
groups include: sub-cortical structures (striatum, lateral septal nucleus - LSN, and
substantia nigra - SN), cortical layers (superficial, intermediate, and deep), the
hippocampus (CA1, dentate gyrus - DG molecular layer, DG granular layer), and white
matter (anterior corpus callosum – aCC, and peri-ventricular corpus callosum - PVCC).
MALDI IMS was analyzed using TissueView software (Version 2, Sciex). A total of 4
tissue sections per brain were used to isolate discrete anatomical regions in order to
quantify the 11 regions of interest in the current study. Peaks corresponding to major aseries gangliosides were isolated, as confirmed through the Lipidmaps database
(www.lipidmaps.org). In order to quantify changes in individual ganglioside species, the
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total signal for each ROI in each image was summed by calculating the area under the
curve (AUC) of the mass spectrum (between m/z 1100-1930) using Graphpad Prism
(Version 7). The AUC of the 3 largest isotopic peaks for each individual ganglioside was
summed and a ratio of the AUC of the individual ganglioside species relative to the total
spectrum AUC of the ROI was determined. For GD1, both Na+ and K+ adduct peaks were
detected and showed similar patterns, therefore, the more abundant K+ adduct was used to
represent GD1 data.

For data analysis pertaining to Figure 2,

the AUC of simple

gangliosides (GM3 and GM2 d18:1 and d20:1) were summed and compared to the total
AUC of all A-series gangliosides at each time point for both Wt and Tg APP21 rats.
Statistical analysis was performed using a two-way ANOVA, followed by a Sidak’s posthoc test +/- SEM.
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Figure 4.1: MALDI IMS Detection and visualization of A-series gangliosides across
rat brain tissue. A-series gangliosides contain species GM3, GM2, GM1, and GD1 and
can be detected using DAN matrix in negative ion mode as d18:1 species (the predominant
form) or d20:1 species via MALDI IMS. (A) Representative MALDI IMS overlaid images
of four tissue sections containing the 11 regions of interest examined in the current study.
Each region of interest is circled in yellow and labelled for reference. (B) Representative
H&E histology sections indicating the coordinates of each section according to the rat brain
atlas by Paxinos & Watson (C) MALDI IMS data plot showing peaks corresponding to
d18:1 and d20:1 a-series gangliosides along a 1100 – 1950 mass range.

131

4.4 Results
4.4.1

Increased proportion of simple gangliosides at 12 m in Tg APP21 rats
across the brain

An accumulation of simple gangliosides has been observed clinically in AD brains,
however it remains unclear whether this accumulation occurs in the prodromal stages of
AD and whether alterations in levels of simple gangliosides can be observed in normal
aging. We predicted that Tg APP21 rats would show a higher proportion of simple
gangliosides than Wt rats and that this difference due to the effect of transgene would
appear at the latest time point (20 m). Although Tg APP21 rats did show a higher
proportion of simple gangliosides, this transgene effect was not observed in 20 m rats. It
was instead observed at 12 m (Fig. 4.2 C) which then disappeared at 20 m (Fig. 4.2 D).
The transgene effect was statistically significant in several brain regions including white
matter regions (PVCC and aCC), intermediate and deep cortical layers, DG gr layer of the
hippocampus, and the striatum (Fig. 4.2 C).
As expected, the highest percentage of simple gangliosides was observed at P0
(Fig. 4.2 A), which then dropped by 3 m and remained relatively stable up to 20 m (Fig.
4.2 B,D). This finding fits with the reported downregulation of simple ganglioside synthetic
enzymes and upregulation of complex ganglioside synthesis during early development in
rats (Rosenberg & Stern, 1966). Although no significant transgene differences were
observed at P0, regional differences were apparent. The DG gr layer of the hippocampus
showed the highest percentage of simple gangliosides along with the DG mol and CA1
hippocampal layers and the LSN (Fig. 4.2 A), while the deep layers of the cortex and the
aCC showed the lowest percentage of simple gangliosides. Interestingly, regional
differences in the quantity of simple gangliosides were less pronounced after birth and
shifted at 3 m such that the PVCC showed the highest proportion of simple gangliosides in
the brain, along with the DG gr layer of the hippocampus and SN (Fig. 4.2 B). At 12 m,
regional differences became more pronounced as the proportion of simple gangliosides
increased in certain brain regions, particularly in Tg APP21 rats, such as the white matter,
DG gr layer of the hippocampus, as well as intermediate and deep cortical layers (Fig. 4.2
C). The regional distribution of simple gangliosides at 20 m was similar to that of 3 m, but
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the highest proportion of simple gangliosides was observed in the DG gr layer of the
hippocampus (Fig. 4.2 D). These results suggest that the quantity and regional distribution
of simple gangliosides in the aging brain varies and that a potentially detrimental shift in
ganglioside homeostasis occurs as early as 12 m in Tg APP21 rats.
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Figure 4.2: The percentage distribution of simple gangliosides in various brain
regions of Tg APP21 rats. MALDI IMS area under curve (AUC) data was pooled for each
A-series gangliosides to show the percentage of simple gangliosides at each time point as
compared to total A-series ganglioside AUC for both Wt and Tg APP21 rats. (A) Highest
percentage of simple gangliosides observed in P0 rats. (B) Simple ganglioside content
decreased at 3 m and showed an alteration in regional abundance, with fewer regional
differences. (C) Transgene differences were observed at 12 m (as indicated by blue *) with
the increase in simple gangliosides being more pronounced in Tg APP21 rats. (D) Simple
ganglioside content dropped again at 20 m and regional differences decreased. Significant
regional differences are indicated with letters a-d. Brain regions with different letters were
found to be statistically different from each other (Wt and Tg APP21 data pooled for
regional analysis) while regions with no letters indicate no significant difference from any
other brain region. *indicates statistical significance, p<0.05 via multiple T-tests; letter
indicates statistical significance, p<0.05 via two-way ANOVA, Tukey multiple
comparisons post-hoc test.
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4.4.2

GD1 d18:1 species decreased in the gray matter of Tg APP21 rats with
maintenance or increases in d20:1 species

A-series gangliosides were analyzed individually (Fig 4.3) relative to P0 in order to better
understand age-dependent shifts in complex and simple gangliosides, and to determine the
source of the increased proportion of simple gangliosides in Tg APP21 rats observed at 12
m in Figure 4.2. The d18:1 and d20:1 species of each a-series ganglioside were analyzed
and presented separately, as the ratio between the d20:1/d18:1 species of complex
gangliosides has been reported to increase in an age-dependent manner during normal
aging in mice (Sugiura et al., 2008) and has shown unique alterations in the hippocampus
of AD patients compared to controls (Hirano-Sakamaki et al., 2015). However, it remains
unclear if the altered ratio is caused by an increase in d20:1 species or a decrease in the
d18:1 species. In general, GD1 d18:1 levels dropped at 12 m in both Wt and Tg APP21 rats
but either dropped more significantly or continued to drop up to 20 m in Tg APP21 rats
whereas levels generally increased at 20 in Wt rats. In the cortex, the abundance of GD1
d18:1 species increased between P0 and 3m in both Wt and Tg APP21 rats, with the
exception of the deep layers of the cortex where levels remained statistically unchanged in
Tg APP21 rats. Levels then dropped between 3 and 12 m and remained stable until 20 m in
the Int and Deep layers. In the Superficial layers, GD1 d18:1 species remained stable
between 3 and 20 m in Wt rats while levels dropped at 12 m in Tg APP21 rats such that
they were no longer significantly different from P0 levels. However, levels then increased
again at 20 m in Tg APP21 rats (Fig. 4.3 B).
Similar to the cortex, GD1 d18:1 levels increased between P0 and 3 m throughout
the hippocampus. Levels then steadily dropped between 3 m and 20 m in Tg APP21 rats
but increased at 20 m in Wt rats. This lead to the Wt, but not Tg APP21 rats showing
significantly elevated levels of GD1 d18:1 species compared to P0 at 20 m in the CA1 and
DG mol layers of the hippocampus (Fig. 4.3 C). Among the subcortical structures, GD1
d18:1 species increased between P0 and 3 m in the striatum and LSN, but only increased
significantly in Wt rats in the SN (Fig. 4.3 D). Levels remained statistically elevated from
P0 in both Wt and Tg APP21 rats up to 20 m in the striatum despite a slight drop at 12 m
(Fig 4.3 D – left panel). Wt and Tg APP21 rats showed opposite patterns at 20 m within the
LSN and SN regions with GD1d18:1 increasing significantly from P0 levels only in Tg
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APP21 rats in the LSN (Fig 4.3 D – center panel) and only in Wt rats in the SN (Fig 4.3 D
– right panel).
Age-dependent increases in the ratio of d20:1/d18:1 species of GD1 have been
reported in the mouse hippocampus during normal aging (Sugiura et al., 2008) While GD1
d18:1 showed between a 2 – 5 fold increase from P0 throughout the brain, d20:1 species of
GD1 increased between 3 – 8 fold, with the largest increase observed in the DG mol layer
of the hippocampus and striatum. This supports the hypothesis that d20:1 species are
indeed increasing in the brain compared to d18:1 species. However, the increase in d20:1
species was not observed to be age-dependent in most brain regions. In the SN, striatum,
hippocampus, DG mol, intermediate and deep layers of the cortex, GD1 d20:1 species
increased between P0 and 3 m then remained significantly elevated but stable up to 20 m in
both Wt and Tg APP21 rats (Fig 4.3 E-G). A similar pattern occurred in the superficial
layers of the cortex but was only significantly elevated from P0 in Wt rats (Fig 4.3 E – left
panel). In the hippocampus, Wt and Tg APP21 rats showed divergent patterns at 20 m with
GD1 d20:1 species decreasing in Tg APP21 rats and increasing in Wt rats, leading to
statistical differences relative to P0 levels (Fig 4.3 F). The only transgene difference
observed for GD1 d20:1 species was in the LSN where levels dropped in Wt rats at 20 m
and increased in Tg APP21 rats, contrary to what was observed in the hippocampus,
leading to a statistical difference between the two groups (Fig. 4.3 G – center panel).
Overall, results of MALDI IMS analysis of GD1 suggests that the increased ratio of
d20:1/d18:1 species previously reported is due to both an increase/stable abundance of
d20:1 species and a decreased in d18:1 species during aging.
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Figure 4.3: Distribution of the GD1 d18:1 and d20:1 species during aging. (A)
Representative MALDI IMS overlaid images showing the anatomical distribution of the
d18:1 (magenta) and d20:1 species (cyan) of GD1. (B-G) Quantification of MALDI IMS
data showing the percent of GD1 d18:1 (B-D) and d20:1 (E-G) species compared to the
total signal at each time point. GD1 d18:1 dropped at 12m in both Wt and Tg APP21 rats
which either continued to drop at 20 m or increased slightly. Statistical differences were
observed in relative to P0 throughout aging (B-D). GD1 d20:1 species increased
significantly between P0 and 3 m which then remained stable or increased slightly at 20 m
(E-G). A transgene difference was observed at 20 m in the LSN in which Tg APP21 rats
showed elevated levels of d20:1 species of GD1 whereas levels dropped in Wt rats (G –
center panel). * indicates statistical significance, p<0.05 via two-way ANOVA, Tukey
post-hoc test.
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4.4.3

Significant increase in GM1 observed during aging with characteristic drop
in d18:1 species at 12 m

The largest increase in complex gangliosides GD1 and GM1 occurred between P0 and 3 m
due to alterations in synthetic enzyme regulation during early post-natal development (Yu
et al., 2009) and was more pronounced for d20:1 species than d18:1 species. The increase
between P0 and 3 m was greater for GM1 d20:1 species (5 – 17 fold) than for GD1 d20:1
species (3 – 4 fold), with a greater degree of anatomical heterogeneity. Unlike GD1, GM1
reached its highest abundance at 20 m in all brain regions, suggesting an age-dependent
accumulation. However, this accumulation was not linear and after the initial increase after
birth, remained either stable or decreased slightly between 3 m and 12 m. GM1 levels then
increased between 12 m and 20 m for both the d18:1 and d20:1 species (Fig. 4.4).
GM1d18:1 species increased from around 5% of the total signal at P0 to 20% at 3
m. The LSN and SN showed the lowest levels of GM1 d18:1 of all gray matter brain
regions at 3 m. The pattern of GM1 d18:1 species abundance was very similar between Wt
and Tg APP21 rats throughout aging, with no transgene differences observed; however,
statistical differences were observed relative to P0 throughout aging which varied
depending on transgene (Fig. 4.4 B-D). Wt rats showed slightly higher levels of GM1
d18:1 in the LSN and SN at 12 and 20 m respectively (Fig 4.4 D – center and right panels),
while Tg APP21 rats showed higher levels of GM1 d18:1 species in the intermediate layers
of the cortex at 3 m (Fig 4.4 B – center panel). Additionally, GM1 d18:1 species decreased
at 12 m in Tg APP21 rats across the brain while levels remained stable in a number of brain
regions examined in Wt rats.
GM1 d20:1 species increased from below 1% of the total signal at P0 to around 4%
at 3 m in cortical and sub cortical brain regions as well as the DG gr layer of the
hippocampus (Fig 4.4 E-F). The CA1 and DG mol layers showed the most significant
increase in GM1 d20:1 species, increasing to 6 and 8% of the total signal by 3 m and
continued to increase to 10% by 20 m in the DG mol. (Fig. 4.4 F – left and center panels).
Overall, GM1 showed an age-dependent increase with only minor variations between Wt
and Tg APP21 rats.
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Figure 4.4: Increased levels of GM1 during aging with characteristic drop at 12 m in
Fischer rats. (A) Representative MALDI IMS overlaid images showing the anatomical
distribution of GM1 d18:1 (magenta) and d20:1 (cyan) species across intact tissue sections
containing all regions of interest. (B-G) Quantification of MALDI IMS data showing the
percent signal of GM1 d18:1 (B-D) and d20:1 (E-G) species relative to total signal.
GM1d18:1 increased between P0 and 3 m which then decreased at 12 m in both Wt and Tg
APP21 rats and increased again by 20 m (B-D). GM1 d20:1 species increased in an agedependent manner throughout the brain with the highest levels observed in the CA1 and
DG mol layers of the hippocampus (E-F). * indicates statistical significance, p<0.05 via
two-way ANOVA, Tukey post-hoc test.
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4.4.4

Decreased GM2 d20:1 species in early life with elevated levels of GM2
d18:1 species in Tg APP21 rats.

Little is known on how simple gangliosides are altered during normal aging. However,
based on their reported upregulation in a number of neurodegenerative injuries and
diseases, including AD, as well as the observed increase in the proportion of simple
gangliosides at 12 m in the current study, we analyzed the anatomical distribution and
abundance of the d18:1 and d20:1 species of simple ganglioside GM3 and GM2 in order to
compare their alterations in abundance to complex gangliosides in Wt and Tg APP21 rats.
GM2 d18:1 species remained statistically unchanged throughout the lifespan of
both Wt and Tg APP21 rats, however, Tg APP21 rats showed a strong trend of increased
abundance over Wt rats (Fig. 4.5 B-D). This was particularly evident at 12 m as Wt rats
showed either stable of decreased levels of GM2d18:1 relative to 3 m whereas levels
increased in Tg APP21 rats. This divergence in d18:1 species patterns led to a statistical
transgene difference in the striatum, with significantly more GM2 d18:1 species observed
in Tg APP21 rats. One exception to this trend was observed in the DG mol layer of the
hippocampus where GM2 d18:1 levels dropped significantly from P0 levels at 20 m.
Interestingly, GM2 d20:1 species showed more robust changes with aging. GM2 d20:1
species dropped significantly in all gray matter regions between P0 and 3 m in both Wt and
Tg APP21 rats and remained stable up to 20 m (Fig. 4.5 E,F). Tg APP21 rats showed a
slight increase in GM2 d20:1 species at 12 m while levels in Wt rats remained stable, with
the exception of the LSN and SN. These results demonstrate that the d20:1 species of GM2,
and not the d18:1 species, were decreased during early development and remained stable
during adulthood and that Tg APP21 rats have slightly elevated levels of GM2 over their
Wt counterparts.
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Figure 4.5: Tg APP21 rats have elevated levels of GM2 with a significant drop in
GM2 d20:1 species in early life for both groups. (A) Representative MALDI IMS
overlaid images showing the anatomical distribution of GM2 d18:1 (magenta) and d20:1
(cyan) species across intact tissue sections containing all regions of interest. (B-G) AUC
Quantification of MALDI IMS data showing the signal corresponding to d18:1 (B-D) and
d20:1 (E-G) species of GM2 as a percentage of total signal. (B-D) GM2 d18:1 species
often showed diverging patterns of abundance between Wt and Tg APP21 rats throughout
the lifespan, with a trend of increased GM2 d18:1 species in Tg APP21 rats, however, this
was not statistically significant. (E-G) GM2 d20:1 species dropped significantly from P0
levels at 3 m in all brain regions and remained stable up to 20 m with a trend of increased
GM2 d20:1 species at 12 m in Tg APP21 rats. * indicates statistical significance, p<0.05
via two-way ANOVA, Tukey post-hoc test.
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4.4.5

Early increases in GM3 in Tg APP21 rats with transgene differences at 12
m.

Simple ganglioside GM3 has been widely studied in the field of oncology due to its ability
to induce apoptosis, decrease angiogenesis, and prevent cell proliferation when
accumulated in vitro (Chung et al., 2009; Nakatsuji & Miller, 2001; Prokazova et al., 2009;
Sohn et al., 2006). In the brain, GM3 has been associated with the propagation of
neurodegeneration after stroke (Caughlin et al., 2015; Whitehead et al., 2011) and the
seeding of toxic Aβ fibrils in mouse models of AD (Kreutz et al., 2011; Oikawa et al.,
2009). GM3 d18:1 was observed to be anatomically located in medial structures of the
brain and lining ventricular regions (Fig. 4.6 A).
Unlike GM2, no consistent trend in the overall GM3 d18:1 species abundance was
observed during aging, rather, Tg APP21 rats and levels varied based on anatomical brain
region. For instance, Tg APP21 rats were born with significantly higher levels of GM3
d18:1 species in the striatum, LSN, and DG gr layer of the hippocampus, with a similar
trend in the DG mol layer (Fig. 4.6 B-D). A significant transgene difference was observed
at 3 m in the CA1 and DG mol layers of the hippocampus, with elevated levels of GM3 in
Tg APP21 rats over Wt rats (Fig. 4.6 C). Finally, a similar transgene difference in GM3
d18:1 species was observed at 12 m in the intermediate layers of the cortex (Fig. 4.6 B). Wt
rats showed a consistent pattern of decreased or stable GM3 d18:1 species at 12 m whereas
this species generally increased in Tg APP21 rats at the same point. GM3 d18:1 species
were most abundant in the striatum, LSN, and DG gr layer of the hippocampus at birth
whereas the cortical layers and SN showed the lowest abundance. Because GM3 d18:1
species showed a trend of accumulating in an age-dependent manner in the DG gr of Tg
APP21 rats, it consistently showed the highest levels throughout aging, reaching 1.6% of
the total signal by 20 m of age (Fig 4.6 C – right panel). Tg APP21 rats also displayed a
more severe fluctuation of GM3 d18:1 species relative to P0 than Wt rats, generally
showing elevated levels from birth, with the exception of the striatum, LSN, and CA1,
which decreased or remained stable after P0. Overall, Tg APP21 rats at some point during
aging had increased levels of GM3 d18:1 species over Wt rats in all brain regions
examined.
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More consistent trends were observed for GM3 d20:1 species across the brain with
similar patterns observed among discrete brain regions. As was observed with simple
ganglioside GM2, a divergence in ganglioside patterns occurred at 12 m between Wt and
Tg APP21 rats. While GM3 d20:1 species either remained stable or decreased between 3
and 12 m in Wt rats, Tg APP21 rats showed elevated levels at this time point. This led to
significant transgene differences in the intermediate and deep layers of the cortex, with a
similar trend in all other selected brain regions, with the exception of the SN. GM3 d20:1
species remained statistically unchanged between P0 and 20 m among all layers of the
cortex (Fig. 4.6 E). Hippocampal layers showed a different pattern, with a drop in GM3
d20:1 species observed between P0 and 3 m which then remained stable up to 20 m (Fig.
4.6 F). This drop was most significant in the CA1 layer with statistical differences from P0
levels observed for both Wt and Tg APP21 rats. The striatum showed a similar pattern to
that of the hippocampal layers with a drop in GM3 d20:1 species between P0 and 3 m.
Levels then continued to drop and became statistically lower than P0 at 12 m only in Wt
rats, whereas levels increased slightly in Tg APP21 rats (Fig. 4.6 G – left panel). The LSN
showed a similar pattern to that of the cortical layers, remaining statistically unchanged
between P0 and 20 m (Fig. 4.6 G – center panel). While GM3 d20:1 species also remained
statistically unchanged during aging in the SN, Wt and Tg APP21 rats showed opposite
patterns during early life, with a slight drop observed in Wt rats between P0 and 3 m which
then gradually increased up to 20 m and a slight increase between P0 and 3 m in Tg APP21
rats which then gradually dropped until 20 m (Fig. 4.6 G – right panel). Overall, these
results indicate that there is an increased abundance of GM3 gangliosides in Tg APP21 rats
in early and mid-life and unique patterns of abundance during aging among Wt and Tg
APP21 rats.
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Figure 4.6: Increased GM3 in Tg APP21 rats. (A) Representative MALDI IMS overlaid
images showing the anatomical distribution of GM3 d18:1 (magenta) and d20:1 (cyan)
species across intact tissue sections containing all regions of interest. (B-G) Quantification
of MALDI IMS data showing the signal corresponding to d18:1 (B-D) and d20:1 species
(E-G) of GM3 relative to total signal. (B-D) Significant transgene differences were
observed at P0, 3 m and 12 m across the various brain regions, with Tg APP21 rats
displaying elevated levels of GM3 d18:1 species over their Wt counterparts. GM3 d20:1
species remained statistically unchanged from P0 in the cortical layers, however, Tg
APP21 rats showed significantly elevated levels over Wt rats at 12 m in the Int and Deep
layers (E). GM3 species dropped between P0 and 3 m in the hippocampus, particularly in
the CA1 region, then remained stable up to 20 m (F). Each sub-cortical layer had a slightly
different GM3 d20:1 species pattern during aging, with the striatum showing a similar
pattern to that of hippocampal regions, the LSN having a similar pattern to that of the
cortical layers, and the SN showing opposite patterns between Wt and Tg APP21 rats (G).
* indicates statistical significance, p<0.05 via two-way ANOVA, Tukey post-hoc test.
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4.4.6

Age-dependent decrease in GD1 d18:1 species in white matter regions with
increases in simple gangliosides only in Tg APP21 rats.

A unique ganglioside pattern was observed in the white matter as compared to gray matter
regions during aging, thus these regions are presented separately. Interestingly, an agedependent decrease in GD1 d18:1 species in the PVCC was observed, with a similar drop
occurring between 3 and 12 m in the aCC (Fig 4.7 A). This pattern is unlike the gray matter
regions, which all showed either a stable or increased abundance of GD1 d18:1 species
during early development. GD1 d20:1 species increased significantly between P0 and 12 m
only in the Wt rats where it then dropped significantly by 20 m. In Tg APP21 rats, GD1
d20:1 species showed a trend of increasing in an age-dependent manner up to 20 (Fig 4.7 B
- left). In the aCC, GD1 d20:1 species increased significantly between P0 and 3 m in both
Wt and Tg APP21 rats where it then gradually decreased up to 20 m (Fig. 4.7 B – right).
Overall, GD1 levels appear to decrease in the white matter during the later stages of the rat
lifespan.
Complex ganglioside GM1 showed similar patterns of abundance in white matter to
what was observed in gray matter regions, with an increase in GM1 d18:1 species between
P0 and 20 m, along with a drop at 12 m (Fig 4.7 C – left panel). However, this drop only
occurred in Tg APP21 rats in the aCC while it remained stable in the Wt rats (Fig 4.7 C –
right panel), suggesting that GM1 levels may be more severely depleted in Tg APP21 rats
at this time point. GM1 d20:1 species increased significantly between P0 and 3 m, and
again between 12 m and 20 m while remaining stable between 3 m and 12 m in the PVCC.
Overall, GM1 species accumulate during both early development and during the later
stages of aging in the rat.
Simple gangliosides GM2 and GM3 also showed unique alterations in abundance in
the white matter as compared to gray matter regions with a number of transgene
differences. For example, GM2 d18:1 species increased between P0 and 3 m in both the
PVCC and aCC where it decreased slightly but remained stable up to 20 m in the Wt rats.
However, GM2 d18:1 species continued to increase or remained stable up to 12 m in Tg
APP21 rats, becoming significantly elevated from P0 levels in the PVCC and remaining
elevated up to 20 m (Fig 4.7 E). The d20:1 species of GM2 decreased slightly between P0
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and 3 m in the white matter where it remained stable in the PVCC of Wt rats and continued
to drop up to 12 m in the aCC, decreasing significantly from P0 levels. Tg APP21 rats
instead showed a slight increase in GM2 d20:1 species at 12 m which then decreased by 20
m (Fig 4.7 F). Overall, Tg APP21 rats showed higher levels of GM2 at 12 m over their Wt
counterparts.
Similar to what was observed in the striatum, LSN, and DG gr regions for GM3
d18:1 species, Tg APP21 rats showed elevated levels of GM3 d18:1 species at birth over
their Wt counterparts, however, this difference was not statistically significant. GM3 d18:1
species remained fairly stable between birth and old age in Wt rats, whereas levels
remained elevated in Tg APP21 rats such that there was a significant transgene difference
observed at 12 m in both the PVCC and aCC before levels dropped at 20 m (Fig 4.7 G). An
age-dependent increase in GM3 d20:1 species was observed only in Tg APP21 rats up to
12 m of age where it became significantly increased from P0 levels in the PVCC and
remained significantly elevated at 20 m. This increase in GM3 d20:1 species up to 12 m led
to a statistical difference between Wt and Tg APP21 rats at 12 m in the aCC (Fig 4.7 H).
Taken together, these results suggest a more severe pathological shift in white matter
ganglioside content during aging that is enhanced in Tg APP21 rats.
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Figure 4.7: Unique ganglioside alterations in white matter regions of the brain during
aging. AUC Quantification of MALDI IMS data in the white matter showing the signal
corresponding to each a-series ganglioside as a percentage of the total signal, with the
d18:1 species on the left and d20:1 species on the right. (A) GD1 d18:1 species decreased
in an age-dependent manner up to 20 m in the PVCC (left). A similar trend was observed in
the aCC, however, the Wt rats only showed a significant decrease after 3 m. (B) GD1 d20:1
species increased in and age-dependent manner in the PVCC up to 12 m in Wt rats and 20
m in Tg APP21 rats, whereas a significant increase in GD1 d20:1 species was only
observed between P0 and 3 m in the aCC before dropping until 20 m. (C+D) GM1 d18:1
species increased between P0 and 20 m, however, the characteristic drop in GM1 content
observed at 12 m was more pronounced in Tg APP21 rats in the aCC. (E) GM2 d18:1
species increased significantly between P0 and 12 m only in Tg APP21 rats and remained
elevated at 20 m in the PVCC. (F) GM2 d20:1 species dropped significantly from P0 levels
at 12 m in the aCC of Wt rats but did not drop until 20 m in Tg APP21 rats. GM3 d18:1
species showed a trend of increased abundance at 12 m in the aCC of Tg APP21 rats (G+H)
Tg APP21 rats showed significantly elevated levels of GM3 at 12 m over their Wt
counterparts as well as a significant increase in GM3 d20:1 species from P0 levels at 12
and 20 m in the PVCC. * indicates statistical significance from P0, # indicates statistical
significance between Wt and Tg APP 21 rats, p<0.05 via two-way ANOVA, Tukey posthoc test.
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4.5 Discussion
This is the first study to examine age and neuroanatomic-specific alterations in the
expression profile of a-series gangliosides in both Wt and Tg APP21 rats using MALDI
IMS. Gangliosides have been observed to shift in a characteristic manner during AD such
that there is a depletion of complex gangliosides, such as GM1, and an accumulation of
simple ganglioside GM3 (Chan et al., 2012; Knight et al., 2014; Svennerholm & Gottfries,
1994; Yamamoto et al., 2006). The reason for this shift in ganglioside homeostasis is
poorly understood but has been suggested to play an important mechanistic role in the
development of AD (Oikawa et al., 2009). MALDI IMS is the only technique capable of
accurately detecting gangliosides based on both their oligosaccharide and ceramide
moieties while simultaneously providing high resolution imaging of the ionic distribution
across intact tissue sections, making it the ideal tool for the study of membrane lipids in the
aging brain. However, it is important to note that this technique is not without limitations.
For example, due to run-to-run variation in sample preparation and instrument variables,
MALDI IMS data is considered to be semi-quantitative. While there is currently no single
approach to quantifying MALDI-IMS data, the goal remains to reduce run-to-run
variability as much as possible in order to obtain the most accurate and meaningful results.
In the current study, we compared the area under the curve corresponding to each
individual ganglioside species to the total signal of the spectrum within a mass range of
1100-1950 in order to minimize sources of variability. While gangliosides account for the
largest peaks in this mass range, as can be seen in Figure 4.1 C, smaller, unidentified peaks
are also present which may fluctuate during aging, thus affecting total signal. Therefore,
while MALDI IMS remains an incredibly powerful tool for the analysis of gangliosides,
limitations surrounding the semi-quantitative nature of the technique should be considered
when interpreting the data.
An examination of the percentage of simple gangliosides GM3 and GM2 compared
to total a-series gangliosides at each time point revealed a high degree of anatomical
heterogeneity in the proportion of simple gangliosides throughout the brain at P0 which
may be related to the function of these brain regions during development and adulthood.
For example, The DG gr layer of the hippocampus showed the highest percentage of simple
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gangliosides at P0 of all the 11 regions of interest across the brain. This layer is composed
largely of the cell bodies of granule cells which project dendrites and processes into the DG
mol layers of the hippocampus. This is a region where neurogenesis is thought to occur, not
only during development, but throughout adulthood as well (Amaral, Scharfman, &
Lavenex, 2007). Neurogenesis in the DG gr layer is said to be in a steady-state as opposed
to an accretion over time, this implies tight regulation of neurogenesis in this region
(Amaral et al., 2007). It is possible that the increased abundance of simple gangliosides in
this region may thus be related to the regulation of neurogenesis in the DG gr layer of the
hippocampus. Indeed, the DG gr layer had one of the highest proportions of simple
gangliosides at every time point, further supporting this hypothesis.
The percentage of simple gangliosides dropped at 3 m, again, matching what has
been reported to occur with ganglioside synthetic enzymes during this period (Rosenberg &
Stern, 1966). Indeed, the most significant increase in complex gangliosides occurred
between P0 and 3 m, which would account for the decreased relative abundance of simple
gangliosides at this time point. One of the most intriguing findings, however, was the
increased percentage of simple gangliosides at 12 m in many brain regions which was
enhanced in Tg APP21 rats such that a number of transgene differences were observed
across the brain. This increase in simple gangliosides was accompanied by a concurrent
drop in complex gangliosides at 12 m, which would account for the significant increase in
the proportion of simple gangliosides at this time point. These findings suggests that a
pathological shift in the homeostasis of gangliosides may be occurring as early as 12 m of
age and is enhanced in Tg APP21. This evidence supports the hypothesis that lipid
alterations may occur in the prodromal stages of AD.
Age-dependent changes in complex gangliosides have been previously examined
using liquid chromatography-based techniques. In a study published in 2000, Aydin et al.
found that ganglioside GM1 increased slightly between 3 and 24 months of age, while GD1
increased up to 12 m then dropped by 20 % by 24 m. A similar pattern was observed in the
current study. Aydin et al. also found an age-dependent increase in GM1 fractions
compared to other complex gangliosides, however, the authors ascribed this finding to a
decrease in GD1 and GT1 components rather than an increase in GM1, which was found to
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remain relatively stable at later time points (Aydin et al., 2000). GM1 d20:1 species in
particular showed a higher fold increase in abundance from P0 than GM1 d18:1 species
and increased up to 20 m in most brain regions. This finding confirms the presence of an
age-dependent accumulation of long chain ceramide species in the brain, as has been
previously reported (Hirano-Sakamaki et al., 2015; Palestini et al., 1993; Sugiura et al.,
2008).
While GM1 was found to be consistently increased during adulthood in both Wt
and Tg APP21 rats, a less pronounced effect was observed for ganglioside GD1. The d20:1
species showed, in most cases, an age-dependent increase up to 12 m which then plateaued
or decreased at 20 m. Wt rats also showed higher levels of GD1 than Tg APP21 rats in a
number of brain regions, particularly at 20 m in the hippocampus. Although the
senescence-related drop in GD1 and GT1 described by Aydin et al., 2000 is not fully
understood, the authors suggest that it may be related to degenerative processes in dendrites
and synapses in which these species are highly expressed. Alternatively, the breakdown of
GD1 may be related to maintenance of GM1 (Aydin et al., 2000). In a study which
measured GM1, GD1, and GT1 levels in the CSF of “probable AD” patients versus agematched controls, an increase in GM1 levels was observed, particularly in younger
“probable AD” patients while GD1 and GT1 levels were decreased, suggesting that this
breakdown may be further enhanced in during AD development and progression (Blennow
et al., 1992). The neuroprotective properties of GM1 have been well documented and are
ascribed to its ability to modulate neurotrophin release and regulate ion transport (Ledeen
& Wu, 2015; Wu & Ledeen, 1994). In fact, of all the a-series gangliosides, GM1 has been
found to have a high degree of functional importance in the maintenance of cells. This is
further supported by the finding of GM1’s resistance to breakdown by sialidase as
compared to other complex gangliosides (Palestini et al., 1993). Multi-sialylated species,
such as GD1 and GT1, are highly susceptible to sialidase (Palestini et al., 1993), leading
some to suggest that it may serve as a reserve pool for the maintenance of GM1 levels in
the brain (Ledeen & Wu, 2015). The transgene difference observed in the current study
with respect to the drop in GD1 levels may therefore be the result of an increased need to
breakdown GD1 in order to maintain GM1 levels in Tg APP21 rats. Future studies should
address the changes in both ganglioside synthetic and catabolic enzymes during aging.
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A previous study in our lab reported a decrease the d20:1/d18:1 species ratio of
GM2 between P0 and 3 m which remained stable up to 20 m (Caughlin et al., 2017b). The
current study confirms that this decreased ratio was due to a significant drop in d20:1
species of GM2 and not an increase in d18:1 species, which remained statistically
unchanged throughout the rat lifespan. Tg APP21 rats also showed a trend of increased
GM2 at 12 m across a number of brain regions and led to a significant transgene difference
in striatum. Interestingly, the accumulation of GM2 has been reported in human brains of
patients with AD and frontotemporal dementia (Pernber et al., 2012), thus, the increased
abundance of GM2 in our Tg APP21 rats may be indicative of a pathological shift in
ganglioside homeostasis.
GM3 has been shown to upregulate pro-apoptotic signaling pathways as well inhibit
VEGF receptor activity leading to toxicity when accumulated in neural cells (Chung et al.,
2009; Nakatsuji & Miller, 2001) and is thought to play an important mechanistic role in the
development of AD (Oikawa et al., 2009). Several transgene differences were observed in
which Tg APP21 rats had significantly elevated levels of GM3 over Wt rats. Interestingly,
Tg APP21 rats were born with higher levels of GM3 d18:1 species than Wt rats which
remained elevated throughout aging. The observed increase in GM3 coupled with elevated
levels of GM2 in Tg APP21 rats suggests that the brains of these rats may be entering a
state of vulnerability earlier than previous thought and supports the hypothesis of a
pathological shift in ganglioside homeostasis in Tg APP21 rats.
Ganglioside-based alterations in the white matter of the aging brain have been
observed to be different than those of the gray matter (Caughlin et al., 2017b). Ganglioside
GD1 d18:1 showed a very unique age-dependent decrease in abundance in white matter
that has not been previously reported. This drop in d18:1 species was accompanied by the
maintenance or increase in d20:1 species. Previous work in our lab examining the ratio of
d20:1 species relative to d18:1 found a significant age-dependent increase in the GD1
d20:1/d18:1 ratio in the PVCC, with a similar trend occurring in the aCC (Caughlin et al.,
accepted). It was assumed that this increased ratio was caused by the age-dependent
accumulation of d20:1 species, as had been reported in gray matter regions. However, the
current study demonstrates that the increased ratio was instead due to a significant drop in
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the d18:1 species, highlighting the importance of analyzing gangliosides individually.
Another unique alteration in white matter was observed for ganglioside GM3 in that levels
of d20:1 species were significantly elevated only in Tg APP21 rats. The white matter of the
brain has demonstrated a particular vulnerability during aging (Gao et al., 2014). While
GD1 was not observed to be a major component of white matter in the current study, it has
been identified as an important binding site for myelin-associated protein (MAG), which
plays a major role in the formation and maintenance of myelin in the central nervous
system (Al-bashir, Mellado, & Filbin, 2016). The age-dependent depletion of GD1 along
with the increased abundance of simple ganglioside GM3 in Tg APP21 rats may be
indicative of a mechanism of neurodegeneration in this region during AD.
The brains of aging Tg APP21 rats are thought to be in a vulnerable state due to the
accumulation of APP. It is possible that the vulnerable state of the Tg APP21 rat brain may
have deleterious effects on the proper functioning of cell membranes and that, in an attempt
to restore/maintain homeostatic GM1 levels, GD1 is degraded to GM1. An examination of
the activities of sialidase and sialyl-transferase enzymes is a future goal and would provide
valuable insight into this hypothesis. A greater understanding of the role of altered lipid
profiles in the aging and injured brain could lead to the development of lipid-based
biomarkers for individuals at risk of developing neurodegenerative diseases as well as more
effective lipid-targeted therapeutics for the early stages of AD.
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Chapter 5 : Restoring ganglioside homeostasis after stroke using
chloroquine is associated with pathological and functional
improvements in Wistar rats

In Chapter 4, a pattern of ganglioside dysregulation was observed in the Tg APP21 rats
whereby the d20:1 species of both GM3 and GD1 were increased in a number of brain
regions susceptible to injury in the aging brain such as the white matter and the DG mol
layer of the hippocampus. Tg APP21 rats also displayed a lower abundance of both d18:1
and d20:1 species of GM1 at the later time points over Wt rats, indicating that the overall
levels of GM1 were lower in the Tg APP21 rats. GM1 is known to exert a number of
neuroprotective functions in the brain and may thus be a mechanism that leaves the brain
vulnerable to injury in the Tg APP21 rats. In the current chapter, we explore the potential
therapeutic benefits of preventing the catabolism of GM1 and the subsequent accumulation
of toxic simple gangliosides after stroke using the lysosomotropic agent Chloroquine.

5.1 Abstract
Perturbations of ganglioside homeostasis have been observed following stroke whereby
simple gangliosides GM2 and GM3 accumulate while protective complex species GM1 and
GD1 are reduced, leading to the hypothesis that complex species are being degraded to
simple species. Thus, there is a need for therapeutic interventions which can prevent
ganglioside dysregulation after stroke. A pharmacological intervention using chloroquine
(CQ) was selected for its transient lysosomotropic properties which disrupt the activity of
catabolic ganglioside enzymes. CQ was administered both in vitro, to primary cortical
neurons exposed to GM3 toxicity, and in vivo, to 3 month old male Wistar rats that
underwent a severe stroke, induced through the co-administration of a striatal endothelin-1
(ET-1) injection and intracerebral-ventricular injections of Aβ(25-35). CQ was
administered (45mg/kg i.p.) for 7 consecutive days beginning 3 days prior to surgery and
gangliosides were examined using MALDI imaging mass spectrometry at 3 and 21 days
after the injury. The ladder motor task was used to examine the functional effects of CQ
treatment on day 20. CQ treatment prevented ganglioside dysregulation 3 d post-stroke and
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partially prevented complex ganglioside depletion 21 d post-stroke. Exogenous GM3 was
found to be toxic to primary cortical neurons which was protected by CQ treatment. Motor
deficits were prevented in the forelimbs of rats with CQ treatment and were associated with
decreased inflammation, neurodegeneration, and an increase in cell survival at the site of
injury. CQ prevents ganglioside dysregulation acutely, protects against GM3 toxicity in
neurons, and is associated with long-term functional and pathological improvements after
stroke in the rat.

5.2 Introduction
Strokes are the most frequent cause of permanent disability in individuals aged 60 years
and older with the global burden of stroke care expected to increase in line with the aging
population (Chamorro, Dirnagl, Urra, & Planas, 2016; Feigin et al., 2014). However, there
is currently no clinically effective approach to prevent the damage caused by stroke with
the exception of tissue plasminogen activator, which has a very narrow therapeutic window
of effectiveness (Zhang et al., 2015). Therefore, the development of new preventative
approaches and therapeutic interventions which can improve recovery after stroke injuries
is imperative. Membrane lipid dysregulation is observed after neurodegenerative injuries in
the brain and is thought to play a key mechanistic role in the propagation of
neurodegeneration (Caughlin et al., 2015), thus, preventing this dysregulation may provide
a novel avenue of intervention for stroke injuries.
Gangliosides are a major component of lipid rafts and play an important role in
protein-lipid interactions on the cell surface leading various signal transduction events.
Structurally, simple minor gangliosides GM2 and GM3, while crucial during
neurodevelopment, have been linked to neurodegeneration in the adult brain. GM3 in
particular has been shown to upregulate pro-apoptotic signaling pathways (Nakatsuji &
Miller, 2001), inhibit angiogenesis (Chung et al., 2009; Seyfried & Mukherjee, 2010) as
well as cell proliferation (Choi et al., 2006), leading to toxicity when accumulated in neural
cells (Prokazova et al., 2009; Sohn et al., 2006). Perturbations in ganglioside homeostasis
resulting in the depletion of the more abundant protective complex species, GM1 and GD1,

158

along with the accumulation of toxic simple species have been observed in response to
neurodegenerative insults such as stroke and traumatic brain injuries (TBI) (Caughlin et al.,
2015; Whitehead et al., 2011; Woods et al., 2013). Additionally, previous work from our
lab has demonstrated that the degree of ganglioside dysregulation is correlated with the
severity of the neurodegenerative insult, with more severe stroke insults resulting in an
earlier and prolonged accumulation of toxic simple ganglioside species (Caughlin et al.,
2015). Altogether, this suggests that ganglioside dysregulation may be playing an important
role in the propagation of neurodegeneration following stroke.
Therapies targeting the restoration of depleted GM1 in the brain through exogenous
administration have demonstrated a strong protective effect in preclinical models of stroke
(Carolei et al., 1991; Karpiak, Li, & Mahadik, 1987; Kharlamov et al., 1994; Li, Tian,
Long, Chen, & Lu, 2016; Zhang et al., 2015) and was found to prevent behavioural deficits
in mice following TBI (Rubovitch et al., 2017). GM1 is thought to exert its protective
effects through modulation of neurotrophin release and the maintenance of ion balance
(Ledeen & Wu, 2015; Lim, Esfahani, Avdoshina, & Mocchetti, 2011; Rabin et al., 2002;
Zhang et al., 2015). However, clinically, GM1 administration alone has produced mixed
results and has often failed to confer adequate protection following stroke (Argentino et al.,
1989; Candelise, 2002; Hoffbrand et al., 1988). One potential explanation for this finding
may be that the restoration of complex gangliosides alone does not prevent those species
from being enzymatically degraded to simple gangliosides during the ischemic cascade,
thus the resulting toxicity is not prevented. Therefore, there is a need for targeted therapies
which can prevent the catabolism of complex gangliosides as well as the resulting
accumulation of toxic simple species in order to better protect cells from the damage
associated with ganglioside dysregulation after a neurodegenerative injury.
Chloroquine is best known as an anti-malarial drug but has also used been used as
an anti-rheumatic agent due to its anti-inflammatory properties (Lehmeyer, 1978). It has
been shown to reduce the accumulation of reactive oxygen species after glutamate-induced
toxicity in hippocampal HT22 cells (Hirata et al., 2011) and block the activity of Toll-like
receptor 3-mediated inflammatory pathway following stroke in rats (Cui et al., 2013). In
addition to its widely acknowledged role in the inhibition of autophagy, low doses of CQ
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have also been shown to have beneficial effects on the vascular system through vessel
normalization (Maes et al., 2014) and protection of the blood brain barrier (Hirata et al.,
2011). CQ freely diffuses across lipid bilayers as it is uncharged at neutral pH, but is a
weak base and becomes protonated upon entering acidic compartments such as lysosomes,
causing it to accumulate in acidic organelles and raise their pH above their acidic optimum
(Ohkuma & Poole, 1978). This disrupts the normal function of acidic lysosomal enzymes
such as β-galactosidase and β-hexosaminidase, the enzymes responsible for the catabolism
of complex ganglioside GM1 to simple species GM2 and GM3 (Riboni et al., 1991). CQ
has been used to inhibit the catabolism of gangliosides in vitro (Riboni et al., 1995; Riboni
et al., 1991; Shacka, Klocke, & Roth, 2006), making it a promising candidate for the
prevention ganglioside dysregulation after stroke.
In the current study, we used several experimental approaches to examine the
effects of CQ treatment in the brain stroke in the rat. Our previous work in this area
demonstrated that co-administration of endothelin-1 (ET-1) into the striatum to produce
focal ischemia, alongside with bilateral intracerebral-ventricular injections of toxic Aβ
(25-35) in Wistar rats, produces a more severe neurodegenerative response as well as
increased ganglioside dysregulation than either ET-1 stroke or Aβ toxicity alone (Caughlin
et al., 2015; Whitehead et al., 2005). Therefore, this particular model was chosen for the
present study as it is the ideal platform to assess the effects of CQ treatment on ganglioside
homeostasis as well as pathological and functional recovery after a severe stroke. In order
to visualize and quantify the abundance of gangliosides in the rat brain, MALDI IMS was
performed at 3 and 21 days post-stroke. For the first time, we further demonstrate the
toxicity of GM3 accumulation on primary cortical neurons and show the neuroprotective
effect of CQ treatment in neurons. Finally, we show the restoration of behavioural deficits
following CQ treatment in rats post-stroke (Fig. 5.1).

160

Figure 5.1: Chloroquine and ganglioside catabolism. (A) Schematic diagram of the
Chloroquine-mediated disruption of gangliosides catabolism. Chloroquine accumulates in
acidic compartments such as lysosomes which raises the pH above its acidic optimum and
disrupts the activity of ganglioside catabolic enzymes β-galactosidase, which cleaves a
galactose (Gal) subunit from the GM1 oligosaccharide chain to form GM2, and βhexosaminidase, which cleaves an N-acetylgalactosamine (GalNAc) sugar subunit to form
GM3. With the catabolic enzymes disrupted, CQ can transiently block the degradation of
complex gangliosides in response to a stroke. (B) Experimental paradigm. Rats in the
treatment group were administered a daily intraperitoneal injection of CQ (45 mg/kg)
beginning 3 days prior to stroke surgery and ending 3 days post-stroke. MALDI and IHC
took place 3 d post stroke (day 7) and 21 d post-stroke. On day 20 post-stroke, rats
underwent behavioural testing.
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5.3 Materials and Methods
5.3.1

Stroke Model

All animal handling and surgical procedures were in accordance with guidelines of the
Canadian Council on Animal Care and approved by the University of Western Ontario
Animal Use Subcommittee. Three month-old male Wistar rats weighing 300–400 g
(Charles River Laboratories, Quebec, Canada) were housed in pairs under standard
conditions (12:12 light/dark cycle) and provided food and water ad libitum. Rats were
randomly assigned to experimental groups and were housed individually following surgery.
To induce the severe stroke injury, rats received both a bilateral intra-cerebral ventricular
injection of the toxic amyloid beta (Aβ) fragment (25-35) followed by a unilateral striatal
injection of ET-1, a potent vasoconstrictor as previously described (Caughlin et al., 2015).
This enhanced stroke model has previously been shown to exacerbate the pathological
response (inflammation, neurodegeneration and infarct size) (Whitehead et al., 2007, 2005)
and more severely perturb ganglioside homeostasis than either injury alone (Caughlin et al.,
2015), providing the ideal platform to test a therapeutic agent aimed at restoring
ganglioside homeostasis. Control surgery rats underwent identical surgical procedures with
injections being replaced with saline. A total of 80 rats were used for the current study with
5 rats per group used for MALDI IMS analysis at 3 and 21 d, 6 rats per group for IHC, and
8 rats per group used for behavioural analysis.
5.3.2

Chloroquine Administration

Chloroquine (CQ, Sigma-Aldrich, St. Louis, USA) was prepared daily at a concentration of
45 mg/mL in 0.9 % saline. Animals were weighed immediately prior to injection and were
administered 45 mg/kg of CQ by intraperitoneal (i.p.) injection for seven consecutive days
beginning 3 days prior surgery and ending 3 days after surgery (Fig 5.1 B).
5.3.3

Immunohistochemistry and Fluoro Jade B

Immunohistochemistry, standard histochemistry, and Fluoro Jade B staining were
performed as previously described (Caughlin et al., 2015).
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5.3.4

Primary cortical neuron cultures

Primary cortical neurons were extracted from Wistar rat embryos and plated on coverslips
in 24-well plates as previously described (Park et al., 2016). Half of the media was
exchanged with fresh neurobasal media (NBM) every 2 days until 14 days in vitro (DIV).
Each coverslip represented a single biological replicate with 8 biological replicates in each
experimental group. Experiments were repeated on 3 separate cultures. On DIV 13, each
well in the 24-well plates were assigned as either control cells, CQ control cells (0.1 µM of
chloroquine dissolved in NBM), 1 µM of GM3, 100 µM of GM3, 1 µM GM3 with CQ, or
100 µM GM3 with CQ. Cells were then fixed with 4 % paraformaldehyde for 15 min then
washed 3x with 10 mM PBS either 1, 6, 24, or 48 h after administration of CQ and/or
GM3. Propidium Iodide (PI) was administered (1 mg/mL) 45 min before cell fixation in
order to assess cell viability via fluoresce microscopy. Cells were also fluorescently stained
with TUNEL using a cell death apoptosis kit (Sigma, St. Louis, MO, U.S.A.) after fixation
to assess apoptotic cell death and mounted onto microscope glass slides with Fluoroshield
(Sigma, Toronto, Canada) containing DAPI (Sigma, Toronto, Canada).
5.3.5

Fluorescence Microscopy

Neurons were imaged with DAPI (blue), TUNEL (green), and PI (red) and quantified using
a Nikon Eclipse Ni (Nikon Instruments Inc., Melville, NY, U.S.A.) microscope and Nikon
Analysis software. Microscope settings for each fluorescent filter were kept consistent for
all analysis. Nikon analysis software allows for cell counting based on staining intensity
and cell shape. This feature was used to perform all quantification of DAPI, TUNEL, and
PI positive cell staining. Positive TUNEL and PI staining was presented as a ratio to total
DAPI positive cells.
5.3.6

MALDI IMS

Rats from each experimental group (n = 5) were sacrificed at either 3 or 21 d post-surgery
for MALDI IMS analysis. Rat brains were removed via fresh frozen extraction and
prepared for MALDI IMS following the protocol published in Caughlin et al., 2017
(Caughlin et al., 2017). Briefly, frozen rat brains were sectioned coronally at a thickness of
10 μm. Sections were obtained from the site of stroke injury (bregma +1.92 mm) then
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mounted onto indium-tin-oxide (ITO) slides. 1,5-Diaminonapthalene (DAN) matrix was
then applied via sublimation followed by overnight incubation at - 20° C. Images were
acquired in negative mode with a 70 uM laser step size. Data was exported to Tissue View
(Sciex, Toronto, Canada) to visualize ganglioside distribution. Representative MALDI
Images were exported from Tissue View to be pseudo-coloured and overlaid in Image J
(Wayne Rasband, National Institutes of Health, Bethesda, MD, U.S.A.). MALDI data was
acquired in Tissue View by isolating a region of interest (ROI) of equal size at the site of
stroke within the striatum and in the corresponding contralateral uninjured striatum
(comparable ROIs were used in control animals when no stroke was present). The
numerical data from each A-series ganglioside species was then imported into Prism
statistical software to determine the area under the curve (AUC) corresponding to the 3
largest isotopic peaks of each species. This AUC measurement was then divided by the
total signal as a means of normalizing the data for between scan comparisons. The AUC of
the individual species relative to total signal was then compared between the ipsilateral
hemisphere and contralateral hemisphere to the stroke.
5.3.7

Ladder task – Motor assessment.

The ladder test was used to assess motor function and determine if CQ treatment could
rescue any motor impairments induced by the stroke. The ladder task consists of two long
pieces of plexi-glass 20 cm apart with metal pegs placed at irregular intervals along the
bottom. The ladder is raised 30 cm above the ground and connects an empty cage to the
rat’s home cage. The rat is placed at one end of the ladder (with the empty cage) and must
cross the ladder to reach its home cage on the opposite side. The home cage and empty
cage are switched sides after 3 successful runs of the ladder in one direction. A total of 6
runs (3 from each direction) were used to calculate the average number of correct paw
placements, errors in paw placement, and peg misses with each limb. Metz et al., described
correct paw placement and total misses along with 5 different types of errors in paw
placement that can occur in the ladder test (Metz & Whishaw, 2002). For the purpose of the
current study, the four variations of errors described by Metz et al., were grouped together
and simply referred to as “errors”.
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5.3.8

Novel Object Recognition – Short Term Memory Task

The novel object recognition task (NOR) can be used to assess both short and long term
memory depending of the experimental paradigm (Antunes et al., 2012). In the current
study, rats were first habituated to an empty box for 10 min at which time they were
returned to their home cage for a delay period of 45 min before being placed back into the
box. The box contained two identical objects, either two robot toys or two dinosaur toys. A
video camera was placed above the box to record the movements of the rats while they
familiarized themselves with the objects for 4 min. The rats were then removed from the
box and placed back in their home cage for a 1 hr delay period. After the 1 hr delay, rats
were placed back in the box for a third time but with one of the objects having been
replaced with a novel objects (one robot, one dinosaur). The rats were then allowed to
explore both objects again for 4 min before being placed back in their home cage. The
objects were rotated for each trial and carefully wiped down with 70% ethanol and allowed
to dry between each session, along with the inside of the box to avoid familiarity based on
scent. The location of the novel object was also rotated to be either on the right of the left
side of the box for each trial. Sham surgery control rats showed no preference for either the
robot or dinosaur objects, despite the variability in colour and shape, and were thus judged
to be suitable objects for this task. The video recording and a stopwatch were used to add
up the total amount of time rats spent interacting with each object during the familiarization
and novel object trials. ”Interaction” was defined as sniffing, touching, standing, or rearing
on the objects There was no statistical difference between the amount of time rats spent
with the two identical objects during the familiarization trial (data not shown). Data is
represented for the NOR trial as the percent of time rats spent with either the familiar or
novel objects out of the total amount of time spent exploring both objects. A two-way
ANOVA and tukey multiple comparisons test was performed to establish statistical
differences between groups (p < 0.05).
5.3.9

Data Analysis

Data are represented as mean +/- the standard error of the mean. Statistical analysis was
performed using a two-way ANOVA with a Tukey’s post-hoc test. N values are described
in each figure legend.
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5.4

Results
5.4.1

Pathological shift in ganglioside homeostasis prevented with CQ treatment
at 3 d

Ganglioside homeostasis has been shown to be severely perturbed in the early stages of
recovery after a stroke such that an accumulation of simple ganglioside species and a
depletion of complex species is observed at the site of injury and is correlated to the
severity of the neurodegenerative insult (Caughlin et al., 2015). This finding would suggest
that complex gangliosides, which are protective to cells, may be undergoing degradation in
response to the injury, leading to the accumulation of toxic simple species, further
perpetuating neurodegenerative damage. Using MALDI IMS, we examined the ability of
CQ (45 mg/kg i.p.) to prevent the dysregulation of ganglioside homeostasis after a severe
stroke injury. Sham surgery rats were used as controls and displayed no significant
differences in ganglioside abundance between the ipsilateral and contralateral sides of the
brain in response to the surgical procedures (Fig 5.2 A+B). Confirming previous findings
from our lab, the stroke-injured rats showed a significant increase in simple gangliosides 3
day after injury. The d18:1 and d20:1 species of GM2 showed the most significant increase
in abundance in response to the injury, while only the d20:1 species of GM3 was
significantly increased at the site of injury (Fig 5.2 A). CQ treatment resulted in a
significant reduction in the abundance of simple ganglioside species at the site of injury
compared to the untreated stroke group, showing no significant differences from shamsurgery controls (Fig 5.2 A). Therefore, CQ treatment successfully prevented the
accumulation of simple ganglioside species 3 days after a severe stroke insult.
In addition to examining the ability of CQ to prevent the accumulation of simple
gangliosides, we examined the abundance of protective complex gangliosides GM1 and
GD1 to determine if CQ treatment can prevent their depletion at the site of the stroke.
Ganglioside GD1 attaches to salt adducts [K+] and [Na+] when analyzed via MALDI IMS.
These two adducts of GD1 have previous been observed to have unique responses
following stroke (Caughlin et al., 2015), therefore we included both adducts in all of the
following analyses. As predicted, both the d18:1 and d20:1 species of ganglioside GM1
were significantly lower at the site of injury compared to controls 3 days post-surgery (Fig
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5.2 B). Similar to what was previously reported for the [K+] and [Na+] adducts of GD1,
they indeed showed unique responses following stroke such that the [K+] adduct of GD1
was significantly depleted at the site of injury, while the [Na+] adduct remained unchanged.
Treatment with CQ prevented the depletion of both the d18:1 and d20:1 species of
ganglioside GM1 and the [K+] adduct of GD1 while significantly increasing the abundance
of d18:1 GD1 [Na+] at the site of injury compared to untreated injured rats. Overall, these
results suggest that CQ treatment is effective at restoring ganglioside homeostasis 3 days
after a severe stroke injury.
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Figure 5.2: Ganglioside homeostasis restored at 3 d in comorbid injured rats treated
with CQ. (A) MALDI IMS overlaid images (left) and data (right) showing the AUC ratio
of simple gangliosides GM3 and GM2 in the ipsilateral versus contralateral hemisphere to
the site of injury in sham surgery, stroke, and CQ treated stroke rats 3 d after surgery.
Gangliosides GM3 d20:1, GM2 d18:1, and GM2 d20:1 were all significantly elevated in
response to the stroke injury which was prevented with CQ treatment. (B) MALDI IMS
overlaid images (left) and quantified data (right) showing the ratio of abundance of
complex gangliosides GM1, GD1[K+], and GD1[Na+] in the ipsilateral versus contralateral
hemisphere to the site of injury at 3 d. Both GM1 and GD1[K+] were significantly depleted
in response to the stroke insult whereas GD1[Na+] remained unchanged. CQ treatment
prevented the depletion of GM1 and GD1[K+] while increasing the abundance of
GD1[Na+] at the site of injury. Data presented as the ratio between the ipsilateral and
contralateral hemispheres to the stroke injury +/- SEM, n = 5 per group. Scale bar is equal
to 4 mm. * Indicates significant difference from control group, # indicates significant
difference between stroke and CQ-treated groups, p < 0.05 via two-way ANOVA, Tukey
post-hoc test.
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5.4.2

Ganglioside homeostasis partially restored by CQ 21 d after comorbid
stroke injury

Previous work from our lab has demonstrated that the comorbid stroke injury used in the
current study results in increased inflammation, larger stroke size, and poorer cognitive
outcomes at the later stages of recovery than when just stroke or Aβ toxicity are present
alone (Whitehead et al., 2007, 2005). This increased neurodegenerative response at later
time points was also associated with an increased abundance of simple ganglioside species
within the site of injury (Caughlin et al., 2015), further supporting the proposed role of
simple ganglioside accumulation in the perpetuation of neurodegeneration after stroke. We
examined the distribution of A-series gangliosides 21 days after stroke, as previously
described, in order to examine the effect of CQ treatment on ganglioside homeostasis
during the later stages of recovery.
Simple ganglioside GM3 showed a significant increase in abundance for both the
d18:1 and d20:1 species 21 days following stroke (Fig 5.3 A). While GM2 levels decreased
from their initial upregulation in the early stages of recovery, d18:1 species of GM2
remained significantly higher than controls even at 21 d (Fig 5.3 A). This response to the
stroke is consistent with what has been previously reported by our group (Caughlin et al.,
2015). CQ treatment was not able to significantly reduce the increased abundance of either
GM3 or GM2 at the site of injury 21 d post-stroke, although d20:1 species of GM3 and
both GM2 species were not significantly different from controls either. This suggests that
the accumulation of certain simple ganglioside species were, at least, partially reduced
during the later stages of recovery with CQ treatment.
Complex gangliosides, on the other hand, were still subject to the protective action
of CQ 21 d post-stroke. Injured rats continued to show a significant depletion of complex
gangliosides GM1 and GD1 at the site of injury, indicating that these species may have
continued to undergo degradation 21 d after the stroke. CQ treatment prevented this
significant drop in GM1 and significantly increased the abundance of GD1 species at the
site of injury, although GD1 [K+] levels in the CQ treated injured rats were still
significantly lower than controls (Fig 5.3 B). While the degree of protection conferred by
CQ in the maintenance of ganglioside homeostasis following stroke was reduced at the
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later stages of recovery, CQ effectively reduced the degree of ganglioside perturbation,
particularly for complex ganglioside species.
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Figure 5.3: Partial restoration of complex ganglioside homeostasis observed at 21 d
via MALDI IMS. (A) MALDI IMS overlaid images (left) and data (right) showing the
AUC ratio of simple gangliosides GM3 and GM2 in the ipsilateral versus contralateral
hemisphere to the site of injury in sham surgery, stroke, and CQ treated stroke rats 21 d
after surgery. GM3 d18:1, GM3 d20:1, and GM2 d18:1 were all significantly elevated over
controls at the site of injury at 21 d after surgery. This increase in simple gangliosides was
not significantly reduced through CQ treatment, however, GM3 d20:1 and GM2 d18:1
were not significantly elevated over controls either. (B) MALDI IMS overlaid images (left)
and quantified data (right) showing the ratio of abundance of complex gangliosides GM1,
GD1[K+], and GD1[Na+] in the ipsilateral versus contralateral hemisphere to the site of
injury at 21 d post-surgery. All complex gangliosides examined, with the exception of
GD1[Na+] d20:1 were significantly reduced at the site of injury 21 d after surgery. GM1
and GD1[Na+] levels were not significantly different from controls in CQ treated rats and
GD1[K+] abundance was significantly increased compared to untreated injured rats. Data
presented as the ratio between the ipsilateral and contralateral hemispheres to the stroke
injury +/- SEM, n = 5 per group. Scale bar is equal to 4 mm. * Indicates significant
difference from controls, # indicates significant difference between stroke and CQ-treated
groups, p < 0.05 via two-way ANOVA, Tukey post-hoc test.
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5.4.3

Exogenous GM3 results in toxicity in primary cortical neurons which is
protected by CQ treatment

Toxicity associated with the accumulation of GM3 has been established in a number of
neural (Nakatsuji & Miller, 2001; Sohn et al., 2006) and non-neural cell lines (Choi et al.,
2006; Chung et al., 2009; Seyfried & Mukherjee, 2010) but has yet to be demonstrated in a
rat primary neuron cell line. Given our previously published and current findings that GM3
is increased post stroke, and that CQ can acutely reduce this increase in GM3, we sought to
determine if GM3 could directly cause neurodegeneration. GM3 was administered to
primary cortical neurons cultured from embryonic Wistar rats after 14 days in vitro (d.i.v.)
at either a low dose (1 μM) or a high dose (100 μM) and cell viability was assessed through
TUNEL and Propidium Iodide (PI) staining 1, 6, 24, and 48 hrs after administration.
The exogenous administration of gangliosides has been shown to lead to their
incorporation into the plasma membrane of mammalian cells (Choi et al., 2006; Riboni et
al., 1991; Nakatsuji & Miller, 2001). A separate experimental group was co-administered a
low dose of CQ (1 μM) along with either the low or high dose of GM3 in order to
determine if CQ can prevent changes in cell viability induced by the exogenous
administration of GM3. CQ administration alone did not significantly alter TUNEL or PI
positive staining from control levels (data not shown). A low dose of GM3 (1 μM) was
found to significantly increase TUNEL and PI positive staining 48 hrs after administration
compared to controls (Fig 5.4 A). While CQ treatment prevented the increase in PI positive
staining at this time point, it did not significantly reduced TUNEL positive staining. In the
high dose (100 μM) GM3 groups, an increase in TUNEL and PI positive staining was
observed at 24 and 48 hrs after administration relative to controls which was significantly
reduced through treatment with CQ (Fig 5.4 B). Overall, our results show that exogenous
administration of both low and high doses of GM3 resulted in a significant increase in
apoptosis and a decrease in cell viability which can be prevented by co-administration with
CQ.
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Figure 5.4: CQ increases cell viability and decreases apoptosis in response to toxic low
and high dose GM3 administration. (A) Quantification of TUNEL and PI positive
staining relative to control primary cortical neurons administered a low dose (1 μM) GM3
or co-administered CQ (1 μM) with low dose GM3. Low dose GM3 significantly increase
TUNEL and PI positive staining relative to controls at 48 hrs after GM3 administration. PI
positive staining, but not TUNEL positive staining was significantly reduced by coadministration of low dose GM3 with CQ. (B) Quantification of TUNEL and PI positive
staining relative to control primary cortical neurons administered a high dose (100 μM)
GM3 or co-administered CQ (1 μM) with high dose GM3. High dose GM3 resulted in a
significant increase in both TUNEL and PI positive staining at 24 and 48 hrs. CQ treatment
significantly reduced TUNEL and PI positive staining at 24 and 48 hrs compared to high
dose GM3 alone. However, a significant increase in TUNEL positive staining was
observed at 48 hrs in the CQ treated cells. Data presented as a fold change relative to
control cells +/- SEM, n = 6 per group *p < 0.05 via two-way ANOVA, Tukey post-hoc
test.
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5.4.4

Stroke-induced motor and cognitive impairments prevented by CQ
treatment.

Impairments in motor function and gait are a common complication of sub-cortical stroke
in the rat, generally affecting both fore- and hind-limbs on the contralateral side of the body
to a greater extent than the ipsilateral side. In order to assess motor function in our rats, we
used the ladder task which examines the rat’s ability to cross a horizontal ladder with
unevenly spaced metal pegs. This task requires the rat to correctly place their paws on each
rung of the ladder in order to reach the other side. We assessed the total number of limb
placement errors (described by Metz et al., 2002) in both the fore-limbs and hind-limbs of
the rat in each of the experimental groups to determine if CQ treatment can protect against
stroke-induced impairments of motor function. As expected, stroke-injured rats displayed
significantly more errors in limb placement during the ladder task than the sham surgery
control group for all four limbs (Fig 5.5 A). Interestingly, the fore-limbs of the injured rats
showed a higher number of limb placement errors than the hind-limbs. As expected, the
contralateral fore-limb, displayed the highest number of limb placement errors. CQ-treated
rats showed a significant reduction in fore-limb placement errors compared to the untreated
stroke group, with no significant differences in performance from the control group (Fig
5.5 A). However, this protective effect of CQ treatment was not observed in the hind-limbs
of the CQ treated rats, which showed a significant increase in limb placement errors
compared to controls, similar to the stroke group. Overall, CQ treatment was effective at
preventing fore-limb, but not hind-limb motor impairments after stroke injury.
CQ has previous been shown to prevent stroke-induced deficits of short-term
memory in Sprague-Dawley rats using an electroshock Y-maze task (Cui et al., 2013). We
therefore assessed the short-term memory of sham surgery, stroke-injured, and CQ-treated
stroke rats 20 days after surgery using a Novel Object Recognition task (NOR). In this task,
rats are first introduced to two identical objects and are given 4 minutes to explore and
interact with the objects. After 1 hr, rats are returned to the box with one of the objects
having been replaced with a novel object and are allowed to again explore and interact with
the objects for an additional 4 min. As expected, Sham-surgery rats spent significantly
more time interacting with the novel object than the familiar object (Fig 5.5 B). This occurs
due to the rat’s preference for interacting with novel objects. Stroke-injured rats, on the
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other hand, spent the same amount of time exploring both the novel and familiar objects
(Fig 5.5 B). The lack of preference for the novel object is indicative of an impairment in
short-term memory in the stroke injured rats (Antunes & Biala, 2012). Interestingly, CQtreated stroke injured rats spent significantly more time with the novel object than the
familiar object. Although the degree of preference for the novel object was not identical to
that of the sham-surgery control group, these results suggest that short-term memory
deficits induced by the stroke injury can be prevented with CQ treatment.
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Figure 5.5: Reduced forelimb Motor and cognitive impairments in stroke injured rats
treated with CQ. (A) Quantification of limb placement errors on the Ladder motor
assessment task (top) with representative image of ladder task (right). Stroke injured rats
showed a significant increase in limb placement errors compared to controls in all four
limbs. The number of limb placement errors was significantly reduced in the forelimbs of
rats treated with CQ. CQ treatment did not significantly reduced the number of limb
placement errors in the hind-limbs of stroke injured rats. (B) Quantification of time spent
with novel and familiar objects on Novel Object Recognition task (NOR – bottom) with
representative image of NOR task. Sham surgery control rats spent significantly more time
with the novel object than familiar object while stroke injured rats spent the same amount
of time with both objects, indicating a deficit of short-term memory, CQ treated rats, like
control rats, spent significantly more time with the novel object than the familiar object,
suggesting that memory deficits were prevented by CQ treatment. * Indicates sig difference
from control group, # indicates sig difference between stroke and CQ-treated group, p <
0.05 via two-way ANOVA, Tukey post-hoc test.
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5.4.5

Reduced brain pathology at 21 d in CQ-treated stroke injured rats

The stroke model used in the current study has previously been shown to produce an
increase in infarct size as well as an exacerbated inflammatory response (Whitehead et al.,
2007, 2005). We used immunohistochemistry to examine cell survival, neurodegeneration,
and inflammation at the site of injury within each experimental group at 3 and 21 d poststroke in order to assess the effects of CQ treatment on pathology at the site of injury.
NeuN, a neuronal nuclear antigen, was used to assess cell survival. Stroke injured rats
treated with CQ had significantly more NeuN positive staining at the site of injury
compared to untreated stroke injured rats at both 3 and 21 d post-stroke (Fig 5.6 A). Fluoro
Jade B was used as a marker of neurodegeneration and was significantly reduced in CQ
treated rats at 21 d compared untreated stroke injured rats (Fig 5.6 B). Inflammation was
assessed using the microglia marker OX-6. Stroke injury led to a significant increase in
OX-6 positive staining at the site of injury at 21 d (Fig 5.6 C). CQ treatment in stroke
injured rats prevented the significant increase in OX-6 positive staining observed in
untreated stroke rats at 21 d post-stroke, indicating that inflammation was significantly
reduced in CQ-treated rats. Overall, the results demonstrate a neuroprotective effect
(increase in NeuN, decrease in FJB) with a concomitant decrease in neuroinflammation
post-stroke with CQ administration.
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Figure 5.6: CQ treatment reduces brain pathology after stroke. IHC Quantification of
NeuN (A), Fluoro jade B (B), and OX-6 (C) staining at the site of injury at 3 and 21 d post
stroke. CQ treatment significantly increased positive NeuN staining at the site of injury at
both 3 and 21 days post stroke compared to the untreated stroke group (A). FJB staining
was significantly reduced at the site of stroke injury at 21 d in CQ treated rats (B). CQ
treatment prevented the significant increase in OX-6 staining observed in the stroke group
at 21 d (C). * Indicates sig difference from stroke 3 d group, # indicates sig difference
between stroke and CQ-treated groups, p < 0.05 via two-way ANOVA, tukey multiple
comparisons.
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5.5 Discussion
In the current study, we used MALDI IMS, IHC, primary cortical neurons, and a
behavioural task to examine the effect of CQ treatment on neurodegeneration. The
combination of these techniques allows for the most in-depth examination of ganglioside
dysregulation after stroke to date and provides novel insight into the benefits of
pharmacological interventions targeting ganglioside metabolism for neurodegeneration.
CQ treatment successfully prevented ganglioside dysregulation of both complex
and simple species 3 d post-stroke. These findings support our hypothesis that CQ can be
used to prevent the degradation of complex gangliosides and accumulation of simple
gangliosides acutely after stroke. Ganglioside dysregulation was partially prevented 21 d
post-stroke by CQ treatment and was more effective at preventing complex ganglioside
degradation than simple ganglioside accumulation. Several additional species of GM3 with
a varied number of carbons in their ceramide moieties were also detected and showed a
similar pattern in response to stroke injury and CQ treatment as the d18:1 and d20:1 species
at both time points (appendix v). Treatment at this time point was also associated with a
significant decrease in inflammation, neurodegeneration, and cell death at the site of injury,
and significantly reduced motor impairments in the forelimbs of stroke-injured rats. It is
possible that preventing ganglioside dysregulation in the early stages of recovery was
sufficient to confer long-term protection during recovery from stroke. Indeed, in the case of
ischemic reperfusion injuries, neuroprotection strategies in the acute stage are crucial in
mediating damage to penumbral regions and ultimately the severity of long term
impairments (Chamorro et al., 2016; Ginsberg, 2016). Alternatively, it is possible that the
pre-treatment phase of the CQ paradigm was able to confer protection to neurons prior to
the stroke, leading to increased membrane lipid integrity and a less severe acute injury
response. In this way, the results of the current study point to a potential preventative
intervention that may be neuroprotective to individuals at high risk of developing stroke
injuries or recurring strokes. The timing of CQ administration may also be an important
factor when considering its therapeutic window (Maes et al., 2014), thus it is possible that
altering the timing of the treatments would provide a more effective long term therapeutic
response.
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Additionally, we showed, for the first time, that the exogenous administration of
GM3 to primary cortical neurons at both a low and high doses was toxic to primary cortical
neurons, supporting the hypothesis that the accumulation of this simple ganglioside at the
site of injury after a stroke may be playing a mechanistic role in the propagation of
neurodegeneration. CQ administration effectively reduced apoptosis and increased cell
viability in primary cortical neurons exposed to exogenous GM3. Although the
mechanisms in which CQ was able to protect primary cortical neurons from GM3 toxicity
remain unclear, it is possible that CQ was able to block GM3 from binding and/or
incorporating into cells to effect cell signaling and alter membrane composition. Further
investigation into the interaction of CQ with GM3 in neural cells are needed to address this
question. Regardless, this finding points to the possibility that CQ may not only be
preventing the breakdown of complex gangliosides in response to the stroke through its
lysosomotropic properties, but may also confer protection against external sources of GM3
present in the extracellular environment during the ischemic cascade.
Rubovitch et al., suggest that the restoration of GM1 shortly after the injury may be
preventing the cascade of events that lead to neurodegeneration after stroke (Rubovitch et
al., 2017). Mechanisms such as excitatory amino acids (EEAs), nitric oxide, inflammatory
mediators, reactive oxygen species, immune modulation, withdrawal of trophic factors, and
apoptosis are all thought to be involved in the development of the ischemic cascade (Zhang
et al., 2015). Interestingly, GM1, like CQ, has been found to inhibit autophagy after a
stroke injury (Li et al., 2016) and can upregulate brain-derived neurotrophic factor (Lim et
al., 2011), promoting cell survival. GM1 has also been associated with the attenuation of
secondary neuronal damage when administered in the acute stages of stroke by blocking of
EEAs-related neurotoxicity (Lipartiti et al., 1990). One of the protective effects of CQ
administration observed in the current study was the restoration of depleted GM1 at the site
of injury. It is, therefore, possible that the decreased pathological response and motor
impairments observed in the treated rats at the later time point were associated with both
the attenuation of simple ganglioside accumulation in the acute stages of recovery along
with the maintenance of GM1 levels throughout.
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Overall, chloroquine treatment can be used to restore ganglioside homeostasis after
a severe ischemic stroke injury and is associated with long-term pathological and
functional improvements in rats. Interventions targeting membrane lipid dysregulation may
be a crucial component of effective multifactorial approaches to stroke prevention and
treatment and are worthy of further investigation.
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Chapter 6 : Discussion
6.1 Summary
The purpose of the studies presented in this work was to better understand the role of
ganglioside dysregulation in neurodegeneration and aging. To accomplish this, we first
used animal models of stroke and Aβ toxicity to examine the interaction between simple
ganglioside accumulation and the severity of neurodegenerative injury. We then considered
the role of simple and complex gangliosides with either 18 or 20 carbons present in their
ceramide moiety in Wt and Tg APP21 Fischer rats to determine if the LCB ratio shifted in
a characteristic manner among all a-series gangliosides. Next, we further examined the
abundance of each individual ganglioside species in the aging brain of Wt and Tg APP21
Fischer rats to better understand the unique patterns of alterations that occur in simple and
complex gangliosides during aging. Finally, a pharmacological agent (CQ) was used to
assess protection from ganglioside dysregulation after a severe stroke in Wistar rats.

6.2 Gangliosides and pathological inflammation
The brain’s major immune/inflammatory cells, astrocytes and microglia, are thought to
play an important role in the accumulation of simple ganglioside species in response to
injury and disease. GM3 has been reported to be an important component of astrocytes.
Indeed, it has been reported to be the major ganglioside in rat and chick primary cultured
astrocytes according to HPTLC and IHC analysis, along with simple species GD3, while
complex species GM1 was not detected (Asou, Hirano, & Uyemura, 1989; Murakami et al.,
1999; Sbaschnig-Agler, Dreyfus, & Norton, 1988). The composition of gangliosides in
astrocytes is thought to be fluid, changing depending on their activation state (Raff et al.,
1983). Kawai et al., found that GD3 was elevated in reactive astrocytes but not normal
astrocytes which the authors hypothesized may be related to astrocyte’s role in lesion repair
as GD3 was increased in glial scars (Kawai et al., 1994). These studies support the
hypothesis that GM3 accumulation is linked to the neuroinflammatory process and
provides an interesting rationale for further investigations of the role of GM3 and GD3 in
astrocytes.
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While little is known of the ganglioside composition of microglia, a similar increase
in simple gangliosides has been reported in microglia in response to environmental
stressors. A study by Simon et al., showed that microglia release simple ganglioside GD3
in response to inflammatory cytokines and lipopolysaccharide (LPS) and that an increase in
GD3 is toxic to oligodendrocytes, leading to apoptosis (Simon et al., 2002).
Oligodendrocytes are particularly vulnerable to inflammatory cytokines, with TNF-α and
interferon-γ thought to play a major role in their degeneration (D’souza, Alinauskas, &
Antel, 1996; Vartanian, Li, Zhao, & Stefansson, 1995). The authors confirmed the toxicity
of elevated GD3 on oligodendrocytes by exogenous administration of several gangliosides
to in vitro cultures of oligodendrocytes and saw that only exogenous GD3 lead to an
increase in cell death markers and condensation/fragmentation of the nucleus of
oligodendrocytes (Simon et al., 2002). Indeed, unpublished work from our lab has shown
that cultured microglia also release GM3 in response to LPS, further supporting the
hypothesis that brain inflammatory cells may be contributing to the accumulation of simple
gangliosides under toxic/stressful conditions.

6.3 Ganglioside dysregulation
This work provides detailed evidence of the degree and location of ganglioside
dysregulation during neurodegeneration and aging in the brain of rats, however, much
remains to be explored. To better understand the accumulation of simple gangliosides,
there is a need for a thorough examination of the enzymes that govern their metabolism.
Chapter 5 provided compelling evidence that the depletion of complex gangliosides is tied
to the accumulation of simple species as the disruption of catabolic enzymes by CQ
restored the homeostatic distribution of all a-series gangliosides acutely after a stroke
injury. A detailed examination of mRNA and protein expression of all catabolic enzymes
using polymerase chain reaction (PCR) and western blotting could reveal if certain
enzymes are more affected than others in response to neurodegeneration, thus providing a
more specific target for ganglioside dysregulation treatments.
Additionally, while the work presented here focuses exclusively on the distribution of
a-series gangliosides, b-series gangliosides have also been implicated in the pathogenesis
of neurodegenerative diseases such as HD (Di Pardo, Amico, & Maglione, 2016), with
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simple ganglioside GD3 being linked to toxicity, similar to GM3 (Desplats et al., 2007;
Scorrano, Petronilli, Lisa, & Bernardi, 1999). An interesting avenue of further study would
be to examine how the ratio of a to b series gangliosides are altered during aging and if the
Tg APP21 rats or rats who have undergone stroke would show a different distribution of
these species. Additionally, although gangliosides have important regulatory functions in
the cell and are thus of particular interest in the context of injury and disease, their
behaviour only scratches the surface of the total burden of lipid dysregulation in the brain.
Other membrane associated lipids such as phospholipids and cholesterol are also altered in
response to changes in the external environment. Techniques such as MALDI IMS can, and
are, being used to better understand the global impact of lipid dysregulation in the brain.

6.4 Role of the ceramide moiety in aging and neurodegeneration
Prior to this work, the accumulation of d20:1 species in the brain was thought to be a
metabolic marker of aging in the brain (Palestini, Masserini, Sonnino, & Tettamanti, 1990;
Sugiura et al., 2008). Chapters 3 and 4 demonstrated that the accumulation of d20:1 species
in the brain is far more complex than previously hypothesized, with a high degree of
anatomical heterogeneity. We showed, for the first time, that the d20:1 species of simple
gangliosides do not increase in an age-dependent manner, with the exception of GM3 in the
white matter. We also showed that an increase in the proportion of d20:1 species relative to
d18:1 does not necessarily mean that that the d20:1 species are accumulating, but rather
could be indicative of a depletion of d18:1 species, as was observed for complex
ganglioside GD1 in the white matter.
While the functional consequences of alterations in the ceramide moiety are thought
to be related to membrane fluidity and cell signaling properties on the membrane, much
remains unknown (Masserini, Palestini, & Freire, 1989; Sonnino & Chigorno, 2000).
However, this work provides new, detailed information regarding their anatomical
distribution during aging, which may help elucidate the role of the ceramide moiety. For
example, Hirano-Sakamaki et al., found that 18 carbon species of GM1 and GD1 are highly
expressed in the hillium and inner molecular layers of the hippocampus. These regions
contain mossy fiber axons and dendrites from granule cells and play a critical role in
memory and learning, which suggests that the 18 carbon species of complex gangliosides
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may be critical to these processes. The increased abundance of complex d20:1 species in
the molecular layer suggest that these species are highly localized on axons and perforant
pathway fibers from entorhinal cortex neurons, a pathway highly susceptible to
neurodegeneration in AD (Hirano-Sakamaki et al., 2015). This study suggests the regional
distribution of ganglioside species with various carbon chain length may be crucial to the
functions of that brain region.
Furthermore, Cutler et al., described a correlation between the location of long
chain ceramide accumulation and brain regions which were susceptible to pathology in AD
patients (Cutler et al., 2004). Therefore, it is possible that the brain regions which showed
the highest ratio of d20:1 to d18:1 species in Chapter 3 are most vulnerable to the
development of pathology in our rats. The regions with the highest overall d20:1/d18:1
ratios included the DG Mol layer of the hippocampus, intermediate layer of the cortex, and
the white matter PVCC for complex gangliosides, and the PVCC, and to a lesser extent the
aCC, striatum, and LSN for simple ganglioside GM3 (GM2 showed a fairly stable ratio in
all brain regions). Indeed, Chapter 4 revealed several differences with regards to the
ceramide moiety in Tg APP21 and Wt rats which support this hypothesis. Firstly, Tg
APP21 rats had elevated d20:1 species of GD1 at 20 m in the PVCC over Wt rats, while the
aCC showed a more severe depletion of d18:1 species at 20 m. Secondly, Tg APP21 rats
accumulated d20:1 species of GD1 earlier than their Wt counterparts in the DG Mol layer
of the hippocampus and did not show an increase in d18:1 species at 20 m that was
observed in Wt rats. Thirdly, the intermediate layer of the cortex showed the largest
discrepancy between d18:1 and d20:1 species of GM1 and GD1 for both Wt and Tg APP21
rats, with relatively stable levels of d18:1 during aging accompanied by a significant
increase in d20:1 species. However, Wt rats had significantly more d18:1 species of GD1 at
12 m, with a similar pattern observed for GM1. Altogether, Tg APP21 rats had either
higher levels of d20:1 species or lower levels of d18:1 species in all three of the
aforementioned brain regions. In terms of simple ganglioside GM3, Tg APP21 rats showed
significantly more d20:1 species in all cortical, subcortical, and white matter brain regions
at 12 m than Wt rats. However, this significant increase only persisted at 20 m in the
PVCC. Thus, while the d20:1 species of GM3 did not necessarily accumulate in an age
dependent manner across the brain, Tg APP21 rats still showed higher levels of these
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species than their Wt counterparts, suggesting that an increase in d20:1 species may be a
mechanism which makes the brain more susceptible to damage in Tg APP21 rats.

6.5 CQ and ganglioside metabolism – limitations/benefits
In chapter 5, CQ treatment prevented the dysregulation of gangliosides 3 d after a severe
stroke injury. However, the effect of this treatment was not as pronounced at 21 d and a
toxic pattern of ganglioside distribution began to emerge. It has been suggested that CQ
may be more effective in treating damage caused by ischemic reperfusion injuries in the
early stages of recovery than later stages (Fang, Liu, Dahmen, & Dirsch, 2013). Further
studies examining the effects of CQ on ganglioside metabolism after stroke are needed to
establish the optimal timing for effective treatment.
The inhibition of ganglioside catabolic enzymes by CQ leads to the accumulation of
GM1 through a number of different mechanisms. Other than preventing direct GM1
catabolism, CQ can increase GM1 indirectly through GD1a. Riboni et al., demonstrated
that GD1a and b can be broken down by sialidase at the level of the plasma membrane,
independent of the lysosome, while the degradation of GM1 to GM2 and GM3 were
lysosome-dependent (Riboni, Prinetti, Bassi, & Tettamanti, 1991). This suggests that CQ’s
ability to increase GM1 likely stems not only from the disruption of catabolic enzymes
which degrade GM1, but also from the normal degradation of GD1 to GM1 by membranebound sialidase which then accumulates as GM1. For this reason, targeting the catabolic
enzymes βGal and βHex may be a particularly effective approach for both preventing the
accumulation of simple gangliosides and increasing/maintaining GM1 levels.
One limitation of using CQ to modulate the catabolism of gangliosides in vivo is
that this compound has a number of biological effects both within and outside of the
lysosome, therefore, the beneficial effects of CQ treatment after stroke demonstrated in
chapter 5 cannot be strictly ascribed to the restoration of ganglioside homeostasis. CQ is a
known inhibitor of autophagy and has been used in pre-clinical models and clinically as an
anti-inflammatory agent (Ferraz et al., 1994; Popert, Meijers, Sharp, & Bier, 1961; Suarez‐
Almazor et al., 2000; Yang et al., 2013), both functions which have also been shown to be
beneficial in treating stroke injuries (Cui et al., 2013; Hirata et al., 2011; Li et al., 2016;
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Zheng et al., 2014). Therefore, it is possible that these mechanisms may also be playing a
role in reducing stroke pathology and preventing behavioural deficits in the rats. However,
chapter 5 also demonstrates, for the first time, that CQ is able to reduce toxicity caused by
the exogenous administration of GM3 in primary cortical neurons. These results directly
link the therapeutic effects of CQ with a ganglioside-derived mechanism of toxicity.
Importantly, these results were recapitulated in the in vivo rat model 3 d post-stroke, in
which the increase in toxic simple gangliosides was prevented by CQ treatment. While the
findings of chapter 2 demonstrated that ganglioside dysregulation was tied to the severity
of neurodegeneration, chapter 5 showed that the restoration of ganglioside homeostasis by
CQ was tied to pathological and functional recovery from a severe neurodegenerative
stroke.
In the end, Chapter 5 serves as a valuable proof of principle that ganglioside
dysregulation can be treated using the anti-malarial drug CQ and that the restoration of
ganglioside homeostasis is associated with pathological and functional recovery. While CQ
itself is known to produce a variety of symptoms in humans, such as severe stomach pains,
psychosis, delirium, vomiting, and blurred vision, synthetic analogues of CQ have been
created which have the same properties but produce milder symptoms. In a clinical setting,
a pharmacological agent, such as CQ, could be administered alone or in conjunction with
other therapies as part of a multi-factorial approach to treatment in patients who have either
suffered a stroke or are at high risk of suffering from recurring strokes. However, further
studies are needed to demonstrate the specific role of βGal and βHex inhibition in
neurodegeneration.

6.6 Alternative approaches for modulation of ganglioside metabolism
In order to better understand the specific effects associated with the restoration of
ganglioside homeostasis during neurodegeneration, catabolic enzymes βGal and βHex
would have to be selectively targeted and transiently blocked. Although there is currently
no pharmacological agent which can accomplish this, genetic approaches may hold the key
to answering this question.
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KO animal models have been developed which lack the synthetic enzymes
necessary for the formation of certain types of gangliosides, leading to a depletion of
downstream gangliosides. These models have been useful in understanding the role of the
depleted species during development and in the adult brain (Chiavegatto, Sun, Nelson, &
Schnaar, 2000; Harlalka et al., 2013; Takamiya et al., 1996). KO models targeting the
catabolic enzymes have also been developed that lead to an accumulation of the upstream
species. For example, the βGal KO mouse model leads to an accumulation of GM1. These
models are generally used to simulate gangliosidoses (Hauser, Kasperzyk, D’Azzo, &
Seyfried, 2004; Tessitore et al., 2004). A permanent KO of any gene associated with
ganglioside metabolism or catabolism would disrupt the normal homeostatic balance
needed at various stages of development. Thus, while KO models can be quite specific in
their genetic target, they do not offer the required transient properties to be a useful
therapeutic approach to treating ganglioside dysregulation and would not be transferable to
a clinical setting. Rather a genetic knock-down approach would be more suitable.
Small interfering ribonucleic acid, or siRNA, is a technique used for sequence
specific knock down of a desired gene, for example, βGal. The sequence is synthetically
created then injected into the cell (in vitro) or desired region (in vivo). The effects are
transient as the siRNA eventually gets degraded or diluted below a therapeutic threshold
(Whitehead, Langer, & Anderson, 2009). siRNA has been shown to last between 3-7 d in
rapidly dividing cells, and several weeks in non-dividing cells (Bartlett & Davis, 2006).
Future studies using siRNA to target βGal and βHex both in in vitro models of toxicity and
in vivo models of stroke may reveal specific neuroprotective mechanisms involved in
preventing ganglioside dysregulation.

6.7 Gangliosides and white matter
One of the most interesting findings from chapter 3 and 4 was the unique changes in
ganglioside composition that occurred in the white matter of both Wt and Tg APP21 rats
during aging. The age-dependent increase in the d20:1/d18:1 LCB ratio of GD1 in the
white matter observed in chapter 3 was revealed to be the result of an age-dependent
depletion of d18:1 species with only a minor increase in the d20:1 species, an effect that
was exacerbated in the Tg APP21 rats. This GD1 pattern was unique to the white matter,
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with an increased or stable abundance of d18:1 species during aging throughout the rest of
the brain. As previously mentioned, GD1 is a major receptor for MAG binding and plays
an important role in the long term stability of axons. Thus, a depletion of these species in
the white matter of the aging brain may represent a mechanism of vulnerability to axonal
damage in the corpus callosum. Indeed, depletion of GD1 and GM1 has been observed in
the corpus callosum of a pre-clinincal model of HD and may, according to the authors,
represent a critical molecular change influencing the pathogenesis of neurodegenerative
diseases (Di Pardo et al., 2016).
Chapter 3 also showed that GM3 had a unique pattern of abundance in the white
matter during aging, with an age-dependent increase in the d20:1/d18:1 LCB ratio. This
ratio either decreased or remained unchanged between birth and old age in every other
brain region. Chapter 4 expanded upon these findings and revealed that both the d18:1 and
d20:1 species of GM3 were significantly higher at 12 m in Tg APP21 rats in brain regions
such as the substantia nigra and cortex, an effect that was masked in chapter 3 due to the
focus on the d20:1/d18:1 ratio. These results suggest that GM3 accumulation during aging
may play a much larger role than anticipated in the brains of Tg APP21 rats. Importantly,
the increased GM3 LCB ratio observed in the PVCC in chapter 3 was found to be the result
of an increase in d20:1 species in Tg APP21 rats at both 12 and 20 m, and not a decrease in
the d18:1 species. The accumulation of GM3 in the white matter of Tg APP21 rats is of
particular interest due to its hypothesized role in the development of vascular dementia.
GM3 was reported to be a major component of vascular smooth vessel walls in the brain
and is thought to be critical driver of Aβ aggregation in blood vessel walls of Tg APP mice
with the Dutch mutation (Yamamoto, Hirabayashi, Amari, & Yamaguchi, 2005). Indeed,
our Fischer Tg APP21 rats are vulnerable to the development of micro-infarcts in the
corpus callosum as they age, a pathology reminiscent of leukaoriosis in human patients
with vascular dementia. Thus, the data presented in this work supports the hypothesis of
GM3 accumulation as a driver of early pathology in AD and an important target for
preventative interventions.
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6.8 MALDI IMS – limitations and future directions
Advancements in the MALDI IMS technique have increased exponentially in the last
decade, not only in terms of technology, but also in sample preparation methodology. The
deposition of dry matrix by sublimation has enabled increased sensitivity and spatial
resolution of lipid imaging that has made the findings reported in this work possible.
However, there remain a number of limitations to the technique that we, and others in the
MALDI IMS field, are working on improving moving forwards.
One of the largest pitfalls of MALDI IMS is the semi-quantitative nature of the data
it produces. Finding new statistical approaches to analyzing the data and reducing error
produced by between scan variability is one the biggest challenges currently facing the
field. In chapter 2, the average peak height corresponding to the three largest isotopic peaks
was used to perform a ratio between the stroke-injured, ipsilateral hemisphere in the rat
brain compared to the undamaged tissue of the contralateral hemisphere. The three largest
isotopic peaks of each species were used to ensure the data was as representative as
possible of abundance of each ion. Although it is often the case, the first isotopic peak is
not always the largest, and thus, measuring only one isotopic peak can be misleading. By
comparing the ratio of each species within two regions of interest of the same image, error
produced by between scan variability was greatly reduced. In chapters 3, 4, and 5, the peak
height analysis was replaced by an area under the curve (AUC) measurement, which has
become a common method of quantifying MALDI IMS data in similar published studies
(Sugiura et al., 2008; Weishaupt, Caughlin, Yeung, & Whitehead, 2015). In chapter 3, this
AUC measurement was used to calculate the ratio between the d20:1 and d18:1 species of
each ganglioside, which, similar to chapter 2, prevented the need for direct image
comparisons. Data from chapters 4 and 5 were further normalized by a total ion current
ratio, comparing the AUC of each species to the total AUC of the mass spectrum, allowing
for between species comparisons. Chapter 5 combined the analytical approaches of
chapters 2 and 4 by both normalizing the data to the total ion current and comparing the
injured ipsilateral hemisphere with the undamaged contralateral hemisphere. Although the
approach to data analysis had evolved throughout this work, the field of IMS is always
pushing for newer, more quantitative approaches to analyzing MALDI IMS data.
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Standards of specific ions of interest can be used for tandem MS (MS/MS) to
identify ions that have a low abundance in tissue samples (Chan et al., 2009; Dufresne et
al., 2017). However, pure standards of each ganglioside species do not currently exist,
limiting the applications of this method for large scale ganglioside identification and
analysis. Using mathematical algorithms to cluster trends in MALDI MS data peak
distribution, called principle component analysis (PCA), has been used to describe
differences between experimental groups or identify patterns in MALDI IMS data (Hong et
al., 2016). These alternative approaches to quantifying and analyzing MALDI IMS data
may increase the robustness of findings.
Advancements in technology are also a key factor in addressing some of the
limitations of MALDI IMS. For example, with the Sciex 5800 MALDI instrument used in
chapters 3 through 5, acquisition of a full rat brain coronal section took upwards of 2 hrs
and 30 min at a spatial resolution of 70 μM. This long acquisition time makes running an
experiment with a large sample size very costly and time consuming. Additionally, certain
dry matrices begin sublimating while under the vacuum of the instrument, further limiting
the types of matrices that can be used to acquire these full images. New MALDI MS
instruments have been developed to address these issues including the recent launch of the
Bruker Rapiflex MALDI MS, which can acquire images several times faster than any
previous model (Prentice & Caprioli, 2016). This opens the door to a new realm of
application opportunities and greatly increases the number of dry matrices that can be used
to acquire large images (Potocnik et al., 2015). Increasing acquisition time makes the
application of full body imaging more practical, which would allow for a more detailed
examination of lipid distribution across the entire body of healthy and diseased/injured
mice or rats, or tracking a peripherally administered drug to its target location. Full body
imaging and Rapiflex technology would offer an interesting expansion to the work
presented here.

6.9 Significance of the research
Our brains are largely composed of lipids, yet their role in aging and disease remains
poorly understood. This work provides a unique interdisciplinary approach to examining
the role of gangliosides during aging and neurodegeneration. Novel insight into the age-

194

dependent accumulation of long chain gangliosides was provided, showing, for the first
time, that it is not a hallmark of the aging process but rather is largely dependent on
ganglioside structure and anatomical location. The white matter was identified as a region
that is particularly susceptible to ganglioside dysregulation in Tg APP21 rats and showed
unique age-dependent alterations in ganglioside composition compared to grey matter
regions. Further, a link between the severity of neurodegeneration and the degree of
ganglioside dysregulation was shown and identified the depletion of complex species GM1
and GD1, along with the accumulation of GM3 and GM2 as major pathological events at
the site of stroke injury. It also demonstrates that ganglioside dysregulation can be
prevented with CQ and provides a foundation upon which refined, specific inhibitors of
ganglioside catabolism can be examined as potential preventative/therapeutic approaches to
ganglioside dysregulation. Overall, ganglioside dysregulation was highlighted as a crucial
component of a highly complex set of pathological events which can play a mechanistic
role in the propagation of neurodegeneration after stroke and increase susceptibility to the
development of neurodegenerative diseases, making it a worthy target of future
investigation. However, in the end, this work underlines the vast gap in knowledge that
exists with regards to the role of membrane lipids in the brain and the need for innovative
interdisciplinary approaches to better understand their role in health, disease, and injury.
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Appendices
Appendix i: Incubation time and spatial resolution
A number of troubleshooting experiments were performed in order to establish a working
protocol that enhanced both the detection of gangliosides as well as spatial resolution. One
experiment which demonstrated superior imaging resolution was the addition of an
incubation period between sublimation and image acquisition. This effect was enhanced
when the tissue was stored at -20° C as opposed to room temperature. This is thought to
occur due to increased interaction time between the matrix and the tissue, as well as a
rehydration effect when the tissue is removed from the freezer and place in the desiccator.
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Appendix i: Effect of incubation time and freezing on spatial resolution of ganglioside
GM1 in MALDI imaging of mouse brain tissue. All tissue samples were sectioned and
sublimated at the same time to avoid day-to-day variation in sample prep parameters. The
left panel shows the spatial resolution of GM1 on a mouse brain tissue section when the
image was acquired as soon as sublimation was completed. The image appears to have an
uneven signal intensity across the tissue and has a “grainy” appearance as compared to the
other images. The middle panel shows a separate tissue imaged after a 24 hr incubation
period at room temperature. The image appears to be much more even and less pixelated.
The final panel on the right show the spatial resolution of a third tissue section after a 24 hr
incubation period in a -20° C freezer. Signal intensity of GM1 appears to have been
increased evenly across the tissue as compared to the other panels and spatial resolution
also increased, making it possible to observe discrete anatomical features of the tissue.
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Appendix ii: Evolution of MALDI IMS sample prep protocols
The development of an optimized sample prep protocol is imperative for the detection and
visualization of gangliosides across brain tissue sections. Significant improvements in
sample prep and instrumentation between chapters 2 and 5 of this work occurred which
allowed for improvements in accurate detection and visualization of A-series gangliosides
across the rat brain.

Appendix ii: The evolution of the MALDI IMS protocol and improvements in signal
intensity and spatial resolution over time. The first panel shows a representative image
from one of the first MALDI IMS experiments at the begging of this work performed using
a Sciex 4700 MALDI instrument and CMBT matrix dissolved in a solvent and sprayed
using a pneumatic sprayer. Refinements in the CMBT protocol led to improved spatial
resolution and increased the signal to noise (S/N) ratio (shown in panel 2). With the
purchase of an updated Sciex 5800 MALDI instrument and the use of a sublimation
protocol with DAN matrix, sensitivity and spatial resolution exponentially increased (panel
3). Finally, further refinements in sample prep methodologies and image processing using
Image J software to pseudocolour and overlay species allowed for the simultaneous
visualization of different species (panel 4).
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Appendix iii: Sublimation protocol
A specialized MALDI IMS sample prep protocol was developed upon completion of
chapter 2 in order to improve MS signal and imaging resolution of gangliosides. This
protocol was created to address limitations in sensitivity observed in chapter 2. For
example, the d20:1 species of GM3 fell below the threshold of detection, thus, valuable
information on the abundance of a toxic ganglioside species in the context of
neurodegeneration was missing. This protocol, in conjunction with an updated MALDI MS
instrument allowed for a more detailed analysis of ganglioside dysregulation in the rat brain
and was published in the Journal of Visualized Experiments in February 2017. This
manuscript was accompanied by a visual demonstration of the protocol to allow other
researchers to replicate the technique used in this work.

Sublimation of DAN Matrix for the Detection and Visualization of
Gangliosides in Rat Brain Tissue for MALDI Imaging Mass Spectrometry
Abstract
Sample preparation is key for optimal detection and visualization of analytes in MALDI
IMS experiments. Determining the appropriate protocol to follow throughout the sample
preparation process can be difficult as each step must be optimized to comply with the
unique characteristics of the analytes of interest. This process involves not only finding a
compatible matrix that can desorb and ionize the molecules of interest efficiently, but also
selecting the appropriate matrix deposition technique. For example, a wet matrix deposition
technique, which entails dissolving a matrix in solvent, is superior for desorption of most
proteins and peptides, whereas dry matrix deposition techniques are particularly effective
for ionization of lipids. Sublimation has been reported as a highly efficient method of dry
matrix deposition for the detection of lipids in tissue by MALDI IMS due to the
homogeneity of matrix crystal deposition and minimal analyte delocalization as compared
to many wet deposition methods (Hankin, Barkley & Murphy, 2007; Thomas,
Charbonneau, Fournaise & Chaurand, 2012). Broadly, it involves placing a sample and
powdered matrix in a vacuum-sealed chamber with the samples pressed against a cold
surface. The apparatus is then lowered into a heated bath (sand or oil), resulting in
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sublimation of the powdered matrix onto the cooled tissue sample surface. Here we
describe a sublimation protocol using 1,5-diaminonaphthalene (DAN) matrix for the
detection and visualization of gangliosides in the rat brain using MALDI IMS.

Introduction
Matrix-assisted Laser Desorption/Ionization (MALDI) Imaging Mass Spectrometry (IMS)
is becoming a highly sought after technique for visualization of the spatial distribution of
lipids, peptides and proteins across intact sample surfaces. MALDI IMS was previously
known as an analytical technique for pre-purified analytes, but in recent years, it has been
drawing attention in many other disciplines because of the ability to combine the accuracy
of mass spectrometry with high resolution visual/anatomical reference points without the
need for any external labelling.
As the scientific pool of researchers utilizing this technique continues to grow, there
is increased need for standardized, easy-to-follow protocols to assist in the development
and optimization of IMS experiments. Gangliosides, a group of membrane lipids highly
abundant in the central nervous system, are ideal for MALDI IMS experiments as their
location, embedded within the membrane, makes certain species impossible to detect using
conventional Immuno-labelling. Additionally, we have shown, using MALDI IMS, that
these lipids, which function as modulators of cell signaling, among other things, have
unique anatomical distribution patterns in the healthy rodent brain that are altered after
brain injury (Caughlin et al., 2015; Weishaupt, Caughlin, Yeung & Whitehead, 2015;
Whitehead et al., 2011). Gangliosides are located at a higher mass range compared to most
lipid species, and are thus most suited to the MALDI imaging platform.
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Figure 1. Workflow of MALDI IMS Experiment.
Diagram of the general workflow of a MALDI IMS experiment using sublimation. Tissue
frozen at -80 °C is sectioned in a cryostat and 10 μm sections are thaw mounted onto
conductive ITO slides. The slide is then placed in a desiccator until sublimation. Slides are
inserted into the sublimation apparatus and an even layer of matrix is applied to the tissue
sample surface. Samples are frozen overnight in a -20 °C freezer then placed in a desiccator
for 10 min. Once standards have been applied, the samples are inserted into the MALDI
instrument where a laser is directed across the tissue causing desorbed molecules in the
matrix to ionize. The ions travel down a flight tube and separate based on their mass (timeof-flight/TOF) until they reach the detector. The information on the ionic abundance of
analytes within a predetermined mass-to-charge (m/z) range is displayed as both a
molecular image and mass spectrum. This data can be used to both visualize and quantify
the ionic abundance of the analyte of interest within the imaged tissue.
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Sample preparation for MALDI IMS is highly variable as each step of the process
must be customized to the analytes of interest. The defining feature of MALDI-based
experiments is the use of a matrix coating deposited onto the sample surface prior to
analysis. In addition to the role of absorbing and transferring radiation energy from the
laser during the ablation process, the matrix also serves to isolate various analytes from the
sample, thereby facilitating the analysis of compounds of interest (Fuchs et al., 2010;
Barcelo-Coblijn & Fernandez, 2015). Homogenous application of the matrix to the sample
surface is the most crucial step in the sample preparation process. Improper matrix
deposition can lead to large heterogeneous matrix crystal formations and the development
of artifacts, low ion-signal, and poor reproducibility (Barcelo-Coblijn & Fernandez,
2015)(Figure 1).
Due to the affinity of certain matrices to isolate specific analytes, the type of matrix
selected for an experiment can significantly alter the outcome. The matrices used for
imaging of proteins and peptides often differ from those used for imaging lipids and the
process is further complicated by the need for additional procedures such as washing and
rehydration steps in order to successfully detect signals from tissue. Although washing
steps exist for the enhancement of lipid signals (Angel, Spraggins, Baldwin & Caprioli,
2012), they are not a prerequisite for the detection of most lipid species. When selecting a
matrix for a lipid imaging experiment, it is important to consider the polarity of the lipid of
interest as this will narrow the range of suitable matrices. For example, gangliosides
contain sialic acid residues which give them an overall negative polarity. There are a
number of matrices that can effectively desorb and ionize gangliosides from tissue;
however, factors such as matrix-derived peaks in the spectrum and stability of the matrix
under vacuum must be taken under consideration. 1,5-diaminonapthalene (DAN) matrix is
sufficiently stable under instrument vacuum conditions for the majority of imaging
applications and has demonstrated a high degree of sensitivity for lipid desorption and can
be used for the analysis of lipids in both positive and negative ion modes (Thomas,
Charbonneau, Fournaise & Chaurand, 2012). DAN matrix, when compared to other
negative lipid affinity matrices such as dihydroxybenzoic acid (DHB), 9-aminoacridine (9AA), and 5-chloro-2-mercaptobenzothiazole (CMBT), was able to most efficiently desorb
gangliosides from rat brain tissue in negative ion mode (manuscript in preparation).
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Selecting the appropriate method of matrix deposition is of equal importance to
selecting the matrix itself. Wet matrix deposition methods wherein the solid matrix is
dissolved in an organic solvent, and deposited by pneumatic or automated sprayers or
spotters, are particularly effective for the desorption of proteins and peptides as the liquid
permeates the sample to allow for extraction of compounds and co-crystallization with the
matrix. Although these techniques can also be used for lipid applications, analyte
delocalization and uneven matrix crystal formations are common occurrences due to the
high abundance and solubility of lipids in solvents, particularly in tissue (Thomas,
Charbonneau, Fournaise & Chaurand, 2012; Murphy et al., 2011). Because lipids are
readily ionized from tissue, dry matrix deposition techniques, such as sublimation, offer a
simple, cost effective alternative to sprayers while circumventing many of the drawback of
these techniques. The success of sublimation in MALDI IMS experiments is attributed to
features such as microcrystalline matrix morphology which increases the surface area for
matrix-analyte binding, increased matrix purity, and homogenous matrix deposition leading
to increased reproducibility compared to wet matrix techniques (Hankin, Barkley &
Murphy, 2007; Jaskolla, Karas, Roth & Steinert, 2009).
Sublimation involves heating a powdered matrix under vacuum immediately below
a cooled sample surface resulting in solid to gas-phase transition of the powdered matrix
followed by deposition onto the tissue sample surface. During sublimation, matrix
deposition can be controlled by varying factors such as time, temperature and pressure to
provide highly reproducible results. A single sublimation experiment can take anywhere
from 5 to 20 min depending on the type of matrix selected, which can be re-used several
times before disposal. The apparatus can be purchased commercially at a fraction of the
price of automated sprayers and is easily taken apart for cleaning and maintenance. The
low cost and relative simplicity of this matrix deposition technique make it ideal for
researchers beginning or expanding upon lipid imaging applications in MALDI IMS.
Although information detailing protocols for sublimation of tissues for IMS have been
reported (Rourke et al., 2015), few standardized protocols exist which focus on the basic
workflow involved with carrying out a sublimation experiment for imaging high mass
lipids in negative ion mode, making it difficult to establish the technique without extensive
trial and error. The following is an experimental protocol aiming to fill that gap for the
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sublimation of DAN matrix onto rat brain sections for high resolution imaging and
detection of gangliosides (Figure 2).
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Figure 2. Sublimation Apparatus.
Photograph (A) and schematic diagram (B) of the sublimation apparatus. The vacuum
pump is connected by rubber tubing to a cold trap filled with 300 mL of ethanol. The cold
trap is then connected by rubber tubing to the sublimation apparatus. The apparatus is made
up of two separate pieces of glassware that are sealed together with a metal U-joint. The
top half of the sublimator contains the condenser which is filled with ice slush. The sample
plate is taped onto the bottom of the condenser, inside the sealed glass apparatus. The
bottom half of the sublimation apparatus contains the DAN matrix, spread out evenly
facing the sample plate. During sublimation, the glass apparatus is placed on a sand bath
heated to 140 °C by a hot plate directly below it. The temperature probe helps maintain a
stable temperature throughout the sublimation experiment through feedback of the sand
bath temperature compared to the preset temperature for the experiment.
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Protocol
All animal handling procedures described below adhere to the University of Western
Ontario's animal care committee (2016-014).
1. Tissue Preparation and Sectioning
1.1. Extract brain tissue from the rat through a process known as "Fresh Frozen Extraction"
(FFE).
a. Euthanize the rat with an overdose of pentobarbital sodium and monitor reflexes
in the limbs. Once all reflexes have ceased, sever the head of the rat using a
guillotine.
b. Carefully separate the muscles and other tissues from the skull using a scalpel.
Use bone-cutting forceps to break the skull to expose the brain, starting from the
base of the skull (foramen magnum) to the anterior portion.
c. Once the brain is exposed, carefully scoop it out with a surgical spatula and
immediately place on crushed dry ice for flash freezing.
NOTE: The brain will be very malleable. Therefore, take extreme care when placing the
brain on dry ice. If the brain is crushed or pressed against a surface, it will alter its shape
and freeze in that position.
1.2. Remove fresh frozen tissue (not perfused with formaldehyde or embedded in OCT)
from - 80° C freezer and place on dry ice.
1.3. Place several drops of water on a cryostat holder and place on either dry ice or cryostat
freeze bar. Press tissue lightly onto cryostat holder as it begins to freeze and hold until
water freezes around the base of the tissue and anchors it in place. Add additional water to
further secure the tissue on the holder if necessary.
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NOTE: Water is used instead of OCT media for mounting tissue in order to avoid
contamination of the tissue with compounds which can affect the detection of the desired
signal.
1.4. Position tissue in cryostat. Section tissue up to the desired anatomical location. Ensure
that the cutting thickness is between 8 - 12 μm.
NOTE: When sectioning tissue in communal cryostat devices, it is imperative that separate
materials such as blades, brushes, anti-roll bars, and holders be used in order to avoid
contamination with embedding compounds. The inside of the cryostat should also be
cleaned thoroughly with ethanol before use.
1.5. Using the cryostat anti-roll bar, slowly section flattened tissue sections. Holes or
markings on the tissue can occur if the roll bar placement is incorrect or blade is dull. Move
the tissue to the center of slicing platform using clean paintbrushes.
1.6. Mounting
a. Freeze conductive slides or metal plates by placing them in the cryostat while
slicing. When the slide is completely frozen, carefully move the sectioned tissue
onto the conductive surface of the slide using clean paintbrushes. Once all tissue
sections are positioned correctly on the slide, place a finger under the slide, opposite
the tissue, and press until the section thaws.
NOTE: Sections may fold or curl during the thawing process when using this mounting
method. This can be reduced by keeping the slide in the cryostat when thawing the tissue.
If these issues become problematic, an alternative, warm-mount method is listed below.
b. Alternatively, take a room temperature Indium-tin Oxide (ITO) slide (or metal
plate) and lightly press down on frozen tissue section on the slicing platform
surface, conductive side down. This will lead to the tissue section thawing evenly
onto the surface of the slide with little curling or folding of the tissue.
NOTE: Condensation may appear below the section when mounting using this method
which may lead to loss of certain proteins and lipids.

213

1.7. Place slides with tissue in a desiccator for 5 - 10 min.
2. Sublimator Apparatus Set-up
NOTE: Perform these steps in a fume hood.
2.1. Place a sand bath in an aluminum container onto a hot plate, with the hot plate on a
metal scissor lift of appropriate surface area (i.e. larger than the hot plate). Turn on the hot
plate and set the temperature to 140 °C.
NOTE: The melting point for DAN matrix is between 187 - 190 °C. Do not exceed this
temperature on the hotplate.
a. If the hot plate is equipped with a temperature feedback probe, use it to monitor
sand temperature throughout the experiment and ensure temperature consistency.
This feature can assist with experiment reproducibility across various sublimation
experiments.
NOTE: The sand bath should be contained within an aluminum container as a glass
container may shatter at high temperatures.
2.2. Place 300 mg of DAN matrix onto the bottom surface of sublimation apparatus. Place
the matrix in the center of the apparatus and spread out in an even layer in the approximate
width and length of the slide being sublimated.
CAUTION: DAN matrix is toxic. Therefore, it is important wear gloves, masks, and safety
goggles at all times when handling the powdered matrix. DAN should be stored in the dark
as it is light sensitive.
2.3. Tape a metal plate onto the inner surface of the apparatus with the plate making direct
contact with the bottom of the condenser in order to ensure even distribution of temperature
cooling across the entire surface of the slide during sublimation. Alternatively, sand the
bottom of the condenser to ensure a flat surface.
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a. Place the tape along the outer edges of the plate and adhere to the sides of the
inner glassware. If the tape is placed under the plate and adheres to the bottom of
the inner glass surface, the temperature distribution may not be even and could
result in uneven matrix distribution across the surface of the slide.
b. Tape a blank (test) slide diagonally across the surface of the metal plate with the
tape again placed on the outer edges of the slide.
2.4. Connect the top and bottom portions of the apparatus, with a rubber O-ring in the
middle to ensure a complete seal.
2.5. Place a metal U-joint around the center of the apparatus and tighten vices until the top
and bottom half of the apparatus are sealed tightly together. Place in the metal O-ring
above the sand bath.
2.6. Take a handful of crushed ice and place it in the condenser. Fill condenser ¼ to ½ full
with cold water to create ice slush. The ice slush will cool the metal plate on the inside of
the apparatus and subsequently the slide adhered to it. Wait at least 5 min for the
temperature to reach a steady state.
2.7. Pour 300 mL of ethanol in the cold trap container and place the glassware into the
container. Drop 2 - 3 small pieces of dry ice into the ethanol in the bottom of the cold trap
container. The cold trap input has a glass tube running to the bottom of the cylinder, while
the output does not.
2.8. Connect the vacuum pump to the cold trap output using rubber tubing. Use another
piece of rubber tubing to connect the cold trap input to the sublimation apparatus. Ensure
that the tubing is tightly secured using metal clamps if available.
2.9. Use the vacuum pump to deliver a vacuum of 30 - 50 mT. Allow the pump to run for at
least 5 min for pressure equilibration. Vices on U-ring of sublimation apparatus may have
to be tightened again once the vacuum pump is turned on because of decreased pressure in
the apparatus.
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NOTE: It is highly recommended that a vacuum gauge be attached to the pump to monitor
the pressure of vacuum during the experiment and to test for leaks in pressure in order to
achieve the highest possible reproducibility between experiments. However, most pumps
are designed to maintain a constant pressure, therefore the gauge may not be essential for
experienced users. Additionally, vacuum seal grease can be used to help maintain vacuum
pressure.
3. Sublimation
3.1. Ensure that the sand bath temperature has stabilized at 140 °C and that the apparatus is
secured in the metal O-ring above the sand bath with all tubing connected and the vacuum
turned on.
3.2. Set timer for 7 min but do not start timer. Slowly raise the scissor lift and sand bath up
to the sublimation apparatus until the U-joint of the sublimator is well above the metal Oring. This extra space allows for adjustment of the apparatus on the sand.
a. Quickly press the sublimator gently on the sand surface to ensure that the
apparatus is sitting evenly on the sand, and then immediately start the timer.
3.3. When the timer sounds, turn off the vacuum pump and carefully lower the scissor lift
until the sublimator is no longer touching the sand bath and is sitting securely in the metal
O-ring.
a. Slowly loosen the micro-vent valve to release pressure in the apparatus. Loosen
the metal clamp around the rubber tubing of the sublimation apparatus and slowly
begin to loosen the tube. Once the rubber tube has been loosened slightly, bend the
tube to one side to allow residual pressure to escape.
b. When ambient pressure returns, carefully remove the rubber tubing from the
sublimation apparatus.
3.4. Loosen the vices on the U-joint of the apparatus and remove. Carefully separate the
two halves of the sublimation apparatus and pull off the slide from the top of the inner
glassware. Examine slide to confirm even matrix distribution.
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NOTE: If matrix is uneven, the powdered matrix in the bottom of the sublimator can be
repositioned or the sublimator apparatus can be repositioned in the sand for the next slide.
The sublimation process can be repeated several times using the same matrix, however, the
matrix will eventually become darker from repeated heat exposure and the quantity of
powder will decrease such that the sublimation time will have to be adjusted slightly to
compensate. For this reason, it is important to monitor the amount of matrix being
sublimated after each experiment to ensure consistency in matrix deposition between slides
3.5. If the distribution and amount of matrix sublimated is sufficient, tape a new slide with
tissue onto the inside of the sublimator and repeat Section 3.
NOTE: For quality control (QC) purposes, the amount of matrix sublimated can be
measured after each experiment by weighing the slide before and after sublimation and
dividing the weight of sublimated matrix with the surface area of the slide 2, it should be
noted that due to the lack of precision of most scales beyond 4 decimal points and
variability between scales, these measurements should be only be used a guide for optimal
matrix deposition as opposed to a fully quantifiable means of QC unless a high precision
balance is used (see Figure 3).
4. Tissue Storage/Rehydration
4.1. After sublimation, store slides in a sealed container or small cassette in sealed plastic
bag.
4.2. Incubate slides in -20 °C freezer for 2 h or overnight.
NOTE: The goal of the freezing process is to act as a rehydration step for the desorption of
tissue materials into the matrix. The freezing process has also been shown to prevent
degradation of lipid signals for up to 1 week when stored at -80 °C (Patterson, Thomas &
Chaurand, 2014). For this reason, the amount of time the samples are stored in the freezer
can be varied to a certain degree to suit the needs of the experimenter without significantly
altering signal detection (as observed in our lab). However, we have noticed some
discoloration of matrix when samples are frozen for longer than 24 h at -20 °C. Thus, we
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recommend imaging the sublimated tissue before that time or storing tissue at -80 °C for
longer incubation periods.
4.3. Remove slides from freezer (and container) and place in a desiccator for 5 - 10 min.
5. Imaging and Analysis
5.1. Remove slides from desiccator and apply instrument standards to ensure mass
accuracy of MALDI instrument during imaging. The type of standards will vary depending
on instrumentation. Standards are generally applied evenly across entire slide, surrounding
tissue to be imaged (Figure 3 D).
5.2. Insert slide into MALDI instrument and follow manufacturer's instructions for imaging
experiments (instrument methods should be optimized for a 1,000 - 2,000 mass range).
Representative result (Figure 4) was acquired in reflectron negative mode with a 70 μm
raster and 20 shots/spectrum (acquisition time ~ 2 h).
Representative Results
Upon completion of the sublimation experiment, the two halves of the glass apparatus are
separated in the fume hood and the slide, taped to the condenser, can be removed (Figure 3
A). At this point, the slide should be examined for uneven matrix distribution and the time,
temperature, or placement of the apparatus in the sand bath may have to be adjusted for the
next slide. A successful DAN sublimation experiment will result in an even coating of
grey/brown matrix along the surface of the slide where the anatomical features of the tissue
can be clearly visualized and the amount of matrix on the glass slide is similar to the
amount on the tissue (Figure 3 B). For example, if too much matrix has been sublimated
on the tissue, the thickness of the matrix will cover the features of the tissue and only the
general shape will be discernable. However, if too little matrix is sublimated, the tissue will
have a darker appearance than the rest of the slide (Figure 3 C). Both too much and too
little matrix will result in poor signal in the MALDI instrument. For quality control
purposes, Thomas et al. weighed the amount of matrix deposited on the slide and divided
the weight by the surface area of the slide. They reported an optimal amount of matrix
deposition for several matrices including DAN (110 μg/cm²) 2. Although most balances
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lack the precision needed to replicate such results, we have attempted this method of QC;
however, due to a high degree of variability, we can only advise a suitable range of matrix
deposition found to be associated successful versus unsuccessful sublimation experiments
with DAN matrix as determined through signal detection in the instrument. A matrix
measurement of below 100 μg/cm² was associated with "too little" matrix conditions while
a measurement of above 140 μg/cm² was associated with "too much". Matrix deposition
between 100 and 140 μg/cm² was found to be an optimal quantity for imaging with DAN
matrix. Calibrating standards should be applied on the glass slide around the tissue samples
to ensure the mass accuracy of the detected IMS signals (Figure 3 D)
In a MALDI IMS experiment, the molecular image allows for the visualization of
the spatial distribution of the analyte of interest along with any unknown species that may
be present in a given mass range. The molecular images of gangliosides in this experiment
were overlaid using ImageJ software to show the anatomical distribution of several
ganglioside species across the cortical and subcortical regions of the rat brain (Figure 4 A).
The most abundant gangliosides in the brain are the A-series species GD1a and GM1 but
also contain gangliosides GM2 and GM3 which can all be found between the 1,000-2,000
m/z mass range, a higher mass range than most common brain lipids, making these
gangliosides easy to identify along the spectrum (Figure 4 B). The ionic abundance of each
ganglioside species can be used to semi-quantify differences or changes in ganglioside
species within the same image. Because a certain amount of variability in sample prep
cannot be avoided in IMS, between scan comparisons are considered to be semiquantitative.
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Figure 3: DAN Sublimation.
Representative results of sublimation of DAN matrix on rat brain tissue. (A) Upon
completion of sublimation, the two halves of the apparatus are separated and the slide is
removed from the condenser. (B) DAN matrix spreads evenly across multiple rat brain
tissue sections on the surface of the slide to allow for highly reproducible results (between
100 - 150 μg/cm²). (C) Examples of failed sublimation experiments where too little matrix
(left - <90 μg/cm²) or too much matrix (right - >150 μg/cm²) was deposited. Too little
matrix will result in insufficient desorption of analytes, while too much matrix will not
allow the laser to penetrate to the tissue during acquisition, resulting in low ion detection.
(D) Slide containing rat brain tissue sections sublimated with DAN matrix and calibration
standards applied is ready for insertion into MALDI instrument for imaging.
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Figure 4: MALDI IMS of Gangliosides in the Rat Brain.
Representative MALDI IMS molecular image and mass spectrum of gangliosides in the rat
brain after sublimation with DAN matrix. The molecular image is a composite of multiple
ganglioside species in the spectrum overlaid and pseudocolored using Image J software to
show the unique anatomical distribution of ganglioside species throughout the brain.
Species GM1d18:1 (red, mass ~1,547 Da), GM1d20:1 (green, mass ~1,573 Da), GM3d18:1
(blue, mass ~1,178 Da), and GM3d20:1 (teal, mass ~1,207 Da) are represented. The mass
spectrum displays ionic abundance of analytes within a 1,000 - 2,000 mass range. The
major A-series gangliosides are labelled along the spectrum.
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Discussion
This work details a standardized protocol of matrix sublimation on tissue for the detection
of negatively charged lipids, such as gangliosides, in MALDI IMS experiments. Sample
preparation for MALDI IMS is highly variable and must be customized to suit the unique
properties of the analyte of interest. The application of matrix onto the tissue sample
surface is a crucial aspect of the sample preparation process with regards to the quality of
results in IMS. Particular care should be taken when selecting matrices, ensuring that the
matrix is compatible with the analyte of interest and is free of matrix-derived artifacts in
the spectrum. Sublimation is a dry matrix deposition technique which provides a high
degree of matrix crystal homogeneity with little delocalization of lipids on tissue. DAN
matrix in particular shows a high degree of sensitivity for the desorption of a group of
negatively charged membrane lipids called gangliosides, as demonstrated in rat brain
sections, and is stable under vacuum for extended periods of time, allowing for
compatibility with the majority of imaging applications. DAN matrix has the additional
benefit of also having a high affinity for positively charged lipid species, thus increasing
the versatility of this matrix for MALDI IMS applications (Thomas, Charbonneau,
Fournaise & Chaurand, 2012). It should also be noted that multiple lipid species, including
phospholipids, can be detected simultaneously when using this IMS protocol.
A thorough examination of the properties of DAN matrix as compared to 9 other
commonly used matrices has been previously published (Thomas, Charbonneau, Fournaise
& Chaurand, 2012). In this article, the authors highlight the increased sensitivity of DAN
matrix in negative ion mode as compared to the other matrices examined as well as the
capability for high resolution imaging using DAN. DAN matrix was found to have the
highest overall performance for negative polarity ions. Interestingly, it performed equally
well for positive polarity ions. Other common matrices which have demonstrated high
affinity for negative polarity ions include DHA, DHB, and 9-AA. The efficiency of DHA
as a matrix is limited by its low stability under vacuum which makes it impractical for most
imaging applications (Thomas, Charbonneau, Fournaise & Chaurand, 2012). 9-AA has the
benefit of producing low background noise and demonstrated enrichment of sulfatide
signals in the 750 - 950 mass range in negative mode compared to DHB matrix (Cheng et
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al., 2010). Although DHB has been shown to be very effective in positive mode, it yields
lower negative polarity ion signal as compared to DAN matrix (Thomas, Charbonneau,
Fournaise & Chaurand, 2012). DAN matrix also demonstrated increased sensitivity in
negative ion mode in the lower mass range (650 - 950) compared to DHB (Thomas,
Charbonneau, Fournaise & Chaurand, 2012). Additionally, it has been reported that DHB
can form significant matrix clusters in negative ion mode up to 750 Da 2.
Another method of dry matrix deposition has been described by Puolitaival et al., in
which ground matrix is passed through a fine sieve and deposited onto the sample surface.
The authors compared this dry method of matrix deposition to a wet matrix manual spray
technique and found that they gave comparable signal for phospholipids in the 450 - 1,200
mass range (Puolitaival, Burnam, Cornett & Caprioli, 2008). One study used both
sublimation and dry-coating with a sieve to examine phospholipid expression, however, the
authors did not comment on how the two techniques compared in terms of image resolution
or ion signal yield (Chaurand, Cornett, Angel & Caprioli, 2011).
In order to ensure the widest possible range of applicability, the protocol presented
was a basic workflow that will allow both new and more specialized users of MALDI IMS
to achieve highly reproducible results for a wide variety of lipid imaging applications.
However, sublimation protocols can be modified to meet the unique circumstances of the
experiment. For example, the fine matrix crystal deposition provided by sublimation allows
for the option to reverse the order of sample preparation by pre-coating slides/plates with
matrix prior to mounting the tissue. The matrix can be sublimated onto the conductive
surface in advance and stored in a dark environment for later use thus reducing sample
preparation time post-sectioning while still maintaining high sensitivity for lipid detection
(Grove, Frappier & Caprioli, 2011; Yang & Caprioli, 2011). Another modification that can
be made to this protocol to enhance signal for the detection of lipids is a 2 min wash with
ammonium formate (Angel, Spraggins, Baldwin & Caprioli, 2012).
Although sublimation can circumvent many of the drawbacks of most wet
deposition techniques, such as smaller, more homogenous matrix crystal deposition
(Hankin, Barkley & Murphy, 2007), decreased delocalization of analytes, and low cost as
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compared to automated sprayers, some variability in the sample preparation process is
unavoidable. In the case of sublimation, there are several factors which may cause minute
differences from one experiment to another and can include the following which have been
observed in our lab. There can be differences in the position of the sublimation apparatus
on the sand. When running several sublimation experiments back-to-back, the sand in the
sand bath may begin to shift its position which can affect the dispersion of heat throughout
the sand bath. Flattening the sand before each round of sublimation can also change the
dispersion of heat as sand that has been displaced may take time to return to a uniform
temperature. Sublimation time may have to be adjusted slightly between each round to
compensate for shifting sand in the sand bath. Alternatively, use of an oil bath may lead to
more homogenous heat dispersion.
Secondly, the amount of matrix at the bottom of the sublimator can vary. DAN
matrix has a clumpy grey appearance and has a tendency to form large clusters. These
clusters can be manually broken up and arranged in the bottom of the sublimator but cannot
be completely eliminated. Large clusters of matrix will take longer to heat and sublimate
than smaller pieces which can affect the end product of the sublimation.
The vacuum output on the sublimation apparatus is another critical factor. Most
sublimators are made with a single vacuum output onto which tubing is attached to connect
it to the vacuum pump during sublimation. Because the pressure is being regulated on that
side of the apparatus, there may be a slight unevenness of the matrix deposition, with more
being deposited on the side with the vacuum output. This can be somewhat compensated
for by shifting either the position of the apparatus in the sand, the position of the matrix in
the bottom of the sublimator, or by changing the position of the slide/plate on the
condenser. These factors are the main drawbacks of the sublimation technique and for this
reason it is crucial to run a test slide through the sublimation process before running
experimental sample so that time can be adjusted to compensate for these variables.
Another reported drawback of sublimation is that the detection of higher mass
analytes is limited by insufficient analyte extraction and/or mixing with matrix. A
rehydration step after sublimation can help pull out these higher mass analytes to
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circumvent this issue. This is typically achieved using a humidity chamber (Gemperline,
Rawson & Li, 2014). However, in this protocol, a freezing step is added after sublimation
which achieves the same purpose. The freezing and subsequent thawing (in a desiccator) of
the samples before insertion in the MALDI instrument causes condensation to form on the
surface of the sample which temporarily rehydrates the sample to allow for the extraction
of higher mass lipids while preserving the tissue for analysis (Patterson, Thomas &
Chaurand, 2014; Yang & Caprioli, 2013).
Overall, sublimation is a highly sensitive and cost effective method of matrix
application for the detection of lipids in MALDI IMS experiments. Indeed, our group has
noticed significant improvements to IMS results when we shifted from using an air-spray
method 3 to a sublimation method 4 for matrix deposition. The present protocol is
appropriate for a number of lipid imaging applications but can be modified to suit the needs
of the experimenter.
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Appendix iv: MS/MS identification of gangliosides
Tandem mass spectrometry (MS/MS) is often performed in MALDI-based experiments in
order to identify molecules of interest within a mass spectrum based on their fragmentation
patterns. Although there are a number of challenges associated with on-tissue MS/MS
fragmentation of ions in negative mode, mostly related to diminished signal as compared to
positive mode, MS/MS was performed, where possible, in order to confirm the identity of
some of the major A-series gangliosides examined in this work.
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Appendix iiii. On-tissue negative mode MS/MS identification of the major ganglioside
species. A. GM1 d18:1 (m/z 1547); B. GM1 d20:1 (m/z 1572); C. GM2 d18:1 (m/z 1384);
D. GM3 d18:1 (m/z 1181). MS/MS spectra produced the diagnostic fragmentation ions
which corresponded to the data reported by Dufresne et al., 2016 (PMID: 27873002).
Generally, fragmentation confirmed that sialic acid produced an intense peak at m/z 290
with additional characteristic fragmentation of various sugar units (m/z 564, 727, and/or
888). Characterization of gangliosides was performed on-tissue using a SCIEX 5800
MALDI TOF-TOF mass spectrometer. DAN matrix was applied onto tissue sections by
sublimation and negative ion MS/MS spectra were acquired. The detector multiplier
voltage was maximized at 2.25 kV and a total of 900 shots per spectrum was acquired in a
continuous stage motion. Following the external calibration at ±50 ppm mass tolerance, the
precursor ion was isolated within an m/z window of 40 FWHM (full width at half
maximum) resolution and fragmented in a posts-source decay mechanism. MS/MS mode
experiments were conducted using 10 to 20% higher laser energy compared to the MS
mode, in order to promote fragmentation of the analytes of interest for structural
identification.
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Appendix v: GM3 species with varied carbon length increase in response to
stroke injury and are decreased with CQ treatment.
Several peaks corresponding to GM3 species with varied carbons in their ceramide
moieties were detected along with the d18:1 and d20:1 species reported in Figures 5.2 and
5.3 of chapter 5. The masses of these GM3 species match what is reported in the Lipidmaps
database for the d16:1 (m/z 1151), d22:1 (m/z 1234), and d24:1 (m/z 1262) species of
GM3.
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Appendix v: GM3 species with varied LCB increase in response to stroke injury and
are decreased with CQ treatment. Quantification of MALDI IMS data along with
representative MALDI images showing the abundance of GM3 species with 16, 22, and 24
carbons in control (left), stroke injured, and stroke injured CQ treatment groups 3 and 21 d
post-stroke. (A) GM3 species were increased within the stroke region compared to control
levels in stroke injured rats 3 d post-stroke. This significant increase was prevented with
CQ treatment in stroke injured rats. (B) GM3 species remained significantly elevated
compared to controls within the stroke region 21 d post-stroke, however, CQ treatment was
associated with a reduction in this increase compared to stroke injury alone. Group with
different letter represent a statistical difference with p < 0.05 via Two-way ANOVA, Tukey
post-hoc.
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